

POSTERS

THU-001 – THU-519

Poster programme version as of 10.04.2020



NAFLD: Clinical aspects except therapy

- THU-001** **Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis**
Top 10%
Amalia GASTALDELLI, *Italy*
- THU-002** **Natural history and prognostic factors of compensated cirrhosis secondary to non-alcoholic steatohepatitis in Catalonia**
YI
Octavi BASSEGODA, *Spain*
- THU-003** **Non-alcoholic fatty liver disease fibrosis score predicts cardiovascular mortality in post percutaneous coronary intervention patients: 5-year results from an observational registry**
Top 10%
Dongyoung LEE, *Korea, Rep. of South*
- THU-004** **The association between liver fibrosis and cognitive impairment in type 2 diabetes: a cross-sectional sub-study of the south London diabetes cohort**
Calum MOULTON, *United Kingdom*
- THU-005** **A new vision of non-alcoholic fatty liver disease: a «cardiac» disease per se and a «vascular» disease only with hypertension**
YI
Filippo CATTAZZO, *Italy*
- THU-006** **NASH is emerging as a leading cause of hospitalisation for cirrhosis: results from a real-life, prospective, consecutive cohort**
Christiane STERN, *France*
- THU-007** **The paradigm of the two faced Janus: NAFLD and cardiovascular disease. An integrated and multidisciplinary new model to approach outpatients affected by diabetes type 2 and NAFLD**
Diego CAROLI, *Italy*
- THU-008** **ALT levels for Asians with metabolic diseases: a meta-analysis of 86 studies with bootstrap modelling and individual patient data validation**
YI
Daniel HUANG, *Singapore*
- THU-009** **Liver histopathology and extracellular matrix biomarkers in patients with advanced hepatic fibrosis from chronic hepatitis C who achieved a sustained virologic response**
Diane SHEVELL, *United States*
- THU-010** **PNPLA3 gene polymorphism and overall and cardiovascular mortality among non-alcoholic fatty liver disease in the United States**
YI
Karn WIJARNPREECHA, *United States*
- THU-011** **Renal failure is associated with increased mortality, morbidity, and hospital charges in patients admitted with non-alcoholic steatohepatitis**
YI
Debashis REJA, *United States*

- THU-012** **Cardiovascular and cerebrovascular co-morbidities in non-alcoholic steatohepatitis**
YI Debashis REJA, *United States*
- THU-013** **Extra-hepatic gastrointestinal malignancies in NAFLD: nationwide inpatient sample 2016**
YI Debashis REJA, *United States*
- THU-014** **Is liver fibrosis the forerunner of clinical cardiovascular disease in non-alcoholic fatty liver disease?**
YI Simna LUBINA, *India*
- THU-015** **Mesenchymal pattern of iron deposition is linked to adverse hepatic outcomes in non-alcoholic fatty liver disease**
 Elmar AIGNER, *Austria*
- THU-016** **Prevalence of non-alcoholic fatty liver in the Netherlands: the Netherlands Epidemiology of Obesity study**
 Gabrielle ALBLAS, *Netherlands*
- THU-017** **Association between non-alcoholic fatty liver disease and nut consumption**
YI Georg SEMMLER, *Austria*
- THU-018** **Myosteatosis and sarcopenia are prevalent in patients with NAFLD even in the absence of advanced fibrosis**
YI Giada PALLINI, *United Kingdom*
- THU-019** **A cholestatic pattern predicts liver outcomes in patients with non-alcoholic fatty liver disease**
YI Grazia PENNISI, *Italy*
- THU-020** **Impact of non-alcoholic fatty liver disease on cardiovascular risk in a general population**
YI Grazia PENNISI, *Italy*
- THU-021** **Serum zinc level and liver fibrosis in male patients with non-alcoholic fatty liver disease**
 Won SOHN, *Korea, Rep. of South*
- THU-022** **Identification of factors associated with engagement and adherence to a very low calorie diet to achieve significant weight loss in patients with advanced non-alcoholic fatty liver disease: a qualitative evaluation**
 Jadine SCRAGG, *United Kingdom*
- THU-023** **Lack of histological steatohepatitis features in advanced fibrosis could impact in screening failure rate: a comparison with FDA clinical criteria**
YI Javier AMPUERO, *Spain*

NAFLD: Clinical aspects except therapy (*Cont.*)

- THU-024** **Risk factors associated to NAFLD-related advanced fibrosis in patients with normal ALT levels**
YI
Javier AMPUERO, *Spain*
- THU-025** **Fibrosis quantification by image morphometry of liver fibrosis predicts clinical outcomes in patients with non-alcoholic fatty liver disease**
YI
Zhengyi WANG, *Australia*
- THU-026** **Non-alcoholic fatty liver disease phenotype and prevalence across the menopause spectrum in women living with HIV**
YI
Jovana MILIC, *Italy*
- THU-027** **Non-alcoholic fatty liver disease: interface between hepatology clinics and primary care**
Kelly HAYWARD, *Australia*
- THU-028** **The association with low skeletal muscle mass and carotid atherosclerosis in patients with non-alcoholic fatty liver disease**
Min Kyu KANG, *Korea, Rep. of South*
- THU-029** **Gender difference and hepatocellular carcinoma incidence in non-alcoholic steatohepatitis patients with advanced liver fibrosis**
Kanokwan PINYOPORNPANISH, *United States*
- THU-030** **Advanced liver fibrosis predicts poor cardiovascular outcomes in patients with type 2 diabetes**
Ho Soo CHUN, *Korea, Rep. of South*
- THU-031** **Histological renal damage and eligibility for kidney donation are worse in patients with biopsy-proven non-alcoholic steatohepatitis compared with simple steatosis**
YI
Lorenzo MULAZZANI, *Italy*
- THU-032** **Evolution of hepatic fibrosis and steatosis during long-term use of metformin in patients with type 2 diabetes**
Hye Won LEE, *Korea, Rep. of South*
- THU-033** **Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials**
Mazen NOUREDDIN, *United States*
- THU-034** **A substantial number of patients with non-alcoholic fatty liver disease and type 2 diabetes have advanced liver fibrosis with a normal serum alanine transaminase**
YI
Michael Patrick JOHNSTON, *United Kingdom*

- THU-035** **Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population**
Mikhail VAN HERCK, *Belgium*
- THU-036** **Association of FIB-4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US clinical practice**
Michelle LAI, *United States*
- THU-037** **Association of FIB-4 score with major cardiovascular events (MACE) in real-world populations diagnosed with NASH or NAFLD in US clinical practice**
Michelle LAI, *United States*
- THU-038** **Relevance of social support and severity of liver disease in biopsychosocial profiles of patients with non-alcoholic fatty liver disease**
Manuel ROMERO GOMEZ, *Spain*
- THU-040** **NAFLD is a rising cause of HCC in women in a prospective populational cohort spanning 24 years (1990-2014)**
Top 10%
Nicolas GOOSSENS, *Switzerland*
- THU-041** **Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity – results from a prospective imaging study**
Nicolas LANTHIER, *Belgium*
- THU-042** **Exercise performance in patients with non-alcoholic steatohepatitis**
Oliver GLASS, *United States*
- THU-043** **Non-alcoholic fatty liver disease all cause mortality is associated with the metabolic syndrome, BMI and the severity of liver disease in hospital admitted patients using big data analytics**
Oranit COHEN EZRA, *Israel*
- THU-044** **Obesity and alcohol intake modify the impact of genetic variants on the risk for incident liver disease in the general population**
Top 10%
Panu LUUKKONEN, *Finland*
- THU-045** **Non-alcoholic steatohepatitis is associated with liver mitochondrial DNA damage and genome instability of cytochrome b, a component of the cellular respirasome supercomplex**
Carlos PIROLA, *Argentina*
- THU-046** **Barriers and motivators to engaging in physical activity in individuals with NAFLD: implications for physical activity adherence**
Philip O'GORMAN, *Ireland*
- THU-047** **Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis**
Quentin ANSTEE, *United Kingdom*

NAFLD: Clinical aspects except therapy (*Cont.*)

- THU-048** **The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care**
Raluca PAIS, *France*
- THU-049** **Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic subjects with non-alcoholic fatty liver disease**
Ramy YOUNES, *Italy*
- THU-050** **NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients**
Rosa LOMBARDI, *Italy*
- THU-051** **Association of non-alcoholic fatty liver disease with incident type 2 diabetes mellitus in men with chronic hepatitis B**
Rei-Chi HSUEH, *Taiwan*
- THU-052** **Clinical and economic impact of non-alcoholic fatty liver disease in Spain**
Salvador AUGUSTIN, *Spain*
- THU-053** **Europe's largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4)**
Top 10% Salvatore PETTA, *Italy*
- THU-054** **Patients receiving liver transplant for NASH cirrhosis have greater muscle loss compared to transplant and non-transplant control**
Samarth PATEL, *United States*
- THU-055** **A national cross-sectional survey of health-related quality of life in Chinese patients with non-alcoholic fatty liver disease**
Rui HUANG, *China*
- THU-056** **Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease**
Taeang ARAI, *Japan*
- THU-057** **Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre**
Tea Lund LAURSEN, *Denmark*
- THU-058** **Health-care burden of NAFLD in European hospital-based outpatient hepatology clinics: real-world prospective data from the CONSTANS study**
Vlad RATZIU, *France*
- THU-059** **Factors associated with increased overall and cause-specific mortality in non-alcoholic fatty liver disease in an ethnically diverse cohort in the United States**
Top 10% Veronica SETIAWAN, *United States*

THU-060 First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes

Wolf Peter HOFMANN, *Germany*

THU-061 Fibrosis non-invasive tests capture changes in patient-reported outcomes of patients with advanced non-alcoholic steatohepatitis

Zobair YOUNOSSI, *United States*

Poster – THU-001 – THU-519

Alcoholic liver disease

- THU-062** Gut transcriptomics reveals potential therapeutic strategies for the restoration of epithelial barrier repair in alcohol-related liver cirrhosis
Antonio RIVA, *United Kingdom*
- THU-063** Specific alterations of the immune checkpoint secretome are linked with antibacterial immunity in alcohol-related liver disease
Antonio RIVA, *United Kingdom*
- THU-064** Proton pump inhibitors increase the risk of oral cancer among patients with alcoholic cirrhosis
YI Astrid Højmark ANDERSEN, *Denmark*
- THU-065** Analysis of the influence of alcoholic abstinence on mortality in patients with alcoholic liver cirrhosis
YI Ángela SUÁREZ-NOYA, *Spain*
- THU-066** Non-invasive criteria for diagnosis of alcoholic hepatitis: use in clinical practice and correlation with prognosis
YI Emma AVITABILE, *Spain*
- THU-067** Early life ethanol exposure has long-term impacts on the transcriptome and epitranscriptome of rat liver
Shu-Huei HSIAO, *Taiwan*
- THU-068** Alcohol recurrence and outcome in patients transplanted for alcoholic cirrhosis: impact of the 6-month rule
Claire-Anna PERIGNON, *France*
- THU-069** Early liver transplantation in active drinkers with and without alcoholic hepatitis: a monocentric case series
YI Debora ANGRISANI, *Italy*
- THU-070** Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function < 32
Degré DELPHINE, *Belgium*
- THU-071** Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways
Eleonora PATSENKER, *Switzerland*
- THU-072** Delisting of liver transplant candidates after improvement in alcohol-related decompensated cirrhosis: a multicentric study on incidence and outcomes
YI Elisa POSE, *Spain*
- THU-073** A novel lymphocyte proliferation assay accurately predicts 90-day survival in severe alcoholic hepatitis patients
YI Euan YATES, *United Kingdom*

- THU-074** **Alcohol use disorder and liver fibrosis – cases are missed through failure to test**
YI Freya RHODES, *United Kingdom*
- THU-075** **Decreasing incidence of alcoholic liver disease in Denmark: a nationwide study**
YI Frederik KRAGLUND, *Denmark*
- THU-076** **Fibroblast growth factor 21 response in a preclinical model of alcohol induced acute-on-chronic liver injury**
 Christidis GRIGORIOS, *Germany*
- THU-077** **Mortality in biopsy-proven alcohol-related liver disease: population-based cohort study of 3,453 individuals**
 Hannes HAGSTRÖM, *Sweden*
- THU-078** **Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial**
 Helmut SEITZ, *Germany*
- THU-079** **Metabolic synapse between hepatocytes and stellate cells drives endocannabinoid-mediated alcoholic steatosis**
YI Hee-Hoon KIM, *Korea, Rep. of South*
- THU-080** **Role of fecal microbiota transplantation in severe alcoholic hepatitis: assessment of impact on prognosis and short-term outcomes**
 Radha DHIMAN, *India*
- THU-081** **In alcoholic hepatitis, cytokeratin 18 serum fragments reflect its severity and predict responsiveness to prednisolone**
 Jane GROVE, *United Kingdom*
- THU-082** **Multi-modal training of specialty clinical trainees improves the detection and subsequent interventions for alcohol use disorder**
 Jasmohan S BAJAJ, *United States*
- THU-083** **Temporal change in the plasma metabolome profile is indicative of outcome in severe alcoholic hepatitis**
YI Jaswinder MARAS, *India*
- THU-084** **Pharmacokinetics of DUR-928 in alcoholic hepatitis patients – a phase 2a study**
 Jaymin SHAH, *United States*
- THU-085** **Alterations and role of bioactive lipid metabolites (oxylipins) in human and experimental ALD: associations with disease severity**
YI Jeffrey WARNER, *United States*

Alcoholic liver disease (*Cont.*)

- THU-086**
YI **Alcohol-induced liver injury is attenuated by human beta defensin in experimental ALD via improvements in the gut-liver axis**
Jeffrey WARNER, *United States*
- THU-087**
YI **Type III interferon lambda derangements are associated with susceptibility to infection in alcohol-related liver disease**
Jennifer RYAN, *United Kingdom*
- THU-088**
YI **The role of PNPLA3, MBOAT7 and TM6SF2 during alcohol detoxification: different mechanisms of fibrosis and steatosis development**
Johannes MUELLER, *Germany*
- THU-089**
YI **Loss of the resolvin D1-formula peptide receptor 2 signaling axis leads to pro-inflammatory transcriptional reprogramming in alcoholic liver disease**
Josiah HARDESTY, *United States*
- THU-090**
YI **High risk of futile over-referrals or late under-referrals among patients suspected of alcohol-related or non-alcohol-related fatty liver disease: real-world evidence reveal opportunities to optimize referral patterns to secondary care**
Katrine PRIER LINDVIG, *Denmark*
- THU-091**
YI **Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase related to impairment of the PD-1/PD-L1 pathway due to high circulating levels of soluble PD-1**
Laura BLACKMORE, *United Kingdom*
- THU-092**
YI **Differential roles of receptor interacting protein 3 and mixed lineage kinase like in murine models and patients with alcohol- and non-alcohol related liver disease**
Laura NAGY, *United States*
- THU-093**
YI **High throughput plasma proteomics in 459 patients reveals patterns of protein dynamics in alcohol associated liver disease: a biopsy-controlled study**
Lili NIU, *Denmark*
- THU-094**
YI **Defective gut adaptive immunity during early alcoholic liver disease**
Luca MACCIONI, *Belgium*
- THU-095**
YI **Metabolic and genetic risk factors predict advanced alcohol-related liver fibrosis regardless of drinking pattern**
Mads ISRAELEN, *Denmark*
- THU-096**
YI **The Stanford integrated psychosocial assessment for transplantation (SIPAT) is an effective tool at identifying limited sobriety candidates with alcohol-related liver disease and low risk of relapse**
Mai SEDKI, *United States*

- THU-097** **The development and severity of alcoholic hepatitis is associated with decreased intestinal microbiome-derived secondary bile acid isoursodeoxycholic acid**
 Mark MUTHIAH, *Singapore*
- THU-098** **H2O2, the major reactive oxygen species produced during alcohol metabolism in liver induces autophagy without involving mTOR**
 Cheng CHEN, *Germany*
- THU-099** **Early diagnosis of alcohol-related liver disease and timely intervention: the role of alcohol care teams**
 Naina SHAH, *United Kingdom*
- THU-100** **A scoring system to predict infection in alcohol-associated hepatitis**
 Daniel PENRICE, *United States*
- THU-101** **Unexpected protective role of the chemokine lix after Gao-binge ethanol feeding in mice**
 Kyle POULSEN, *United States*
- THU-102** **Shedding light on BASH: a novel experimental model of advanced liver damage**
 Raquel BENEDE, *Spain*
- THU-103** **Duration of alcohol abstinence as a predictor of alcohol relapse – the more the better?**
 Ricardo CRESPO, *Portugal*
- THU-104** **Alcohol-related liver cirrhosis patients have higher-disease severity, one-year morbidity and mortality after index hospitalisation- followup of a cohort of 5,138 patients**
 S Muralikrishna SHASTHRY, *India*
- THU-105** **Comparative hepatic proteome analysis in low and high dose ab libitum alcohol mice model of liver injury**
 Sudrishti CHAUDHARY, *India*
- THU-106** **Neuro-immunological pathway alters the phenotype of bone marrow F4/80+CD11b+ macrophages during chronic alcohol consumption**
 Young-Ri SHIM, *Korea, Rep. of South*
- THU-107** **Epigenetic basis of monocyte dysfunction in severe alcoholic hepatitis**
 Thierry GUSTOT, *Belgium*
- THU-108** **Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis**
 Verhelst XAVIER, *Belgium*
- THU-109** **Role of NOX1 on hepcidin signaling in the crosstalk between macrophages and hepatocytes**
 Linna YU, *Germany*

Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology

THU-110 **Single-cell analysis of self-antigen-specific CD4 T cells reveals the B helper signature and the peripheral reservoir of autoreactive T cells in autoimmune hepatitis**

Amédée RENAND, *France*

THU-111 **FXR agonists repress innate and adaptive effector cytokine production in primary sclerosing cholangitis**

Top 10%

Astha MALIK, *United States*

YI

THU-113 **Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through modulating hepatic and intestinal inflammatory signaling**

Claudia FUCHS, *Austria*

THU-114 **Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 months in patients with primary biliary cholangitis**

David JONES, *United Kingdom*

THU-115 **Cell specific transcriptomic analysis reveals a disassociation between treatment response and peripheral markers of immune activation in primary biliary cholangitis**

YI

Evaggelia LIASKOU, *United Kingdom*

THU-116 **Distinct intrahepatic molecular signature between relapse and sustained remission of autoimmune hepatitis before initiation of immunosuppression withdrawal**

YI

Finn DERBEN, *Germany*

THU-117 **Metagenomic sequencing in primary sclerosing cholangitis highlights microbial metabolism of essential nutrients and multiple altered species**

Top 10%

Johannes R. HOV, *Norway*

THU-118 **Obeticholic acid but not bezafibrate treatment improves cholestasis-induced cognitive decline**

YI

Lucy GEE, *United Kingdom*

THU-119 **Negative immune regulator LNK/SH2B3 contributes to the development of autoimmune liver disease in mice under fatty-metabolic stress**

Taizo MORI, *Japan*

THU-120 **Mast cell activation mediates biliary immunobiology and subsequent immune response in a model of primary biliary cholangitis**

YI

Lindsey KENNEDY, *United States*

- THU-121** **MSCs attenuate cona-induced autoimmune hepatitis in mice through Nrf2/HO-1 pathway by altering macrophage polarization**
YI
 WENTIAN LIU, *China*
- THU-122** **Klebsiella in the mucosal gut microbiota in primary sclerosing cholangitis is associated with more severe disease**
YI
 Mikal Jacob HOLE, *Norway*
- THU-123** **Downregulation of the bile acid receptor TGR5 in livers of PSC patients and ABCB4-/- mice**
 Maria REICH, *Germany*
- THU-124** **Insufficient deletion of autoreactive CD4 T cells and plasticity of Tregs drive spontaneous autoimmune hepatitis in mice**
YI
 Max PRETI, *Germany*
- THU-125** **MIR-506 as one of potential determinants of different phenotypic presentation of ulcerative colitis in patients with primary sclerosing cholangitis (PSC)**
 Malgorzata MILKIEWICZ, *Poland*
- THU-126** **Co-stimulatory molecules OX40 and CD30 mediates the regeneration of the liver epithelium in a mouse primary sclerosing cholangitis model**
YI
 Naruhiro KIMURA, *United Kingdom*
- THU-127** **Developing antigen-specific immunotherapy for autoimmune hepatitis type 2 by identification of T cell epitopes**
YI
 Naomi RICHARDSON, *United Kingdom*
- THU-128** **Relevance of epidermal growth factor receptor kinase activity in a model of cholestatic liver injury**
YI
 Nerea LAZCANOITURBURU, *Spain*
- THU-129** **The role of cellular senescence in the natural course of primary sclerosing cholangitis**
YI
 Nora CAZZAGON, *Italy*
- THU-130** **Upregulation of hepatic TH17 response is associated with large duct disease and advanced hepatic fibrosis in pediatric autoimmune liver disease**
YI
 Simon LAM, *United States*
- THU-131** **Elevated levels of systemic bacterial vesicles in autoimmune hepatitis are associated with non-response to corticosteroid therapy**
YI
 Sukriti SUKRITI, *India*
- THU-132** **Single cell RNA sequencing reveals naive T cells ready for effector function in livers of patients with primary sclerosing cholangitis**
YI
 Tobias POCH, *Germany*

Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology (*Cont.*)

- THU-133** Integrated analysis of GWAS and mRNA microarray identified IFN- γ and CD40I as the central upstream-regulators in primary biliary cholangitis
Kazuko UENO UENO, *Japan*
- THU-134** FcRL4+ b cells are associated with inflamed bile ducts in patients with primary biliary cholangitis and locally capture IGA immune complexes
Yuxin Susan LIU, *United Kingdom*
- THU-135** Bile from patients with chronic liver diseases activates MAIT cells
Fei ZHENG, *Norway*

Cirrhosis and its complications: Experimental and pathophysiology

- THU-136** **Inhibition of toll-like receptor 4 signaling reduces hyperammonemia by modulating urea cycle function**
YI Annarein KERBERT, *United Kingdom*
- THU-137** **Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis**
YI Alberto ZANETTO, *Italy*
- THU-138** **Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis**
YI Sofia MONTEIRO, *Portugal*
- THU-139** **Impaired splenic function in liver cirrhosis: a study in 69 patients with cirrhosis from outpatient hepatology clinic in a tertiary hospital in northern Greece**
 Lamprini KIRKINESKA, *Greece*
- THU-140** **Histological characterization of muscle and adipose tissue in patients with cirrhosis receiving liver transplant**
YI Maryam EBADI, *Canada*
- THU-141** **A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals**
 Elisabetta DEGASPERI, *Italy*
- THU-142** **The bone marrow pool of megakaryocytes and their ability to proliferate are preserved in rats with advanced cirrhosis**
YI Iris ASENSIO, *Spain*
- THU-143** **Bile acids modify ROS production, impair chemotaxis and delay apoptosis of neutrophils in vitro**
YI Irina KOMAROVA, *Austria*
- THU-144** **Neuro and hepatic inflammation and steatosis are modulated by gut microbial changes after isolated hepatic vagotomy and antibiotics in cirrhosis**
 Jasmohan S BAJAJ, *United States*
- THU-145** **Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis**
 Maurizio BALDASSARRE, *Italy*
- THU-146** **SLU7 downregulation potentiates liver damage through hepatic de-differentiation**
YI María GÁRATE-RASCÓN, *Spain*

Cirrhosis and its complications: Experimental and pathophysiology (Cont.)

- THU-147** **Endotrophin predicts clinical outcome and mortality in patients with compensated cirrhosis**
YI
Mette Juul NIELSEN, *Denmark*
- THU-148** **Characterization of lymphocyte subsets in ascites during spontaneous bacterial peritonitis: MAIT cells show the strongest increase**
YI
Christian NIEHAUS, *Germany*
- THU-149** **Immune cell response in progressing liver cirrhosis is dominated by neutrophil granulocytes**
YI
Rhea VEELKEN, *Germany*
- THU-150** **Proagio: a protein designed to target integrin alpha V beta 3 outside ligand binding site is an effective way to target activated hepatic stellate cells**
YI
Ravi Chakra TURAGA, *United States*
- THU-151** **Hepatocytes undergo pyroptosis in response to lipopolysaccharide exposure, and can be sensitised to cell death by ER stress**
Ugo SOFFIENTINI, *United Kingdom*
- THU-152** **Faecal cytokines provide novel insights into the role of gut mucosal inflammation in acute decompensation of cirrhosis**
Top 10%
Vishal C PATEL, *United Kingdom*
- THU-153** **Hypofibrinolysis as a contributing mechanism of cirrhotic portal vein thrombosis as evidenced by rotational thromboelastometry (ROTEM)**
Vladimir MARQUEZ, *Canada*
- THU-154** **Lecithin-cholesterol acyltransferase deficiency as an explanatory mechanism for both relative adrenal insufficiency and spur cell anemia in cirrhosis**
Zachary HENRY, *United States*

Acute liver failure and drug induced liver injury

- THU-155** **Plasma perfusion combined with plasma exchange improved survival in chronic hepatitis B related acute-on-chronic liver failure patients**
Tao CHEN, *China*
- THU-156** **The role of urea on the prognosis of severe acute liver injury and acute liver failure**
Top 10%
Ana CRACIUN, *Portugal*
YI
- THU-157** **Idiosyncratic drug-induced liver injury in the elderly: an analysis of cases from the Spanish DILI registry**
Top 10%
Raul J. ANDRADE, *Spain*
- THU-158** **Use of the molecular adsorbent recirculating system in acute liver failure: a North American multicenter experience**
YI
Andrew MACDONALD, *Canada*
- THU-159** **MELD score is the best predictor for transplant-free survival in patients with acute liver injury**
YI
Carolina SIMÕES, *Portugal*
- THU-160** **Ketamine for maintenance sedation in critically ill burned patients is associated with liver dysfunction and acute kidney injury**
YI
Christian DE TYMOWSKI, *France*
- THU-161** **The therapeutic role of iNOS-expressed myeloid derived suppressor cells in acetaminophen induced acute liver failure**
Chien-Hao HUANG, *Taiwan*
- THU-162** **Prevalence, incidence, and characteristics of hepatorenal syndrome-related acute kidney injury in the United States**
Manfred BILZER, *Denmark*
- THU-163** **Bioenergetics defect of CD14+ monocytes are associated with increased mortality in acute liver failure**
YI
Dhananjay KUMAR, *India*
- THU-164** **Ferroptosis related regulatory protein NCOA4 and its lncRNA-mRNA co-expression network in patients with anti-tuberculosis drug-induced liver injury**
Jun CHEN, *China*
- THU-165** **AARC score has better accuracy at predicting 90-day mortality in drug induced acute-on-chronic liver failure (DILI – ACLF)**
Top 10%
Sushrut SINGH, *India*
- THU-166** **Clinical characteristics and prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by gynura segetum**
Jing ZHANG, *China*

Acute liver failure and drug induced liver injury (Cont.)

- THU-167** **Umbilical cord-derived mesenchymal stem cells regulate ferroptosis via the activation of NRF2 are signaling pathway for the treatment of acute liver failure**
Top 10%
YI
 Cong DU, *China*
- THU-168** **Novel in vivo tracing of the hepatocyte origin of extracellular vesicles in mice with experimental liver disease**
YI
 Elena BLÁZQUEZ-LÓPEZ, *Spain*
- THU-169** **Markers of neutrophil extracellular traps are associated with poor outcome in patients with acute liver failure**
Top 10%
YI
 Fien VON MEIJENFELDT, *Netherlands*
- THU-170** **Activation of the aryl hydrocarbon receptor sensitizes to acetaminophen-induced acute liver failure**
YI
 Fenja SCHURAN, *Germany*
- THU-171** **Human bone marrow mesenchymal stem cell's small extract vesicles promote hepatocyte regeneration in acute liver failure**
YI
 Juan GAO, *China*
- THU-172** **Cut-off level of serum cytokeratin 18 for diagnosis of acute-on-chronic liver failure in chronic hepatitis C cirrhosis**
 Hany SHABANA, *Egypt*
- THU-173** **Air-liquid interactive bioartificial liver embedded with 3D-layered human hepatocyte-derived liver progenitor-like cells rescues porcine acute liver failure**
Top 10%
 Hexin YAN, *China*
- THU-174** **Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience**
 Ilker TURAN, *Turkey*
- THU-175** **Expression of microRNA-124 in Kupffer cells modulates liver injury**
YI
 Jinyu WANG, *China*
- THU-176** **Predictors of acute liver failure and death among patients with dengue-induced severe hepatitis**
YI
 Tongluk TEERASARNTIPAN, *Thailand*
- THU-177** **Clinical and radiological features for early identification of malignancy induced acute liver failure**
 Liane RABINOWICH, *United Kingdom*

- THU-178** **Deletion of XBP1 in liver parenchymal cells ameliorates acetaminophen (APAP)-induced hepatotoxicity via activation of IRE1alpha-JNK1-ATG5-dependent autophagy**
Top 10%
YI
 Hui YE, *Spain*
- THU-179** **Larazotide acetate reduces the frequency of bacterial translocation in the thioacetamide-induced liver failure in rats**
Top 10%
 Muhsin Murat HARPUTLUOGLU, *Turkey*
- THU-180** **The protective effects of a sense oligonucleotide drug targeting inducible nitric oxide synthase for a rat model of acute liver injury**
YI
 Richi NAKATAKE, *Japan*
- THU-181** **Hasi-iquest: investigating viral etiologies of acute liver failure of unknown cause**
YI
 Nicolas GILLE, *France*
- THU-182** **Poly(adp-ribose) polymerase plays a critical role in oxidative stress- and hypoxia/reoxygenation-induced programmed cell death in mouse liver cells**
 Michitaka OZAKI, *Japan*
- THU-183** **Investigation into the cut-off point for chronicity of drug-induced liver injury through metabolomic profiling**
 Jia-bo WANG, *China*
- THU-184** **Hepatic steatosis predicts fibrosis in long-term methotrexate use**
 Alnoor RAMJI, *Canada*
- THU-185** **Novel therapy with anti-miR-873-5p at late stages of acetaminophen overdose**
YI
 Rubén RODRÍGUEZ AGUDO, *Spain*
- THU-186** **A novel HER2-targeted liposomal formulation for reducing the risk of liposome-induced hepatotoxicity**
 Sara DE MARTIN, *Italy*
- THU-187** **Combination of sivelestat and n-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury**
YI
 Sarah RAEVENS, *Belgium*

Gut microbiota and liver disease

- THU-189** **Administration of lactobacillus alleviates experimental NASH by reducing miR-21 in the liver**
YI André A. SANTOS, *Portugal*
- THU-190** **Disease severity and proton pump inhibitor use impacts strongest on faecal microbiome composition in cirrhosis**
YI Angela HORVATH, *Austria*
- THU-191** **Deoxycholic acid-producing clostridium scindens influences host metabolism**
Annika WAHLSTRÖM, *Sweden*
- THU-192** **Alteration of the gut microbiota in patients with primary sclerosing cholangitis and concomitant dominant strictures**
Christian RUPP, *Germany*
- THU-193** **Gut microbiota and metabolites associated with response to ursodesoxycholic acid in patients with primary biliary cholangitis**
Bin GAO, *China*
- THU-194** **Gut microbiota are associated with minimal hepatic encephalopathy (MHE) in cirrhosis regardless of country of origin**
Jasmohan S BAJAJ, *United States*
- THU-195** **Microbiota modulates ischemia-reperfusion injury in mouse liver transplantation**
YI Shoichi KAGEYAMA, *United States*
- THU-196** **Gut microbiota composition is difference between HCV mono-infection and HCV/HIV co-infection**
Natthaya CHUAYPEN, *Thailand*
- THU-197** **Transplantation of gut microbiota derived from MCJ-KO genotype determines a protective profile against non-alcoholic fatty liver disease in germ-free mice**
YI Naroa GOIKOETXEA, *Spain*
- THU-198** **Effects of anti-TNF α treatment on Crohn's disease induced hepatic steatosis**
Paul Peter MANKA, *Germany*
- THU-199** **Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease**
YI Paula BOEIRA, *United Kingdom*
- THU-200** **Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis**
Top 10% Rohit LOOMBA, *United States*

- THU-201** **Novel metagenomic signature of fungal mycobiome in NAFLD-cirrhosis with validation in a geographically independent cohort**
Rohit LOOMBA, *United States*
- THU-202** **Lactobacillus rhamnosus GG improve fungal dysbiosis on liver cirrhotic rats**
Ding SHI, *China*
- THU-203** **Protective effects of akkermansia muciniphila against non-alcoholic fatty liver disease through modulation of gut microbiota**
YI Wenrui WU, *China*
- THU-204** **Identification of gut bacterial candidates involved in hepatic encephalopathy by the analysis of feces DNA from patients administered rifaximin**
YI Yoshimi MUTO, *Japan*

Liver development, physiology and regeneration

- THU-205** **Modulation of native decellularized liver matrix enhances hepatic cells proliferation, viability and functions on 3D-bioscaffolds**
YI Abhishak GUPTA, *India*
- THU-206** **Hepatocyte-targeted R-spondin mimetic for liver regeneration**
Top 10% Helene BARIBAULT, *United States*
- THU-207** **Primed liver regeneration in protein convertase subtilisin/kexin type 9 knockout mice is associated with increased lipids uptake and hypercholesterolemia**
YI Jacopo GAVINI, *Switzerland*
- THU-208** **Targeting the embryonic liver with ultrasound-guided in utero nano-injection to manipulate gene expression during liver development and hematopoiesis**
Top 10% Jingyan HE, *Sweden*
YI
- THU-209** **Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotyping screening – application on metabolic diseases**
Karim SI-TAYEB, *France*
- THU-210** **Dynamic characterization of revascularization in decellularized whole-liver scaffold**
Jun LI, *China*
- THU-211** **Optimal liver metabolism and proliferation require the tight junction protein claudin-3**
Top 10% Felix Alexander BAIER, *Switzerland*
YI
- THU-212** **Liver disease modelling with human pluripotent stem cells derived organoids**
Nadzim RAMLI, *Singapore*
- THU-213** **Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver**
Nurdan GULDIKEN, *Germany*
- THU-214** **Macrophage regulation of PKM2 during liver regeneration process**
YI Nicolas MELIN, *Switzerland*
- THU-216** **Diploid hepatocytes drive physiological liver renewal in adult humans**
YI Paula HEINKE, *Germany*
- THU-217** **Imaging human liver regeneration by multiphoton microscopy**
YI Scott DAVIES, *United Kingdom*

THU-218 **Thyroid hormone and TGF- β inhibition drive functional maturation of human pluripotent stem cell-derived hepatocytes**

YI

Sarah WITHEY, *Australia*

THU-219 **Nicotinamide riboside promotes liver regeneration by enhancing mitochondrial fatty acid oxidation**

Sarmistha MUKHERJEE, *United States*

THU-220 **Potential role of two novel agonists of thyroid hormone receptor-beta on liver regeneration**

YI

Simona ONALI, *Italy*

Poster – THU-001 – THU-519

Liver transplantation and hepatobiliary surgery: Clinical aspects

- THU-221** **Parenchyma-sparing hepatectomy improves salvageability and survival for solitary small intrahepatic cholangiocarcinoma**
YI Hui LI, *China*
- THU-222** **Reducing length of stay in patients following a liver transplant**
Abdulrhman ALAMR, *Canada*
- THU-223** **The presence and outcome of biliary sphincter disorders in liver transplant recipients according to the Rome IV classification**
Andres CARDENAS, *Spain*
- THU-224** **Impact of sarcopenia in patients awaiting simultaneous liver and kidney transplantation: a cohort of study on clinical outcomes**
Alessandra MAZZOLA, *France*
- THU-225** **Recent trends and intention-to-treat survival of liver transplantation for non-alcoholic steatohepatitis: an Italian liver transplant registry study. On behalf of AISF, FIRE, SITO and CNT**
Alessandro VITALE, *Italy*
- THU-226** **The application of immunoglobulins after liver transplantation influences the occurrence of donor-specific antibody associated complications**
Top 10%
YI Alexandra FREY, *Germany*
- THU-227** **A new score including anthropometric measurement for weight improved prediction of mortality in adolescents on the liver transplantation waiting list: a US nationwide study**
Abdel-Aziz SHAHEEN, *Canada*
- THU-228** **Post-transplant lymphoproliferative disease after adult liver transplantation has a higher incidence after primary sclerosing cholangitis and can be prevented by surveillance of Epstein-Barr viral load with a pre-emptive strategy – a long-term study**
Bart VAN HOEK, *Netherlands*
- THU-229** **De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study**
YI Chiara BECCHETTI, *Switzerland*
- THU-230** **Phase angle is a prognostic nutritional marker in patients on the waiting list and after liver transplantation**
YI Berenice M. ROMÁN-CALLEJA, *Mexico*
- THU-231** **Differences of bile microbiology and antibiotic susceptibilities in liver transplant recipients from a non-transplant population with acute biliary infection**
Sukwon SUH, *Korea, Rep. of South*

- THU-232** **Transplantation of hepatitis C virus (HCV) infected livers into HCV uninfected recipients**
Natalie BZOWEJ, *United States*
- THU-233** **Safety of marginal grafts in liver transplantation: a single-center experience**
YI Hui TANG, *China*
- THU-234** **Severe obesity increases death and dropout from liver waiting list: French liver transplant cohort**
YI Claire DELACÔTE, *France*
- THU-235** **The effect of the six-month waiting rule on liver transplant patients with hepatocellular carcinoma**
Dilip MOONKA, *United States*
- THU-236** **Liver transplantation assessment: what are the factors associated with contraindication for listing or delayed activation on waiting list?**
YI Domitille ERARD-POINSOT, *France*
- THU-237** **Anticoagulation in liver transplant candidates: a case control study**
Top 10% Domitille ERARD-POINSOT, *France*
YI
- THU-238** **Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and systematic review**
YI Péter Jenő HEGYI, *Hungary*
- THU-239** **Women benefit more from having a potential living liver donor than men**
YI Ravikiran SINDHUVALADA KARNAM, *Canada*
- THU-240** **Transmission and impact of donor allergies in living donor liver transplantation**
YI Ravikiran SINDHUVALADA KARNAM, *Canada*
- THU-241** **Postreperfusion biopsy as predictor of outcomes after liver transplantation**
YI Esteban FUENTES VALENZUELA, *Spain*
- THU-242** **Sarcopenia HIBA score predicts the presence of sarcopenia and mortality in patients on the waiting list for liver transplant**
YI Ezequiel MAURO, *Argentina*
- THU-243** **A novel nomogram based on liver stiffness to predict the comprehensive complication index after liver resection in patients with hepatocellular carcinoma**
Top 10% Federico RAVAIOLI, *Italy*
YI
- THU-244** **Physical frailty predicts liver transplant waiting list mortality: United Kingdom experience**
YI Felicity WILLIAMS, *United Kingdom*

Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

- THU-245** **Early versus late hepatocellular carcinoma (HCC) recurrence after liver transplantation for HCC: patterns and long-term outcome**
Faouzi SALIBA, *France*
- THU-246** **Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single-center experience**
Federica INVERNIZZI, *Italy*
- THU-247** **Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology**
Federica INVERNIZZI, *Italy*
- THU-248** **Re-establishing abstinence after alcohol relapse after early transplant (LT) for alcoholic hepatitis (AH) provides survival advantage**
George THERAPONDOS, *United States*
- THU-249** **Predictors of success in the treatment of anastomotic biliary stricture after liver transplantation**
Helena KATCHMAN, *Israel*
- THU-250** **Survival after liver transplant in recipients of different age groups: a systematic review and meta-analysis**
Ho Ming CHENG, *Hong Kong*
- THU-251** **Prophylactic rifaximin use in liver transplant candidates is associated with false positive results of the alcohol biomarker, ethyl sulphate**
Ian WEBZELL, *United Kingdom*
- THU-252** **Predictive factors of symptomatic nodular regenerative hyperplasia after liver transplantation**
Top 10%
Ilias KOUNIS, *France*
YI
- THU-253** **Transplanting livers from hepatitis C positive donors: is it worth the risk?**
YI
Jacobus MENSINK, *Netherlands*
- THU-254** **Long-term outcomes of persistently positive hepatitis B surface antigen after liver transplantation for chronic hepatitis B**
Top 10%
Yan Yue James FUNG, *China*
- THU-255** **Living donor liver transplantation should be considered cautiously in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection**
Jong Man KIM, *Korea, Rep. of South*
- THU-256** **NASH is the leading indication for liver transplantation in elderly patients**
YI
Justin STEGGERDA, *United States*

- THU-257** **Hepatitis B immunoglobulin prophylaxis for prevention of de novo Hepatitis B infection from hepatitis B core antibody-positive donors**
Kyeongdeok KIM, *Korea, Rep. of South*
- THU-258** **Improved patient and graft survival from kidney transplantation in liver transplants for congenital hepatic fibrosis and Caroli's disease**
Khalid KHAN, *United States*
- THU-259** **Outcomes of liver transplantation for metabolic disorders in children**
Khalid KHAN, *United States*
- THU-260** **Assessment of long-term risk of cardiovascular disease after liver transplantation**
Kirsty MILES, *United Kingdom*
- THU-261** **Hypertension prevalence, treatment and control among liver transplant recipients and associations with cardiovascular events and mortality**
Madeline BERTHA, *United States*
- THU-262** **Portal venous thrombosis and liver transplant: incidence and evolution in the 1st year after transplant**
Maria Angeles LOPEZ GARRIDO, *Spain*
- THU-263** **Utility of anticoagulation in portal venous thrombosis before and after liver transplant**
Maria Angeles LOPEZ GARRIDO, *Spain*
- THU-264** **Safety and efficacy of a cardiac risk stratification protocol based on traditional cardiac risk-factors in patients undergoing liver transplantation**
Top 10%
Marcus ROBERTSON, *Australia*
- THU-265** **Projection of liver transplant activity per indication in France and United Kingdom**
Mark CONNOLLY, *Netherlands*
- THU-266** **The impact of gender and comorbidity burden on liver transplant eligibility and patient survival**
Marwan GHABRIL, *United States*
- THU-267** **Risk factors for fatty liver of donors after living donor liver transplantation**
Hisamitsu MIYAAKI, *Japan*
- THU-268** **Accuracy of triple echo MRI in predicting hepatic steatosis in potential liver donors**
Mohammed ALJAWAD, *Saudi Arabia*
- THU-269** **Preliminary results of a prospective pilot program for transplantation of patients with alcohol-related liver disease and less than 6 months abstinence**
Nazia SELZNER, *Canada*

Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

- THU-270** **Positive complement-dependent cytotoxicity crossmatch results do not influence long-term graft or patient survival following liver transplantation**
Neil HALLIDAY, *United Kingdom*
- THU-271** **Pregnancy outcomes after liver transplantation: a systematic review and meta-analysis**
YI
Nelson VALENTIN, *United States*
- THU-272** **Clostridium difficile infection in liver transplant recipients is uncommon and does not impact long-term survival: a case-control study**
YI
Nicholas KORTT, *Australia*
- THU-273** **Pure laparoscopic versus open right hepatectomy in live liver donors: a propensity score matched analysis**
Suk Kyun HONG, *Korea, Rep. of South*
- THU-274** **Patient social and lifestyle factors associated with cardiovascular risk affect decisions regarding transplant candidacy more than factors associated with psychological and financial well-being**
YI
Oliver TAVABIE, *United Kingdom*
- THU-275** **Inequality in access to liver transplant: are satellite liver transplant centres the answer?**
YI
Oliver TAVABIE, *United Kingdom*
- THU-276** **Usefulness of phosphatidylethanol and urinary ethyl glucuronide to monitor alcohol abstinence in patients awaiting liver transplantation**
Olivier MENARD, *France*
- THU-277** **Poor dental health is a risk factor for infections by streptococci after liver transplant**
YI
Philipp GÖBEL, *Germany*
- THU-278** **Pre-formed donor specific antibodies and aetiology of liver disease are associated with increased incidence of acute cellular rejections after liver transplantation**
YI
Preya PATEL, *United Kingdom*
- THU-279** **Sustained virological response with DAAs decreases glucose level but do not improve renal function, lipid metabolism and blood pressure in liver transplanted patients: a 3-year, long-term follow up**
Raffaella LIONETTI, *Italy*
- THU-280** **Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donors**
Raymond RUBIN, *United States*

- THU-281** **Incidence and prognostic impact of cancer after liver transplantation**
Manuel RODRÍGUEZ-PERÁLVAREZ, *Spain*
- THU-282** **Gender disparity in cardiovascular morbidity and mortality post liver transplantation**
YI
Samarth PATEL, *United States*
- THU-283** **GFR reset point at 3 months after liver transplant is a superior predictor of liver and kidney disease related outcomes: analysis from a large cohort of NASH patients (nail NASH consortium)**
Top 10%
Sanjaya SATAPATHY, *United States*
- THU-284** **Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients**
Top 10%
YI
Sergio RODRÍGUEZ-TAJES, *Spain*
- THU-285** **Pre-transplant diabetes independently predicts atherosclerotic vascular event and death due to cardiovascular disease in liver transplant recipients: a long term multicenter observational study**
Stefano GITTO, *Italy*
- THU-286** **A novel scoring system for predicting risk of relapse following referral for liver transplantation in patients with alcohol-related liver disease**
YI
Stephanie TURNER, *Australia*
- THU-287** **Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or mortality**
YI
Thomas HORVATITS, *Germany*
- THU-288** **An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation**
Teng-Yu LEE, *Taiwan*
- THU-289** **Proximal splenorenal shunt as a secondary prophylaxis for isolated gastric bleeding in patients with non-cirrhotic portal hypertension: a report from a single-center case-series**
Utpal ANAND, *India*
- THU-290** **Usefulness of the «AFP model» to predict recurrence tumor in patients transplanted with carcinoma hepatocellular within Milan criteria**
Victor J BELTRÁN, *Spain*
- THU-291** **Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC**
YI
Vito SANSONE, *Italy*

Liver transplantation and hepatobiliary surgery: Clinical aspects (Cont.)

- THU-292** **Geographic disparities and socioeconomic determinants in liver transplantation referral at the Scottish Liver Transplant Unit**
Wilson SIU, *United Kingdom*
- THU-293** **Pre-operative biliary drainage in perihilar cholangiocarcinoma: an overview of systematic reviews**
YI
Xinwei CHANG, *Netherlands*
- THU-294** **Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR**
YI
Amare AREGAY, *Germany*
- THU-295** **The FOXO1-hedgehog signaling axis regulates NLRP3 inflammasome activation in liver ischemia and reperfusion injury**
Top 10%
Bibo KE, *United States*
- THU-296** **Mesenchymal stem cells-derived extracellular vesicles carried lncRNA-CEP95 ameliorates acute liver rejection by modulating phenotype of natural killer cells**
Top 10%
YI
Liang CHEN, *China*
- THU-297** **Hepatic ischemia induces a time-dependent increase in SERPINB3 gene expression**
YI
Cristian TURATO, *Italy*
- THU-298** **Esomeprazole attenuates hepatic ischemia/reperfusion injury by modulation of TLR4-mediated signaling in mice**
Min SUNG KIM, *Korea, Rep. of South*
- THU-299** **MSC-EVs induce liver transplantation tolerance by promoting CD8+CD28- T cells differentiation and immunomodulatory function via lncRNA MALAT1/IRF4 signaling**
Top 10%
Xin SUI, *China*
- THU-300** **Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate hepatic ischemia-reperfusion injury by regulating neutrophils polarization and suppressing neutrophil extracellular traps formation**
Top 10%
YI
Xiaomei ZHANG, *China*
- THU-301** **Antibodies against huntingtin interacting protein 1-related protein are more prevalent in patients with antibody-mediated rejection after liver transplantation**
YI
Bastian ENGEL, *Germany*

THU-302 **Inhibition of gamma glutamyl transpeptidase ameliorates hepatic/reperfusion injury in rats with fatty liver**
Joseph GEORGE, *Japan*

THU-303 **Influence of PML, RASSF6 and NLRP12 on growth and recurrence of human hepatocellular carcinoma**
Natalie VOGEL, *Germany*

THU-304 **Serum glycomics early after liver transplantation relate to graft loss 3 months after liver transplantation independently of early allograft dysfunction**
Top 10%
Verhelst XAVIER, *Belgium*

THU-305 **YAP attenuates hepatic ischemia reperfusion injury by inducing autophagy through p38/ERK MAPK pathway**
YI
Shuguang ZHU, *China*

THU-306 **Extracellular vesicles derived from human umbilical cord mesenchymal stem cell protect liver ischemia/reperfusion injury by reducing CD154 expression on CD4+ T cells via CCT2.**
Top 10%
YI
Jun ZHENG, *China*

Molecular and cellular biology

- THU-307** **Decreased level of KEAP1 and activation of NRF2 contribute to sorafenib resistant in hepatocellular carcinoma**
Shi JIANG, *China*
- THU-308** **Unravelling the molecular determinants of metabolic syndrome thanks to NMR-metabolomics of urine and serum samples**
Chiara BRUZZONE, *Spain*
- THU-309** **The hedgehog effect: mediating crosstalk between liver and adipose tissue**
Fritzi OTT, *Germany*
- THU-310** **MicroRNA-26b-5p sensitizes hepatocellular carcinoma CD133+ cancer stem cells to cisplatin through downregulation of Jag1-Hes1 and increased BBC3-mediated apoptosis**
Hamed HEMATI, *India*
- THU-311** **TMBIM6 regulates ageing and high-fat diet-induced lipid accumulation**
Han-Jung CHAE, *Korea, Rep. of South*
- THU-312** **Decreased expressions of p70S6K in NK cells of F4-NAFLD patients inhibited F-actin and was correlated with their impaired function**
Johnny AMER, *Israel*
- THU-313** **A fatty acid amide hydrolase inhibitor, URB597, inhibits MICA and MICB shedding**
Kazuma SEKIBA, *Japan*
- THU-314** **A trans-activator of transcription-fusion bone morphogenetic protein 7 polypeptide suppresses CCL4 induced-hepatic fibrogenesis in mice**
Kyung Joo CHO, *Korea, Rep. of South*
- THU-315** **Dickkopf-1 enhances tumourigenic potential by inducing liver angiogenesis**
Kyung Joo CHO, *Korea, Rep. of South*
- THU-316** **The FXR agonist obeticholic acid decreases matrix metalloproteinase activity via RECK and TIMP modulation in hepatic ischemia/reperfusion injury**
Laura Giuseppina DI PASQUA, *Italy*
- THU-317** **Cross-linking of liver metabolism – hedgehog as a key regulator of energy metabolism, regulating mechanistic target of rapamycin activity**
Luise SPORMANN, *Germany*
- THU-318** **Functional consequences of metabolic zonation in murine livers: new insights for an old story**
Madlen MATZ-SOJA, *Germany*

- THU-319** **PXB-cells for the study of lipid metabolism: robust and human-specific lipid profile in human hepatocytes freshly isolated from chimeric mice with humanized liver**
Masaki TAKAHASHI, *Japan*
- THU-320** **Ductular reaction and its microenvironment is aetiology driven**
YI Matthias VAN HAELE, *Belgium*
- THU-321** **Increased autophagy is linked to exosomes secretion in ductular cells of cirrhosis**
Top 10% Tzu-Min HUNG, *Taiwan*
- THU-322** **Screening of components involved in activation of innate immune responses and inflammation in NEMO KO mice**
YI Mick FRISSEN, *Netherlands*
- THU-323** **Establishment of murine model of acute-on-chronic liver failure**
YI Nidhi NAUTIYAL, *India*
- THU-324** **The method of spheroid formation for 3D cultures of primary hepatocytes influences hepatocellular functions and hepatotoxicity**
YI Natalia SANCHEZ-ROMERO, *Spain*
- THU-325** **Bioengineering of 3D bile ducts from 2D micropatterns by self-organogenesis**
Pascale DUPUIS-WILLIAMS, *France*
- THU-326** **Histidine triad nucleotide-binding protein-2 is present at the cross-road of ER-mitochondria interactions and modulates adaptive stress response in hepatocytes**
YI Pavitra KUMAR, *Switzerland*
- THU-327** **Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease**
Peter REVILL, *Australia*
- THU-328** **Tolerogenic dendritic cells modulate pathogenic CD4+ T cells in an ex vivo co-culture system in a concanavalin A -mice model of type-I autoimmune hepatitis**
YI Prabhsimran SINGH, *India*
- THU-329** **Hepatic inflammation upregulates netrin-1 in mice and in vitro through translational activation and transcript topology alteration in a LA-related protein-1 (LARP1)-dependent manner**
YI Romain BARNAULT, *France*
- THU-330** **Cirrhotic extracellular matrix affects Hic-5 expression in primary human hepatic stellate cells**
YI Simona ONALI, *Italy*

Molecular and cellular biology (*Cont.*)

THU-331 Phenotypic characterization of ABCG5/G8 deficiency: selective knockout in liver or intestine leads to genocopies

Top 10%

YI

Susanne N WEBER, *Germany*

THU-332 Synthesis and comparative assessment of bile acid C3-hydroxyl stereoisomers as farnesoid X receptor modulators

Tarek MOUSTAFA, *Austria*

THU-333 Upregulation of CCNB1, CDC20 and CENPF genes is associated with poor prognosis in hepatocellular carcinoma (HCC)

YI

Tengfei SI, *United Kingdom*

THU-334 Bax inhibitor-1 inhibits acetaminophen induced hepatotoxicity by reducing the drug induced ER stress through regulating the RIDD activity of IRE1 alpha

Top 10%

YI

Thoufique Alam RIAZ, *Korea, Rep. of South*

THU-335 Circular RNA circ-TEX2 acts as the sponge of miR-182 and miR-184 to suppress hepatocellular carcinoma proliferation and invasion

YI

Rong LI, *China*

THU-336 CircRNA_104797 mediates acquired sorafenib resistance in hepatocellular carcinoma through regulating ROS

YI

Junjie XU, *China*

THU-337 Ubiquilin 1 mediates sorafenib resistance in hepatocellular carcinoma through targeting mitochondrial biogenesis via regulating PGC1?

YI

Junjie XU, *China*

THU-338 Investigating the mechanism of treating acute-on-chronic liver failure with human bone marrow-derived mesenchymal stem cells via hepatocytes exosomal miRNAs

YI

Jing ZHANG, *China*

Viral hepatitis C: Clinical aspects except therapy

- THU-339** **A novel hepatitis C intervention in Denmark to test and treat people who inject drugs**
Anne ØVREHUS, *Denmark*
- THU-341** **Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK**
Brendan HEALY, *United Kingdom*
- THU-342** **Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care**
Benedict ROGERS, *United Kingdom*
- THU-343** **Improving female street sex worker (FSSW) access to hepatitis C testing and treatment**
Catherine WIGGLESWORTH, *United Kingdom*
- THU-344** **Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center**
Cristina MARCOS FOSCH, *Spain*
- THU-345** **Integrating hepatitis C virus screening by dry blood spot test into colorectal cancer screening: a randomized controlled trial**
YI
María Cristina REYGOSA CASTRO, *Spain*
- THU-346** **Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada**
YI
Dahn JEONG, *Canada*
- THU-347** **The electronegative low-density lipoprotein in patients with chronic hepatitis C infection**
Top 10%
Chia-Yen DAI, *Taiwan*
- THU-348** **Telemedicine and decentralized treatment dispensation to rescue patients in a hepatitis C micro-elimination program based on on-site dried blood spot testing in drug addiction centers**
YI
Dalia MORALES ARRAEZ, *Spain*
- THU-349** **The success of outreach hepatitis C screening among a Belgian population of drug users in a rural and urban setting**
YI
Dana BUSSCHOTS, *Belgium*
- THU-350** **Angiopietin 2 levels decrease with SVR and correlate with dynamics of portal hypertension in patients with HCV-induced advanced chronic liver disease**
Top 10%
YI
David JM BAUER, *Austria*

Viral hepatitis C: Clinical aspects except therapy (Cont.)

- THU-351** **A program of hepatitis C surveillance with linkage to care for inpatients from non-infectious departments in two tertiary hospitals from Jiangsu, China**
Chao WU, *China*
- THU-352** **Feasibility and acceptability of self-testing for hepatitis C infection among the general population in Egypt**
Elena IVANOVA, *Switzerland*
- THU-353** **The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis**
Enrico GALMOZZI, *Italy*
- THU-354** **The impact of universal access to DAA and real-world treatment outcome amongst genotype 3 hepatitis C virus-infected prisoners**
YU JUN WONG, *Singapore*
- THU-355** **Hepatitis C reflex testing in Spain in 2019: a story of success**
Federico GARCIA GARCIA, *Spain*
- THU-356** **Cracks in the hepatitis C cascade of care: real-life outreach data from four Central London services**
Hui Mei WONG, *United Kingdom*
- THU-357** **Seroprevalence of hepatitis B virus co-infection among HCV infected patients screened during the national campaign for HCV eradication in Egypt**
Hadeel GAMAL ELDEEN, *Egypt*
- THU-358** **Risk of liver and non-liver-related mortality among hepatitis C virus and human immunodeficiency virus co-infected persons in a cohort of Brazilian blood donors: a twenty-year study**
Helio Ranes FILHO, *Brazil*
- THU-359** **Emergency department screening for hepatitis C carriers does not improve linkage to care – a single-center prospective study**
Inbal HOURI, *Israel*
- THU-360** **Treating patients with DAAs helped to save €1 billion in France – a budget impact model from 2014 to 2018**
Ingrid RODRIGUEZ, *France*
- THU-361** **Outcomes of community and prison-based hepatitis C treatment using an eHealth model of care**
James HARIDY, *Australia*
- THU-362** **Testing and linkage to treatment programme for hepatitis C in different homeless locations in Greater Manchester, UK**
F Javier VILAR, *United Kingdom*

- THU-363** **Achieving micro elimination of hepatitis C across a network of prisons in the north-west of England covered by a single treatment provider**
F Javier VILAR, *United Kingdom*
- THU-364** **Hepatitis C virus care cascade assessment: one step closer to micro-elimination**
YI
Jehan CHOWDHURY, *United States*
- THU-365** **Global timing of hepatitis C virus elimination in high-income countries: an updated analysis**
Top 10%
Jean-Michel PAWLITSKY, *France*
- THU-366** **Anticipated timing of elimination of hepatitis C virus in Canada's four most populous provinces**
Jordan FELD, *Canada*
- THU-367** **Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients**
Julia DIETZ, *Germany*
- THU-368** **Improving the referral of hepatitis C virus positive patients to specialists through an electronic «pop-up» alert system**
Kamil OZDIL, *Turkey*
- THU-369** **Predictors of disengagement or delay after hepatitis C assessment**
YI
Kathleen BRYCE, *United Kingdom*
- THU-370** **Predictors of workload in a hepatitis C treatment pathway**
YI
Kathleen BRYCE, *United Kingdom*
- THU-371** **Micro-elimination of hepatitis C in mental health care settings**
Kristen MCKEE, *Australia*
- THU-372** **Triple E (engagement, education and eradication) for patients with chronic hepatitis C infection: > 2 years of results of a successful, collaborative US model for improving education, screening and linkage to care in an underserved population**
Marcelo KUGELMAS, *United States*
- THU-373** **Prevalence of hepatitis C in a gastrointestinal endoscopy unit. An active search for asymptomatic subjects**
Laura GOMEZ-ESCOLAR VIEJO, *Spain*
- THU-374** **Why didn't I see you in my clinic? Patients with HCV positive serology but never a confirmed infection. A retrospective analysis at 10 years**
Matias ESTEVEZ, *Spain*
- THU-375** **Timing of hepatitis C elimination in the United States: estimating the year each state will meet the World Health Organization's elimination targets**
Nancy S REAU, *United States*

Viral hepatitis C: Clinical aspects except therapy (*Cont.*)

- THU-376** **Managing hepatitis C in people who inject drugs (PWID) using the internist-addiction medicine-hepatology (IAHC) model to achieve Hep C micro-elimination**
Naren Srinath NALLAPETA, *United States*
- THU-377** **Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed?**
Nicki PALMER, *United Kingdom*
- THU-378** **Hepatitis C virus antigen detection as a tool for diagnosis of acute hepatitis C in patients with negative hepatitis C virus antibody**
Rajneesh KUMAR, *Singapore*
- THU-379** **Screening for chronic liver diseases in the general population reveals an unexpectedly high prevalence of hepatitis C and advanced NAFLD**
Sebastian BACHMAYER, *Austria*
- THU-380** **Does additional information obtained from multiple visits change the timing of HCV treatment decisions**
Shawn GREENAN, *Canada*
- THU-381** **Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project**
Francesco SANTOPOLO, *Italy*
- THU-382** **Epidermal growth factor gene polymorphism in hepatitis C virus patients with hepatocellular carcinoma**
Sara ASAR, *Egypt*
- THU-383** **Impact of dysmetabolism on liver damage severity and evolution in a real-life cohort of patients treated for chronic hepatitis C**
Serena PELUSI, *Italy*
- THU-384** **Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain**
Sergio RODRÍGUEZ-TAJES, *Spain*
- THU-386** **Patients with hepatitis C (Redpath): a randomised controlled trial of telephone contact or offer of an incentive, in addition to a standard letter**
Stephen BARCLAY, *United Kingdom*
- THU-387** **Overdose events among active drug users successfully treated for HCV: the impact of homelessness**
Tianna MAGEL, *Canada*
- THU-388** **Micro-elimination in prisons: a high-intensity test and treat (HITT) programme**
Tracey STIRRUP, *United Kingdom*

THU-389 **Oncogenic implications of sofosbuvir on the development of hepatocellular carcinoma**

Wei-lun TSAI, *Taiwan*

THU-390 **Epidemiological evolution of viral hepatitis in uremic patients in Taiwan – the Formosa like group**

Yu-Ju WEI, *Taiwan*

Poster – THU-001 – THU-519

Viral hepatitis C: Therapy and resistance

- THU-391** **Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial**
Xiaoyu WEN, *China*
- THU-392** **Expansion of a multidisciplinary support program for patients with addictions and hepatitis C: strategies for an effective approach**
Montserrat GARCIA-RETORTILLO, *Spain*
- THU-393** **Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program**
Alessandra MANGIA, *Italy*
- THU-394** **Real-life efficacy and safety of direct-acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: EpiTer-2 study**
Aleksandra BERKAN-KAWIŃSKA, *Poland*
- THU-395** **Concomitant use of direct-acting antivirals (DDAs) and central nervous system drugs in current chronic hepatitis C patient profile**
Antoni SICRAS, *Spain*
- THU-396** **Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the grand plan study**
Brian CONWAY, *Canada*
- THU-397** **Direct-acting antiviral treatment in patients infected with a non-epidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study**
Top 10%
Cas ISFORDINK, *Netherlands*
- THU-398** **A real-world study of treating advanced liver cirrhosis due to chronic HCV infection genotype 1b with sofosbuvir+ ledipasvir with or without ribavirin: results from a cohort of 349 patients**
Carmen Monica PREDA, *Romania*
- THU-399** **Alcohol use does not influence treatment uptake or outcomes in the DAA era**
Curtis COOPER, *Canada*
- THU-400** **Influence of baseline resistance on treatment outcome in patients treated for chronic hepatitis C in Denmark: a nationwide study**
YI
Christina SØLUND, *Denmark*
- THU-401** **Inadvertent «off label» DAA treatment in the real-world and importance for virologic outcome – data from the German hepatitis C-Registry (DHC-R)**
Christoph SARRAZIN, *Germany*

- THU-402** **Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir**
Top 10%
YI David A SMITH, *United Kingdom*
- THU-403** **Resistance and phylogenetic analysis in HCV-2c infected patients within the Italian network VIRONET-C**
YI Velia Chiara DI MAIO, *Italy*
- THU-404** **Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplant**
Faisal ABAALKHAIL, *Saudi Arabia*
- THU-405** **Drug – drug and drug – disease interactions in the treatment of hepatitis C in patients with liver cirrhosis: a single-center experience**
YI Ekaterina NABATCHIKOVA, *Russian Federation*
- THU-406** **Integrated efficacy and safety analysis of GT1-6 treatment-naïve, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir**
Eli ZUCKERMAN, *Israel*
- THU-407** **Hepatitis C micro-elimination pilot strategy in Pakistani migrants in Catalonia through the implementation of a community intervention: interim results of the HepC-link study**
Elisa MARTRÓ, *Spain*
- THU-408** **Characteristics of adults with difficult-to-treat hepatitis C virus genotype subtype 4r infection in Rwanda: a secondary analysis of a clinical trial in Sub-Saharan Africa (shared study)**
Fredrick KATEERA, *Rwanda*
- THU-409** **The importance of medical specialists and services coordination to effectively treat hepatitis C infection in patients who inject drugs: the Trieste model of care**
YI Mauro GIUFFRÈ, *Italy*
- THU-410** **The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings**
Gina NAGUIB, *Egypt*
- THU-411** **Resistance-associated variants conferring quite a high level of resistance to all approved NS5A inhibitors in genotype 2 hepatitis C virus**
Goki SUDA, *Japan*
- THU-412** **A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection**
Rui HUA, *China*

Viral hepatitis C: Clinical aspects except therapy (Cont.)

- THU-413** **Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/GZR): results from the German hepatitis C registry (DHC-R)**
Dietrich HÜPPE, *Germany*
- THU-414** **Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort**
Irene CACCIOLA, *Italy*
- THU-415** **Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C**
Jeffrey WANG, *United States*
- THU-416** **Factors associated with efficacy of retreatment with grecalevir/pibrentasvir therapy in prior DAA failed patients – nationwide multicenter study in Japan**
Jun ITAKURA, *Japan*
- THU-417** **Impact of the universal access to direct-acting antivirals in the profile of hepatitis C treated patients**
Jordi LLANERAS, *Spain*
- THU-418** **Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease – data from the German hepatitis C-registry (DHC-R)**
Johannes WIEGAND, *Germany*
- THU-419** **HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C**
Joss O'LOAN, *Australia*
- THU-420** **Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naïve hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry**
Juan TURNÉS, *Spain*
- THU-421** **Baseline features of hepatitis C patients associated to prescription of pangenotypic antiviral treatments: results from the real-world Spanish Hepa-C registry**
Juan TURNÉS, *Spain*
- THU-422** **The English hepatitis C registry shows only a modest effect from non-completion of directly-acting antivirals for hepatitis C: SVR rates over 80% in genotype 1, 2 or 3 HCV if more than one third of planned treatment is completed**
Kate DRYSDALE, *United Kingdom*

- THU-423** **Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany – analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)**
Karl-Georg SIMON, *Germany*
- THU-424** **The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review**
Katherine DAVIDSON, *United Kingdom*
- THU-425** **Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection**
Lisette KRASSENBURG, *Canada*
- THU-426** **Virological patterns of HCV-patients with failure to second generation direct-acting antivirals**
Laura OCCHIELLO, *Italy*
- THU-427** **Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness**
Lisa BARRETT, *Canada*
- THU-428** **Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees**
Lorenzo ONORATO, *Italy*
- THU-429** **Elimination of hepatitis C in a remand prison using a rapid point of care driven test and treat pathway**
Louise DAVIES, *United Kingdom*
- THU-430** **Dermatological manifestations in the era of new direct acting antivirals: a single-center experience**
Mohamed TALKHAN, *Egypt*
- THU-431** **Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction services in Kenya**
Matthew AKIYAMA, *United States*
- THU-432** **Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting**
Mary FLANAGAN, *Ireland*
- THU-433** **Treatment of hepatitis C at the Stockholm needle syringe program – treatment success, reinfection rates and challenges for HCV elimination**
Martin KÄBERG, *Sweden*
- THU-434** **Epidemiological and clinical analysis of foreign patients treated with direct antivirals for hepatitis C in a high immigration area**
Matias ESTEVEZ, *Spain*

Viral hepatitis C: Clinical aspects except therapy (Cont.)

- THU-435** **Drug-drug interactions (DDIs) with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C; understanding the populations at risk and real-world care management**
Michael CURRY, *United States*
- THU-436** **Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR**
Olav DALGARD, *Norway*
- THU-437** **Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment**
Naveed JANJUA, *Canada*
- THU-438** **A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects**
Ounisha MUNGUR, *Mauritius*
- THU-439** **Frequency and characteristics of DAAs failure in hepatitis C therapy**
YI Pablo FLOREZ DÍEZ, *Spain*
- THU-440** **Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries**
Pietro LAMPERTICO, *Italy*
- THU-441** **Fast-track-consultation protocol: an interdisciplinary and useful tool for treating drug user hepatitis C infection in addiction out-patient units**
Silvia ACOSTA-LÓPEZ, *Spain*
- THU-442** **Achieving hepatitis C elimination in people who inject drugs – interim results of an innovative screen-and-treat program in Austria**
Top 10%
YI Caroline SCHMIDBAUER, *Austria*
- THU-443** **Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of non-adherence – real-world data from Vienna, Austria**
YI Caroline SCHMIDBAUER, *Austria*
- THU-444** **Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population**
Sabela LENS, *Spain*
- THU-445** **In-depth molecular characterization of inherently resistant African HCV genotype 1, subtype 1I, in patients failing DAA-based therapy**
Top 10% Slim FOURATI, *France*

- THU-446** **Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment**
YI Igor STARINSKIJ, *United Kingdom*
- THU-447** **Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with «navigator» figure and telemedicine**
 Susana LLERENA, *Spain*
- THU-448** **Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence**
YI Tianna MAGEL, *Canada*
- THU-449** **Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis**
 Tim PAPALUCA, *Australia*
- THU-450** **Management of hepatitis C in primary healthcare in the country of Georgia**
 Tengiz TSERTSVADZE, *Georgia*
- THU-451** **HCV DAA treatment failure is associated to hepatocellular carcinoma presence**
 Ubaldo Visco COMANDINI, *Italy*
- THU-452** **Challenges in hepatitis C elimination despite highly effective antiviral agents – experience of a tertiary hepatology centre**
YI Christian URAK, *Austria*
- THU-453** **Reasons for hepatitis C direct acting antiviral failure: experience from the field**
 Vincent THIBAUT, *France*
- THU-454** **Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience**
Top 10% Vincenzo MESSINA, *Italy*
- THU-455** **Hepatitis C positive organ transplantation to negative recipients at a multi-organ Canadian transplant centre: ready for prime time**
Top 10% Waleed ALGHAMDI, *Canada*

Liver tumours: Clinical aspects except therapy

- THU-458** **Neutrophil-lymphocyte ratio predicts the risk of developing hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B under antiviral therapy**
Ke SHI, *China*
- THU-459** **Differentiation and management of hepatobiliary mucinous cystic neoplasms: a single-center experience for 10 years**
Junhao ZHENG, *China*
- THU-460** **Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection**
Hui LI, *China*
- THU-461** **Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis**
Ainhua LAPITZ, *Spain*
- THU-462** **Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC)**
Ainhua LAPITZ, *Spain*
- THU-463** **Investigating the impact of extrahepatic metastasis in patients with HCC: does location matter?**
Aline MAEHRINGER-KUNZ, *Germany*
- THU-464** **Combination of AFP, AFP-I3 and PIVKA-II levels improves diagnostic accuracy of hepatocellular carcinoma (ALPS score)**
Han Ah LEE, *Korea, Rep. of South*
- THU-465** **The PNPLA3 G-allele is common in patients with HCC but does not affect tumor characteristics and tumor biology**
Benedikt SCHAEFER, *Austria*
- THU-466** **Long-term risk of HCC in persons with cirrhosis: national, population-based cohort study of 7,322 individuals**
Bonnie BENGTSOON, *Sweden*
- THU-467** **Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma**
Gian Paolo CAVIGLIA, *Italy*
- THU-468** **Contrast-enhanced ultrasound using sonazoid in liver imaging reporting and data system category 3 and 4 observations on gadoxetate-enhanced magnetic resonance imaging**
Yeun-Yoon KIM, *Korea, Rep. of South*

- THU-469**
YI **Active chronic hepatitis B increases the risk of liver metastasis – a retrospective observational study of 7,187 consecutive newly diagnosed colorectal cancer**
Yue YANG, *China*
- THU-470** **Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma**
Dave MORGENSTERN, *United States*
- THU-471** **Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC)**
David J. PINATO, *United Kingdom*
- THU-472** **Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma**
David J. PINATO, *United Kingdom*
- THU-473**
YI **MALDI-imaging mass spectrometry of N-glycan profiles of molecular subclasses of human hepatocellular carcinoma**
Andrew DELACOURT, *United States*
- THU-474** **The burden of percutaneous liver biopsy use in hepatocellular carcinoma**
Ahmad KHAN, *United States*
- THU-475** **Epidemiological trends of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease in Italy. On behalf of the ITA.LI.CA study group**
Fabio FARINATI, *Italy*
- THU-476**
YI **Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization**
Filippo PELIZZARO, *Italy*
- THU-477**
YI **Natural history of hepatobiliary-hypointense only nodules found at magnetic resonance imaging with Gd-EOB-DTPA: time-dependent effects of dimensional increase and diffusion weighted imaging alterations**
Francesca BENEVENTO, *Italy*
- THU-478**
YI **Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study**
Giovanni MARASCO, *Italy*
- THU-479**
YI **Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization**
Giulia PESERICO, *Italy*

Liver tumours: Clinical aspects except therapy (Cont.)

- THU-480** **Risk of hepatocellular carcinoma in hepatitis D co-infected patients compared to hepatitis B mono-infected patients: a systematic review and meta-analysis**
Habiba KAMAL, *Sweden*
- THU-481** **The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma**
YI
Johann VON FELDEN, *Germany*
- THU-482** **Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome**
YI
Jenny KRAUSE, *Germany*
- THU-483** **Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer**
John CONNELL, *United Kingdom*
- THU-484** **Care pathway for patients with hepatocellular carcinoma in France in 2017: management overview, description of nurse coordinators' role and its impact**
Julie DEVICTOR, *France*
- THU-485** **Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides**
Julien CALDERARO, *France*
- THU-486** **Deep learning for cost-effective accurate diagnosis of liver tumor based-on magnetic resonance imaging and clinical information: a retrospective study**
Top 10%
YI
Shihui ZHEN, *China*
- THU-487** **Elevated serum myostatin level is associated with development of hepatocellular carcinoma in patients with alcoholic liver cirrhosis: a multicenter study**
Ji Hyun KIM, *Korea, Rep. of South*
- THU-488** **The risk of hepatocellular carcinoma recurrence following resection or ablation is dependent on underlying etiology**
Laura TELEP, *United States*
- THU-489** **High subcutaneous tissue density correlates negatively with survival in patients with hepatocellular carcinoma**
Leona VON KOECKRITZ, *Switzerland*
- THU-490** **The protective role of urea-containing cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma**
Young-Sun LEE, *Korea, Rep. of South*

- THU-491** **Applicability of the «six and twelve model» in patients with hepatocellular carcinoma treated with DEB-TACE**
 Maria PIPA MUÑIZ, *Spain*
- THU-492** **Application of acoustic radiation force impulse elastography in non-invasive diagnosis of focal nodular hyperplasia**
 Mariana FORLINO, *Italy*
- THU-493** **Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma**
 Natthaya CHUAYPEN, *Thailand*
- THU-494** **Incidence of hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors: impact on outcomes and tissue biomarker analysis**
 Nicola PERSONENI, *Italy*
- THU-495** **External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients**
 Osman Cavit OZDOGAN, *Turkey*
- THU-496** **Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2**
 Peter GALLE, *Germany*
- THU-497** **AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategy**
 Philip JOHNSON, *United Kingdom*
- THU-498** **The prognostic and diagnostic significance of the neutrophil to lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study**
 Philip JOHNSON, *United Kingdom*
- THU-499** **Quantitative assessment of the impact of viral state on the rate of tumour progression in patients receiving sorafenib for advanced hepatocellular carcinoma**
 Philip JOHNSON, *United Kingdom*
- THU-500** **Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis**
 Pietro GUERRA, *Italy*
- THU-501** **Refining the immune class of hepatocellular carcinoma**
 Roser PINYOL, *Spain*

Top 10%

Liver tumours: Clinical aspects except therapy (Cont.)

- THU-502** **Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation**
YI Sabine URBAN, *Germany*
- THU-503** **Cholangiocarcinoma miscoding in hepatobiliary centres**
Shaun SELVADURAI, *United Kingdom*
- THU-504** **Non-alcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study**
YI Stefania DE LORENZO, *Italy*
- THU-505** **Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic hepatitis B and C patients**
YI Stijn VAN HEES, *Belgium*
- THU-506** **TERT mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish HCC patients**
YI Stine KARLSEN, *Denmark*
- THU-507** **Comparison of hepatocellular carcinoma between the current decade and the past – a study of 3,013 cases**
Chee-Kiat TAN, *Singapore*
- THU-508** **Cholangiocarcinoma in England – a national study examining changes in incidence, diagnostic routes and overall survival**
Tracey GENUS, *United Kingdom*
- THU-509** **Reduced incidence of hepatobiliary cancers in helicobacter pylori infected persons in a population-based cohort study**
Top 10% Hendrik VILSTRUP, *Denmark*
- THU-510** **Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model**
YI Vito SANSONE, *Italy*
- THU-511** **Identifying core fucosylated glycopeptides via LC-MS in hepatocellular carcinoma tissue specifically using a targeted approach from dual enzymatic MALDI-MSI**
YI Connor WEST, *United States*
- THU-512** **Use of a novel thyroid-stimulating hormone model for predicting the progression of hepatocellular carcinoma**
YI ZhiYun YANG, *China*

- THU-513** **A scoring system based on artificial neural network for predicting progression in HBV-related hepatocellular carcinoma**
YI
ZhiYun YANG, *China*
- THU-514** **Prediction of long-term survival of patients with hepatocellular carcinoma based on NK cells count novel model**
YI
ZhiYun YANG, *China*
- THU-515** **Chronological improvement in long-term outcomes of surgical resection for patients with hepatocellular carcinoma: two large-volume center studies**
Yun Bin LEE, *Korea, Rep. of South*
- THU-516** **Glucose variability and risk of hepatocellular carcinoma in diabetic patients: a nationwide population-based study**
Top 10%
Su Jong YU, *Korea, Rep. of South*
- THU-517** **Estimation of hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance**
Yewan PARK, *Korea, Rep. of South*
- THU-518** **Indeterminate nodules in hepatocellular carcinoma surveillance: an analysis of the frequency, outcomes and costs**
YI
Yu Meng LI, *United Kingdom*
- THU-519** **Serum creatinine / cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma**
Kazufumi KOBAYASHI, *Japan*

POSTERS

FRI-001 – FRI-520

Poster programme version as of 10.04.2020



NAFLD: Diagnostics and non-invasive assessment

- FRI-001** **The development of the naf3 score to accurately predict the presence of active NASH with advanced fibrosis**
Naim ALKHOURI, *United States*
- FRI-002** **Advanced transcriptomics identifies the tweak receptor as a novel biomarker in non-alcoholic steatohepatitis: biomarker discovery from gene expression signature to plasma protein**
Anja BENGTTSSON, *Denmark*
- FRI-003** **Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis**
Andrew BECK, *United States*
- Top 10%**
- FRI-004** **Serum proteomics identifies biomarkers of fibrotic severity in NASH patients**
Arathi KRISHNAKUMAR, *United States*
- FRI-005** **Performance of non-invasive fibrosis tests among non-alcoholic fatty liver disease (NAFLD) patients with normal alanine aminotransferase (alt): data from a large North American primary care NAFLD pathway**
Abdel-Aziz SHAHEEN, *Canada*
- FRI-006** **Non-invasive detection of NASH and significant fibrosis in NAFLD patients with low FIB-4**
Heike BANTEL, *Germany*
- FRI-007** **Impact of elevated liver stiffness and hepatic steatosis on maximum liver function capacity**
Valentin BLANK, *Germany*
- FRI-008** **Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH)**
Brenda REINHART, *Switzerland*
- FRI-009** **Non-invasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results**
Amy LAW, *United States*
- FRI-010** **13c-octanoate breath test in a predictive score for the diagnosis of non-alcoholic steatohepatitis**
Carmen FIERBINTEANU BRATICEVICI, *Romania*
- FRI-011** **Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease**
Chiara ROSSO, *Italy*

- FRI-012** **Comparison of diagnostic accuracy of magnetic resonance ideal-iq sequence and controlled attenuation parameter for detecting liver steatosis**
Xiaoling CHI, *China*
- FRI-013** **Mack-3: an accurate blood test for the diagnosis of fibrotic NASH and**
YI **a candidate biomarker to monitor disease progression**
Clémence CANIVET, *France*
- FRI-014** **Diagnostic performance of three non-invasive fibrosis scores (Hepamet,**
FIB-4, NAFLD score) on NAFLD in a mixed Latin American population
Claudia OLIVEIRA, *Brazil*
- FRI-015** **Identification of significant fibrosis in patients with non-alcoholic**
steatohepatitis using non-invasive tests: determination of optimal thresholds
based on cross-sectional analyses of patients screened for a phase 3
randomised controlled trial
Darshini SHAH, *United States*
- FRI-016** **Patients with non-alcoholic fatty liver disease referred from primary care**
have a significant serum fibrosis marker and liver stiffness measurement
discordance
David HARMAN, *United Kingdom*
- FRI-017** **Comparison of point-shear wave elastography (elastPQ) and fibroscan**
transient elastography (F-TE) for liver fibrosis staging in patients
with NAFLD.
Davide ROCCARINA, *United Kingdom*
- FRI-018** **Digital image analysis for quantitative evaluation of fibrosis, steatosis,**
YI **inflammation and iron overload in patients with non-alcoholic fatty liver**
disease
David MARTI-AGUADO, *Spain*
- FRI-019** **2d-shear wave elastography and attenuation imaging: a novel non-invasive**
method for assessment of non-alcoholic steatohepatitis
Dong Ho LEE, *Korea, Rep. of South*
- FRI-020** **Metabolomics composite biomarkers selected by machine learning predicts**
NASH
Elizabeth BROWN, *United States*
- FRI-021** **Diagnostic accuracy of acoustic radiation force impulse elastography for**
YI **the staging of hepatic fibrosis in non-alcoholic fatty liver disease:**
a systematic review and meta-analysis
Emmanuel SELVARAJ, *United Kingdom*
- FRI-022** **Three is enough: optimization of regions of interest selection for accurate**
estimation of proton density fat fraction in liver from magnetic resonance
images
Florent ROCHE, *France*

NAFLD: Diagnostics and non-invasive assessment (*Cont.*)

- FRI-023** **Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis**
YI
Ferenc MOZES, *United Kingdom*
- FRI-024** **Investigation of a composite imaging biomarker for identification of non-alcoholic steatohepatitis (NASH) patients in a Japanese population**
Filza ASLAM, *Singapore*
- FRI-025** **External validation of hepatic estimated steatosis index using magnetic resonance image**
Dong Hwi RIM, *Korea, Rep. of South*
- FRI-026** **The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus**
Geert ROBAEYS, *Belgium*
- FRI-027** **Validation of interleukin-32 as a new circulating fatty liver biomarker**
YI
Guido Alessandro BASELLI, *Italy*
- FRI-028** **Simple non-invasive prediction of advanced fibrosis in NAFLD – a stepwise approach and external validation study to reduce indeterminates and biopsy**
Heather M KOSICK, *Canada*
- FRI-029** **Adherence to established process measures in the evaluation of hepatic steatosis on imaging in a large tertiary care network**
Hersh SHROFF, *United States*
- FRI-030** **Value of FIB-4 and NAFLD fibrosis scores for screening of liver fibrosis in the general population**
Isabel GRAUPERA, *Spain*
- FRI-031** **Utilizing pre-existing imaging and data lake technology in the search of clinically neglected non-alcoholic fatty liver disease (NAFLD)**
YI
Iiro KARHIAHO, *Finland*
- FRI-032** **Factors associated with NAFLD and advanced liver fibrosis and accuracy of liver biopsy in patients with diabetes mellitus type 2: a cross sectional study**
Ivana MIKOLASEVIC, *Croatia*
- FRI-033** **FIB-4 first strategy for non-alcoholic fatty liver disease might not be appropriate for ruling-out advanced liver fibrosis with current cut-off values in patients with type 2 diabetes mellitus**
Ivica GRGUREVIC, *Croatia*
- FRI-034** **Accuracy of cytokeratin-18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis**
YI
Jenny LEE, *Netherlands*

- FRI-035** **Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160,000 blood samples**
Johannes WIEGAND, *Germany*
- FRI-036** **Composite biomarkers selected by machine learning predict severe fibrosis in NASH**
John THOMPSON, *United States*
- FRI-037** **Low transient elastography score appropriately identifies patients that can stay within primary care practice**
YI
Jaspreet SURI, *United States*
- FRI-038** **Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States**
Karen SCHLAUCH, *United States*
- FRI-039** **A combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels**
YI
Kenneth I. ZHENG, *China*
- FRI-040** **Macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with non-alcoholic fatty liver disease**
Konstantin KAZANKOV, *Denmark*
- FRI-041** **Diagnostic accuracy of controlled attenuation parameter compared to ultrasound for detecting steatosis in children with obesity**
YI
Laura DRAIJER, *Netherlands*
- FRI-042** **ELF test should be used concurrently with elastography in NAFLD to maximize diagnostic accuracy**
YI
Laura IOGNA PRAT, *United Kingdom*
- FRI-043** **Evaluation of a novel histology-based fibrosis phenotypic composite score and its correlation with NASH-CRN fibrosis scores in patients with NASH**
Li CHEN, *United States*
- FRI-044** **Serum exosomal miRNA-4668-5p as potential biomarker for advanced fibrosis in non-alcoholic fatty liver disease**
Young-Sun LEE, *Korea, Rep. of South*
- FRI-045** **Mitochondrial ferritin as a biomarker for the diagnosis of non-alcoholic steatohepatitis**
Miwa KAWANAKA, *Japan*
- FRI-046** **Patient-reported symptoms and impact in non-alcoholic steatohepatitis: an evaluation of the NASH-check, a novel prom in NASH**
Maria Magdalena BALP, *Switzerland*

NAFLD: Diagnostics and non-invasive assessment (*Cont.*)

- FRI-047** **The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis**
Marno RYAN, *Australia*
- FRI-048** **Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis**
Matthew BRECKONS, *United Kingdom*
- FRI-049** **Systematic review and meta-analysis of FIB-4 for the diagnosis of advanced fibrosis due to non-alcoholic steatohepatitis**
Mazen NOUREDDIN, *United States*
- FRI-050** **Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers**
Michael CURRY, *United States*
- FRI-051** **Analysis of the prevalence of metabolic syndrome components and other factors as predictors of disease progression among an urban population with NAFLD and/or NASH**
Magdy ELKHASHAB, *Canada*
- FRI-052** **The impact of ethnicity on incidence of NAFLD/NASH among patients referred to the Toronto liver centre for non-invasive evaluation with transient elastography**
Magdy ELKHASHAB, *Canada*
- FRI-053** **Drivers of diagnosis and referral decisions in non-alcoholic fatty liver disease patients**
Michael RODEN, *Germany*
- FRI-054** **Validation of the accuracy of the fast score for detecting non-alcoholic steatohepatitis patients at high risk of becoming cirrhotic in a North American cohort**
Mariana LAZO, *United States*
- FRI-055** **Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population**
YI
Monika LEWINSKA, *Denmark*
- FRI-056** **Difference between antinuclear antibody-positive non-alcoholic steatohepatitis and autoimmune hepatitis based on differential patterns of peripheral T lymphocytes**
Akira KADO, *Japan*
- FRI-057** **Utility of metabolomic biomarkers to identify non-alcoholic fatty liver disease in liver transplant recipients**
YI
Christopher MOWRY, *United States*

- FRI-058** **Cost-effectivity analysis of several non-invasive test strategies for detection and referral of patients with non-alcoholic fatty liver disease at risk of advanced fibrosis**
Manuel ROMERO GOMEZ, *Spain*
- FRI-059** **Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease**
Münevver DEMIR, *Germany*
- FRI-060** **The accuracy of the fast score in predicting NASH with significant fibrosis**
Nabil NOUREDDIN, *United States*
- FRI-061** **Pnfp – a new predictor for pediatric NAFLD fibrosis**
Nibin NAHAZ, *India*
- FRI-062** **Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort**
Philip N NEWSOME, *United Kingdom*
- FRI-063** **A diagnostic approach of non-alcoholic fatty liver disease with a machine learning model using parameters derived from ultrasound B-mode examination**
Pavlos ZOUMPOULIS, *Greece*
- FRI-064** **Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH**
Peter MESENBRINK, *United States*
- FRI-065** **Liver derived apoptotic microparticles as biomarkers to detect transition from simple steatosis to steatohepatitis in non-alcoholic fatty liver disease**
Rocio MUNOZ HERNANDEZ, *Spain*
- FRI-066** **Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial**
Rohit LOOMBA, *United States*
- FRI-067** **Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease**
Salvatore PETTA, *Italy*
- FRI-068** **Glympse liver test for noninvasive monitoring of combination drug therapy in a rat model of non-alcoholic steatohepatitis (NASH)**
Sophie CAZANAVE, *United States*
- FRI-069** **Too many to refer? FIB-4 scores in primary care patients with abnormal liver tests**
Andrew SCHREINER, *United States*

Top 10%

NAFLD: Diagnostics and non-invasive assessment (*Cont.*)

- FRI-070** **Circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non- alcoholic fatty liver disease**
YI Sheila GATO ZAMBRANO, *Spain*
- FRI-071** **Non-invasive liver fibrosis markers, FIB-4, PRO-C3 and ADAPT, are significantly elevated in biopsy confirmed NAFLD patients at high risk of developing coronary heart disease and cardiovascular disease and are promising clinical decision making tools**
YI Samuel DANIELS, *Denmark*
- FRI-072** **The FIB-8 score: validation of a model to screen patients with non-alcoholic fatty liver disease for significant fibrosis**
YI Pimsiri SRIPONGPUN, *United States*
- FRI-073** **Continuous CAP algorithm: reduced variability in a prospective cohort**
YI Stephen HARRISON, *United States*
- FRI-074** **Ultrasound small vessel imaging and deep learning; a novel approach to FLD screening**
YI Tim HOOGENBOOM, *United Kingdom*
- FRI-075** **Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients**
YI Thomas KARLAS, *Germany*
- FRI-076** **Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease**
YI Tuulia HYÖTYLÄINEN, *Sweden*
- FRI-077** **Optimal non-invasive screening strategy for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes**
YI Veeral AJMERA, *United States*
- FRI-078** **The acNASH index – a novel, non-invasive test for accurately identifying non-alcoholic steatohepatitis in individuals with biopsy-proven NAFLD**
YI Xi-Xi WU, *China*
- FRI-079** **Use of the fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: a targeted literature review and feasibility assessment**
YI Ying QIU, *United States*
- FRI-080** **Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study**
YI Zobair M. YOUNOSSI, *United States*
- FRI-081** **Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians**
YI Zobair YOUNOSSI, *United States*

NAFLD: Therapy

- FRI-082** **A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH)**
Adrian DI BISCEGLIE, *United States*
- FRI-083** **Weight loss and change in alanine aminotransferase (ALT) among patients with non-alcoholic fatty liver disease (NAFLD) receiving standard care in real world clinical practice: TARGET-NASH**
Andrew MOON, *United States*
- FRI-084** **Gw9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease**
Anja BAUMANN, *Austria*
- FRI-085** **Obesity management during the rise of NAFLD: real world outcomes of the medical weight loss approach using a very low energy diet**
Ann FARRELL, *Australia*
- FRI-086** **Supplementing diet with olive oil does not prevent the progression of non-alcoholic fatty liver disease**
Annette BRANDT, *Austria*
- FRI-087** **Sustained FXR agonist MET642 shows improved potency and efficacy relative to MET409 in a diet-induced obese biopsy-confirmed mouse model of NASH and in non-human primate pharmacodynamics**
Brandee WAGNER, *United States*
- FRI-088** **Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants**
Christopher JONES, *United States*
- FRI-089** **Decline in NASH and atherosclerosis-associated oxidised phospholipids and 7-ketocholesterol in response to icosabutate therapy**
David A. FRASER, *Netherlands*
- FRI-090** **Aramchol improves glucose and lipid homeostasis in NASH via regulation of AMPK and mTOR**
Top 10%
José M. MATO, *Spain*
- FRI-091** **Saroglitazar for the treatment of NAFLD patients: a single- center observational study at 52 weeks follow up**
Santosh D. HAJARE, *India*

NAFLD: Therapy (*Cont.*)

- FRI-092** **The pharmacokinetics, pharmacodynamics, and short-term safety of cilofexor, a nonsteroidal farnesoid X receptor agonist, in subjects with hepatic impairment**
Elijah WEBER, *United States*
- FRI-093** **Concentration-QT analysis of firsocostat, a liver-targeted acetyl-coa carboxylase inhibitor**
Elijah WEBER, *United States*
- FRI-094** **The safety and pharmacokinetics of fenofibrate in patients with advanced fibrosis including those with non-alcoholic steatohepatitis (NASH)**
Elijah WEBER, *United States*
- FRI-095** **Novel strategies to optimize animal models of human non-alcoholic steatohepatitis for drug development**
Francois BRIAND, *France*
- Top 10%**
- FRI-096** **A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers**
Seon-Ah HA, *Korea, Rep. of South*
- FRI-097** **Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with NAFLD**
Imran PATANWALA, *United Kingdom*
- FRI-098** **Motile sperm domain-containing protein 2: a novel therapeutic target for the treatment of non-alcoholic steatohepatitis**
Itzhak MENDEL, *Israel*
- Top 10%**
- FRI-099** **The efficacy of vitamin D supplementation on NAFLD: a randomized, double-blind, placebo-controlled 12- month trial on 311 patients**
Ivana MIKOLASEVIC, *Croatia*
- FRI-100** **Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis**
Jerome DEVAL, *United States*
- FRI-101** **The first double-blind randomized placebo-controlled phase 2 study to assess the efficacy and safety of insulin sensitizer in patients with non-alcoholic steatohepatitis in Asia- an interim report**
Jee-Fu HUANG, *Taiwan*

- FRI-102** **Efficacy and feasibility of a very low calorie diet to achieve 10% weight loss in patients with advanced non-alcoholic fatty liver disease**
 Kate HALLSWORTH, *United Kingdom*
- FRI-103** **IDL-2965: a selective, highly potent, clinical-stage integrin antagonist for treatment of non-alcoholic steatohepatitis**
 Karl KOSSEN, *United States*
- FRI-104** **The effectiveness of Mediterranean diet versus calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review with clinical implications**
 Top 10%
 YI
 Laura HAIGH, *United Kingdom*
- FRI-105** **Therapeutic efficacy of the chitotriosidase inhibitors in STAM model of non-alcoholic steatohepatitis**
 Michal MLACKI, *Poland*
- FRI-106** **Endoscopic gastric plication (endosleeve) improves hepatic steatosis and liver fibrosis in patients with grade 1-2 obesity, preliminary results at 6 months**
 Michel BLE CASO, *Mexico*
- FRI-107** **Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice**
 Michelle LAI, *United States*
- FRI-108** **BI089-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption**
 Top 10%
 Moti ROSENSTOCK, *Israel*
- FRI-109** **EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis**
 YI
 Mozhdeh SOJJOODI, *United States*
- FRI-110** **Characterization of EYP001 a novel, potent and selective FXR agonist in vitro 3D human liver models of NASH**
 Pauline RADREAU – PIERINI, *France*
- FRI-111** **Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet**
 Ryo YAMAUCHI, *Japan*
- FRI-112** **Methylnaltrexone and rifaximin treatments significantly improve chronic «leaky gut» in a diet-induced mouse model of non-alcoholic fatty liver disease**
 Rebecca CAFFREY, *United States*

NAFLD: Therapy (*Cont.*)

FRI-113 **Recombinant glutamine synthetase (AM-535): a novel therapeutic approach for the treatment of hyperammonaemia and its deleterious effects on multiple systems**

YI

Antria SIAKALLI, *United Kingdom*

FRI-114 **Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxylase inhibitor induced hypertriglyceridemia in patients with NAFLD**

Top 10%

Roberto CALLE, *United States*

FRI-115 **A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects**

Seungjae BAEK, *Korea, Rep. of South*

FRI-116 **Change in hepatic output of palmitic acid after weight loss in type 2 diabetes**

Top 10%

Shaden MELHEM, *United Kingdom*

YI

FRI-117 **GLP-1/glucagon dual receptor agonist ALT-801 is superior to semaglutide in improving NASH endpoints in a biopsy-confirmed DIO mouse model**

Top 10%

M. Scott HARRIS, *United States*

FRI-118 **Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study**

Sven FRANCKE, *Belgium*

FRI-119 **Novel autophagy inducer, a4368 improves non-alcoholic steatohepatitis in mice**

Top 10%

Seung-Woo YEON, *Korea, Rep. of South*

FRI-120 **Intrahepatic microcirculation disorders and increased blood ammonia at the chronic liver diseases with initial stage of liver fibrosis**

Tatiana ERMOLOVA, *Russian Federation*

FRI-121 **Composite targeting of nuclear receptors protects against diet-induced NAFLD**

Top 10%

Tawhidul ISLAM, *Portugal*

YI

FRI-122 **Patient-reported benefits for future non-alcoholic steatohepatitis therapy: a global real-world study among 1,035 patients across 12 countries**

Top 10%

Victoria HIGGINS, *United Kingdom*

FRI-123 **Effects of kaempferol on CFLAR-JNK pathway in mice with non-alcoholic steatohepatitis**

YI

Yue SHEN, *China*

Autoimmune and chronic cholestatic liver disease: Clinical aspects

- FRI-124** **Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase**
Top 10%
YI
Alessio GERUSSI, *Italy*
- FRI-125** **Ursodeoxycholic acid and/or ciprofibrate for treating patients with presumptive diagnosis of low phospholipid cholelithiasis, a clinical spectrum of progressive familial intrahepatic cholestasis type 3**
YI
Ana CARDOSO, *Brazil*
- FRI-126** **Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients**
YI
Anna REIG, *Spain*
- FRI-127** **Histological features of non-alcoholic steatohepatitis are common in patients with autoimmune hepatitis who have advanced fibrosis at diagnosis**
Ashleigh LIMA, *United Kingdom*
- FRI-128** **Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase**
Benedetta TERZIROLI, *Switzerland*
- FRI-129** **Ursodeoxycholic acid response in primary biliary cholangitis is associated with a significant reduction in decompensation and mortality in compensated cirrhosis**
Binu JOHN, *United States*
- FRI-130** **Male gender is associated with a high rate of decompensation and mortality in primary biliary cholangitis with well compensated cirrhosis**
Top 10%
Binu JOHN, *United States*
- FRI-131** **Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease**
Brandon FOSTER, *United States*
- FRI-132** **Effectiveness of obeticholic acid (OCA) in southern European patients with primary biliary cholangitis (PBC) as a second line therapy. A multicenter, international, real- world cohort**
Conrado Manuel FERNANDEZ RODRIGUEZ, *Spain*
- FRI-133** **Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study**
Top 10%
Cynthia LEVY, *United States*

Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.)

- FRI-134** **Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors**
Top 10%
YI Débora TERRABUIO, *Brazil*
- FRI-135** **Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid x receptor (FXR)-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase ? study**
 Yanhua DING, *China*
- FRI-136** **Temporal trends of autoimmune hepatitis related hospitalizations: a descriptive study**
Top 10%
 Ahmad KHAN, *United States*
- FRI-137** **Ursodeoxycholic acid reduces cholestatic hepatitis and maternal bile acid levels in intrahepatic cholestasis of pregnancy**
 Madhumita PREMKUMAR, *India*
- FRI-138** **Poor diagnostic accuracy of blood igG4/igG RNA ratio for discriminating igG4-related disease from pancreatic or biliary cancer (DIPAC): a prospective cohort study**
Top 10%
 Elsemieke DE VRIES, *Netherlands*
- FRI-139** **Glucuronidation directs systemically available norursodeoxycholic acid (norUDCA) to the kidney**
 Emina HALILBASIC, *Austria*
- FRI-140** **Predictive factors of response to corticosteroid therapy in acute severe autoimmune hepatitis: a national multicentric study**
YI Eugenia SÁNCHEZ RODRÍGUEZ, *Spain*
- FRI-141** **Antibodies against glycoprotein 2 and anti-neutrophil cytoplasmic antibodies targeting the serine proteinase 3 are markers of severe primary sclerosing cholangitis (PSC) and progression to cholangiocarcinoma (CCA)**
Top 10%
 Ewa WUNSCH, *Poland*
- FRI-142** **Analysis of 1,776 patients with primary sclerosing cholangitis from a laboratory database**
 Friedrich MITTERMAYER, *Austria*
- FRI-143** **The treatment response and corticosteroid therapy was predicted by GGT, chol, and fibrosis in patients of PBC-AIH overlap syndrome: a real-world study**
YI Xiaoli FAN, *China*

- FRI-144** **Risks and benefits of percutaneous transhepatic cholangiodrainage in patients with primary sclerosing cholangitis**
Gustav BUESCHER, *Germany*
- FRI-145** **Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study**
Nikolaos GATSELIS, *Greece*
- FRI-146** **Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the poise criteria**
Gideon HIRSCHFIELD, *Canada*
- FRI-147** **Enhanced liver fibrosis test and liver stiffness variation over time in a prospective cohort of primary sclerosing cholangitis patients**
Top 10% Guri FOSSDAL, *Norway*
- FRI-148** **An international perspective on cholestatic pruritus in primary biliary cholangitis (PBC)**
Helen SMITH, *United Kingdom*
- FRI-149** **Magnetic resonance imaging features of primary biliary cholangitis**
Ilkay S. IDILMAN, *Turkey*
- FRI-150** **Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis**
Top 10% Ilkay S. IDILMAN, *Turkey*
- FRI-151** **The inter-relationship between primary sclerosing cholangitis and socioeconomic status**
Jessica DYSON, *United Kingdom*
- FRI-152** **Change in risk of primary biliary cholangitis is associated with the evolution of coal mining**
Jessica DYSON, *United Kingdom*
- FRI-153** **The simple cholestatic complaints score is a valid and reliable questionnaire for cholestatic symptoms in PSC patients**
YI Kim N. VAN MUNSTER, *Netherlands*
- FRI-154** **The clinical significance of programmed cell death-1 rs11568821 and interleukin-28b rs12979860 polymorphisms in autoimmune hepatitis**
YI Kalliopi AZARIADI, *Greece*
- FRI-155** **Histological characteristics of primary biliary cholangitis with an incomplete response to ursodeoxycholic acid**
Kenichi HARADA, *Japan*

Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.)

- FRI-156** **Maternal and foetal outcomes, biochemistry and immunology changes during pregnancy in patients with autoimmune hepatitis**
YI Kathryn OLSEN, *United Kingdom*
- FRI-157** **Impaired sulfation capacity may deteriorate clinical course in patients with primary sclerosing cholangitis (PSC)**
YI Karolina Maria WRONKA, *Poland*
- FRI-158** **Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis**
Top 10% Laura CRISTOFERI, *Italy*
YI
- FRI-159** **Ciprofibrate: a new option of fibrate for primary biliary cholangitis with incomplete response to ursodeoxycholic acid**
YI Laura GUEDES, *Brazil*
- FRI-160** **Utility of thiopurine metabolite testing in autoimmune hepatitis: defining an optimal therapeutic range for disease management and measurement may avert relapse and adverse drug reactions**
Lena Susanna CANDELS, *Germany*
- FRI-161** **Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis**
Lei LING, *United States*
- FRI-162** **Higher prevalence of hepatitis E virus in autoimmune hepatitis: the role of false positive antibodies**
Laura Patricia LLOVET, *Spain*
- FRI-163** **Development and validation of a novel risk score predicting long -term survival in autoimmune hepatitis**
YI Maaïke BIEWENGA, *Netherlands*
- FRI-164** **Safety and efficacy of temporary placement of fully covered metallic stent for dominant stricture among primary sclerosing cholangitis patients**
Mahmud MAHAMID, *Israel*
- FRI-165** **Understanding of central and peripheral fatigue in primary biliary cholangitis**
Naw April PHAW, *United Kingdom*
- FRI-166** **Genetic variant c.711 in the hepatobiliary phospholipid transporter ABCB4 is associated with clinically relevant liver stiffness in chronic liver diseases**
YI Marcin KRAWCZYK, *Poland*

- FRI-167** **Response to treatment in autoimmune hepatitis determines the health-related quality of life**
Maurice MICHEL, *Germany*
- FRI-168** **Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis**
Top 10% Michael TRAUNER, *Austria*
- FRI-169** **Removal of fibrosis-related genes identifies a hepatic gene expression signature that identifies canonical signaling pathways and is correlated with clinical outcomes in patients with primary sclerosing cholangitis**
Michael TRAUNER, *Austria*
- FRI-170** **Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis**
Top 10% Michael TRAUNER, *Austria*
- FRI-171** **Simultaneous liver and spleen stiffness measurements as complementary methods for fibrosis quantification in autoimmune hepatitis**
Maciej K. JANIK, *Poland*
- FRI-172** **Pregnancy outcomes for women with primary sclerosis cholangitis and primary binary cholangitis**
Matthew CAULDWELL, *United Kingdom*
- FRI-173** **Machine learning models accurately interpret liver histology and are associated with disease progression in patients with primary sclerosing cholangitis**
Nate TRAVIS, *United States*
- FRI-174** **CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2-/- mouse model.**
Top 10% Neta BARASHI, *Israel*
- FRI-175** **Belimumab: a promising third line treatment option for refractory autoimmune hepatitis**
YI Pinelopi ARVANITI, *Greece*
- FRI-176** **European Association for the Study of the Liver primary biliary cholangitis guideline clinical care standards: the patient experience as recorded by PBC Foundation app and International Patient Registry**
Robert MITCHELL THAIN, *United Kingdom*
- FRI-177** **A multi-disciplinary approach to IgG4 related disease aids in diagnosis and management**
Rory PETERS, *United Kingdom*

Autoimmune and chronic cholestatic liver disease: Clinical aspects (Cont.)

- FRI-178** **Long-term prevalence of gastro-oesophageal varices in early primary biliary cholangitis patients with good response to treatment**
Toru SETSU, *Japan*
- FRI-179** **Symptom burden in patients living with primary biliary cholangitis:**
YI **indigenous Canadians report significantly higher PBC-40 quality of life scores**
Surain ROBERTS, *Canada*
- FRI-180** **Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study**
Leroy VINCENT, *France*
- FRI-181** **Lost in the system: identification of patients with undiagnosed primary biliary cholangitis**
YI Jorge YEBRA CARMONA, *Spain*

Cirrhosis: ACLF and Critical illness

- FRI-182** **Low growth hormone levels predict poor outcome of hepatitis B virus-related acute-on-chronic liver failure**
YI Lingjian ZHANG, *China*
- FRI-183** **Mesenchymal stem cells regulated DX5 – liver natural killer cells in rescuing acute-on-chronic liver failure murine**
YI Jing XIONG, *China*
- FRI-184** **Selecting patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF) admitted to the intensive care unit for liver transplantation**
 Sophie-Caroline SACLEUX, *France*
- FRI-185** **Improving the survival rate of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis**
YI Jinjun CHEN, *China*
- FRI-186** **Soluble immune checkpoints are involved in the immunopathogenesis of ACLF**
Top 10% Douglas CORRIGALL, *United Kingdom*
YI
- FRI-187** **Prevalence, profile and predictors of invasive fungal infections in acute-on-chronic liver failure; analysis of Asia Pacific Association for Study of the Liver, Acute -on -Chronic Liver Failure Research Consortium (AARC) data base**
YI Pratibha RAMCHANDRA KALE, *India*
- FRI-188** **Differential hepatic mRNA and miRNA expression patterns in a novel mouse model of bacterial infection related to acute-on-chronic liver injury**
 Ersin KARATAYLI, *Germany*
- FRI-189** **The prevalence of multi-resistant bacterial infections in patients with decompensated cirrhosis admitted to the intensive care unit**
 Fischer PETRA, *Romania*
- FRI-190** **Acute-on-chronic liver failure as defined by the European (EASL-CLIF) versus North American (NACSELD) diagnostic criteria in their prediction of short-term prognosis in patients with decompensated cirrhosis admitted into hospital**
 Florence WONG, *Canada*
- FRI-191** **Novel experimental animal models for acute decompensation and acute-on-chronic liver failure**
YI Frank USCHNER, *Germany*
- FRI-192** **Artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure patients**
 Tao HAN, *China*

Cirrhosis: ACLF and Critical illness (*Cont.*)

- FRI-193** **Global hemostatic status in patients with acute-on-chronic liver failure and patients with sepsis without underlying liver disease**
Ton LISMAN, *Netherlands*
- FRI-194** **Muscle quality as assessed by computed tomography-derived skeletal muscle density is associated with 28- day mortality in mechanically ventilated critically- ill patients with cirrhosis**
Jaya BENJAMIN, *India*
- FRI-195** **Refining the renal failure criteria of the EASL-CLIF diagnostic model for defining acute- on- chronic liver failure (ACLF)**
Joana CALVÃO, *Portugal*
- FRI-196** **Regulation of IL-22 in a rat model for acute-on-chronic liver failure (ACLF)**
Katharina Maria SCHWARZKOPF, *Germany*
- FRI-197** **Thymosin alpha 1 for patients with hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial**
Top 10%
Bingliang LIN, *China*
- FRI-198** **Derivation and validation of prognostic nomogram for HBV-related acute-on-chronic liver failure**
Bingliang LIN, *China*
- FRI-199** **Efficacy evaluation of artificial liver support system (ALSS) in treatment of HBV-ACLF patients based on metabolomics**
Jie WANG, *China*
- FRI-200** **Mesenchymal stem cells regulate hepatocytes excessive autophagy and apoptosis through miR-125b/TRAF6 pathway in acute- on- chronic liver failure**
Dengna LIN, *China*
- FRI-201** **Predictors and outcome of emergent liver transplantation for patients with acute-on-chronic liver failure**
YI
Ji Eun KIM, *Korea, Rep. of South*
- FRI-202** **Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives**
YI
Nagel MICHAEL, *Germany*
- FRI-203** **Reversal of immune paralysis to immune homeostasis: effect of plasma exchange on monocyte merTK and HLA-DR expression in patients with acute-on- chronic liver failure**
YI
Siddharth MITTAL, *India*

- FRI-204** **Different transcriptome characteristics of peripheral blood mononuclear cells are associated with survival outcome in hepatitis B-related acute-on-chronic liver failure**
YI Shanshan MA, *China*
- FRI-205** **Granulocyte colony-stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis**
Rosa MARTIN- MATEOS, *Spain*
- FRI-206** **Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells**
YI Sabrina RUESCHENBAUM, *Germany*
- FRI-207** **Functional activin-HNF4A-coagulation axis in liver progenitor cells determines MELD score and outcome of acute-on-chronic liver failure**
YI Tao LIN, *Germany*
- FRI-208** **Serum cholinesterase, an underestimated marker in the prediction of acute-on-chronic liver failure, organ failure and LTx -free survival in patients with liver cirrhosis?**
YI Tammo Lambert TERGAST, *Germany*
- FRI-209** **Low eosinophil count: a predictor of in-hospital mortality in cirrhotic patients with sepsis**
YI Tharun OOMMEN, *India*
- FRI-210** **Single- centre experience of implementing a hepatology outreach service to improve patient care for emergency admissions of acutely decompensated cirrhosis**
YI Tomi ASHAYE, *United Kingdom*
- FRI-211** **Using bilirubin to define hepatotropic insult in patients with chronic liver disease and acute exacerbation: a prospective multicenter cohort study**
YI Liang QIAO, *China*
- FRI-212** **Clinical features and natural history of acute-on-chronic liver failure precipitated by any indeterminate factor: single-center observational study**
Hitomi HOSHI, *Japan*
- FRI-213** **Granulocytic myeloid-derived suppressor cells contribute to HBV-related acute-on-chronic liver failure infection and mortality by inducing T cell exhaustion**
YI Xueping YU, *China*

Fibrosis

- FRI-214** **Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis**
Naim ALKHOURI, *United States*
- FRI-215** **Diagnostic accuracy of a pocket-size ultrasound device in identifying liver surface nodularity for fibrosis staging in chronic liver disease**
Andrea COSTANTINO, *Italy*
- FRI-216** **Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model**
Archana VIJAYAKUMAR, *United States*
- FRI-217** **PBI-4050 promotes hepatic stellate cell deactivation by shifting energy metabolism**
Brigitte GROUX, *Canada*
- FRI-218** **Diagnostic accuracy of WFA+ – M2BP for significant hepatic fibrosis determined by MR elastography**
Mi Mi KIM, *Korea, Rep. of South*
- FRI-219** **ZLN005, PGC-1? activator, induces oxidative phosphorylation and lipogenesis in myofibroblasts to reverse liver fibrosis**
Jianye CAI, *China*
- FRI-220** **Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population**
Kyung A KANG, *Korea, Rep. of South*
- FRI-221** **GLI1, but not smoothened-dependent, signaling in hepatic progenitor cells promotes a ductular reaction, which aggravates liver fibrosis**
Jiamei CHEN, *China*
- FRI-222** **Enigma proteins control YAP1 related mechano-transduction in hepatic stellate cells**
Dina ABDELMOTTALEB, *United Kingdom*
- FRI-223** **Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells**
Zhen DAI, *Germany*
- FRI-224** **The IL-17a and IL-22 cytokines like triggers of human liver fibrosis**
Daria KARTASHEVA-EBERTZ, *France*
- FRI-225** **Fib-4 score for assessment of liver fibrosis is useful in general practice**
Denis OUZAN, *France*

- FRI-226** **Analysis of PNPLA3 SNP variants in human hepatic stellate cells in 3D human liver extracellular matrix scaffolds reveals key PNPLA3-dependent pro-fibrogenic features**
Elisabetta CAON, *United Kingdom*
- FRI-227** **An HSV-TK / valganciclovir mouse model enables the study of fibrocytes in liver fibrosis**
Felix HEMPEL, *Germany*
- FRI-228** **Factors predicting liver histological changes under long-term follow-up chronic hepatitis C patients treated with pegylated-interferon-alpha plus ribavirin**
Jung-Ta KAO, *Taiwan*
- FRI-230** **TGF-beta3 plays a prominent role in murine parenchymal liver fibrosis**
Hiroyuki ABE, *Germany*
- FRI-231** **MUDENG (mu-2 related death-inducing gene) overexpression accelerates liver fibrosis in carbon tetrachloride-induced cirrhosis**
Ju-Yeon CHO, *Korea, Rep. of South*
- FRI-232** **Thrombofibrosis: inherited thrombophilia as a cause of significant liver fibrosis**
Iranzu EZCURRA, *Spain*
- FRI-233** **C-Rel acts as a metabolic switch controlling macrophage and hepatocyte phenotype in response to liver injury and is required for fibrosis**
Jack LESLIE, *United Kingdom*
- FRI-234** **An improved method for liver fibrosis assessment using magnetic resonance elastography**
JunSheng, Jaryl CHENG, *Singapore*
- FRI-235** **Expression of cyclin E1 and CDK2 in hepatic stellate cells is critical for initiation and progression of liver fibrosis in mice**
Julia HENNINGS, *Germany*
- FRI-236** **Non-canonical autophagy in myeloid cells constrains hepatic and systemic inflammation and limits fibrosis**
JingHong WAN, *France*
- FRI-237** **Reduction in types I and III collagen gene expression by an alphavbeta1 integrin inhibitor correlates with a decrease in PRO-C1 and PRO-C3 levels in precision-cut liver tissue slices from cirrhotic non-alcoholic steatohepatitis patients**
Johanna SCHAUB, *United States*

Fibrosis (Cont.)

- FRI-238** **Active role of sphingosine-1-phosphate in promoting peripheral-dominant liver fibrosis in mice model of congestive hepatopathy**
YI
Hironari KAWAI, *Japan*
- FRI-239** **CRV431 decreases diet- and chemical-driven fibrosis in livers of mice**
YI
Joseph KUO, *United States*
- FRI-240** **Fibrosis progression in NASH: real- world data from the US population**
Leonardo RUIZ CASAS, *United Kingdom*
- FRI-241** **Nanoparticle bisphosphonate induces an anti-fibrotic response by modulation of fibrosis associated genes and pathways in (non-) parenchymal liver cells in CCL4 fibrotic mice**
YI
Leonard KAPS, *Germany*
- FRI-242** **Microscopy-based fibrosis phenotypic analysis of animal and human NASH cohorts reveal translational traits of fibrosis progression and severity**
Li CHEN, *United States*
- FRI-243** **Fibrosis phenotypic analysis of collagen stained liver histology sections discern anti-fibrotic agents in DDC- induced cholangitis mouse model**
Li CHEN, *United States*
- FRI-244** **Dietary wheat amylase trypsin inhibitors activate myeloid cell toll-like receptor 4 to enhance chronic liver disease in murine liver fibrosis and hepatocellular carcinoma**
Top 10%
YI
Muhammad ASHFAQ-KHAN, *Germany*
- FRI-245** **Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis**
Maite G FERNANDEZ-BARRENA, *Spain*
- FRI-246** **FIB-4 and APRI scores re-validation; a cohort study of 69106 chronic hepatitis C patients**
Mahasen MABROUK, *Egypt*
- FRI-247** **Integrin alphaVbeta1 inhibition ameliorates liver fibrosis in mice**
Min LU, *United States*
- FRI-248** **AlphaVbeta6 inhibitor stabilizing the bent closed integrin conformation is effective in primary sclerosis cholangitis mouse model**
Min LU, *United States*
- FRI-249** **Endotrophin, a hormone derived from type VI collagen, activates fibroblasts and drives fibrosis in the liver, lung, kidney, and heart**
Morten KARSDAL, *Denmark*

- FRI-250** **Hepatocytic C-jun NH2 terminal kinase activity confers protection against cholestatic liver injury in mice**
 Mohamed Ramadan MOHAMED, *Germany*
- FRI-251** **Prevalence of heterogeneous fibrosis in liver biopsies with congestive hepatopathy: an institutional experience**
 Michelle LIN, *United States*
- FRI-252** **Novel Rho associated coiled kinase inhibitor improves hepatic fibrosis in mice model of non-alcoholic steatohepatitis (NASH)**
 Quaisar ALI, *United States*
- FRI-253** **Non-invasive test cut-offs for the identification of advanced liver fibrosis in a diabetes cohort with non-alcoholic steatohepatitis: data from the phase 3 AURORA study**
 Quentin ANSTEE, *United Kingdom*
- FRI-254** **What did we learn from a large cohort of more than 24,000 patients evaluated by transient elastography in a single- center?**
 Roxana SIRLI, *Romania*
- FRI-255** **The impact of LOXL2 inhibition on fibrosis progression in-vitro and in-vivo**
 Sarah A TOWNSEND, *United Kingdom*
- FRI-256** **Hydrophobic bile acids promote proliferation and activation of hepatic stellate cells by PI3K-dependent mechanisms**
 Sebastian ZIMNY, *Germany*
- FRI-257** **Modulation of liver fibrogenesis by interleukin-37**
 Steffeni MOUNTFORD, *Germany*
- FRI-258** **Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients**
 Stephen HARRISON, *United States*
- FRI-259** **Small extracellular vesicles from mesenchymal stem cells pre-conditioned with interferon- γ can improve liver fibrosis by inducing anti-inflammatory macrophages with high migratory and phagocytotic abilities**
 Suguru TAKAUCHI, *Japan*
- FRI-260** **Aspirin induces autophagy and alleviates liver fibrosis by reducing oxidative stress and inflammation in mice model of chronic liver injury**
 Adil BHAT, *India*
- FRI-261** **Carabin deficiency promotes liver fibrosis via regulating RAS and calcineurin pathway in macrophage**
 Rong XUE, *China*

Fibrosis (Cont.)

FRI-262 (pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF- β 1/Smad3 pathway

Yun-Cheng HSIEH, *Taiwan*

FRI-263 Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients

Zeynep MELEKOĞLU ELLIK, *Turkey*

FRI-264 Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis

Top 10%

Zobair M. YOUNOSSI, *United States*

Imaging & drug targeting

- FRI-265** **Contrast-enhanced ultrasound algorithms for the non-invasive diagnosis of hepatocellular carcinoma in high-risk patients – a prospective multicentre study (DEGUM-CEUS HCC trial)**
Top 10%
YI
 Barbara SCHELLHAAS, *Germany*
- FRI-266** **Simultaneous multislice accelerated breath-holding diffusion weighted imaging of the liver using double air coils: comparison to standard diffusion weighted imaging**
 Yedaun LEE, *Korea, Rep. of South*
- FRI-267** **Evidence-based dilemma in the image-guided therapeutic management of uncomplicated amoebic liver abscess: a systematic review and meta-analysis**
 Ramesh KUMAR, *India*
- FRI-268** **Complementary role of computed tomography texture analysis for differentiation of hepatocellular carcinoma from intrahepatic peripheral cholangiocellular carcinoma on single portal-venous phase computed tomography**
YI
 Kaspar EKERT, *Germany*
- FRI-269** **Ph-responsive polymersomes for matrix metalloproteinase-1 delivery as a promising therapeutic strategy for the treatment of liver fibrosis**
YI
 Eline GEERVLIJT, *Netherlands*
- FRI-270** **Diagnostic value of magnetic resonance elastography in cirrhotic portal hypertension**
 Guanhua ZHANG, *China*
- FRI-271** **Prognostic value of spleen volume obtained from preoperative computed tomography images in patients with hepatocellular carcinoma**
 Jae Seok BAE, *Korea, Rep. of South*
- FRI-272** **Predicting prognosis of hepatocellular carcinomas according to treatments by using hepatobiliary phase images of gadoxetic acid-enhanced magnetic resonance imaging**
Top 10%
 Jae Seok BAE, *Korea, Rep. of South*
- FRI-273** **Kahweol activates Nrf2/HO-1 by a pathway different from p62 and autophagy dependent degradation**
 Byoung Kuk JANG, *Korea, Rep. of South*
- FRI-274** **Role of Kupffer phase image using sonazoid on CEUS LI-RADS® and diagnostic performance for hepatocellular carcinoma**
Top 10%
 Jeong Ah HWANG, *Korea, Rep. of South*
- FRI-275** **Impact of contrast-enhanced ultrasound on detection of colorectal liver metastases and therapeutic strategy in patients with newly diagnosed colorectal carcinoma after staging with computertomography. A prospective cohort study**
Top 10%
 Mikael SAWATZKI, *Switzerland*

Rare liver diseases (including pediatric and genetic)

- FRI-276** **YI** **The phenotype of compound heterozygous BSEP deficiency patients is determined by the combined residual function of the two ABCB11 mutations: results from the NAPPED consortium**
 Antonia FELZEN, *Netherlands*
- FRI-277** **Top 10%** **YI** **Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease**
 Alvaro SANTOS-LASO, *Spain*
- FRI-278** **Persistently low platelet count and splenomegaly after treatment with oxaliplatin as markers of development of portal sinusoidal vascular disease**
 Angela PUENTE SANCHEZ, *Spain*
- FRI-279** **Cross-talk between regulation of iron homeostasis and gluconeogenesis in a murine model of hereditary hemochromatosis**
 Elena BUZZETTI, *Italy*
- FRI-280** **Custom-designed next generation sequencing panel for genotype identification in cholestasis**
 Carola DRÖGE, *Germany*
- FRI-281** **YI** **ABCB4/MDR3 gene mutations in young patients with symptomatic cholelithiasis**
 Catarina GOUVEIA, *Portugal*
- FRI-282** **YI** **Efficacy of zinc on human hepatic copper uptake depending on zinc type and dose regimen quantified with 64-CuCl2 PET/CTscan**
 Ditte Emilie MUNK, *Denmark*
- FRI-283** **YI** **High burden of future liver disease in intrahepatic cholestasis of pregnancy patients**
 Erica MONROSE, *United States*
- FRI-284** **YI** **Impact of nitisinone treatment and discontinuation on the metabolome of wild type and hereditary tyrosinemia type 1 mice**
 Haaike COLEMONT-SVRONINKS, *Belgium*
- FRI-285** **Top 10%** **Prognosis in persons with an HFE-mutation: population-based cohort study of 3,645 individuals**
 Hannes HAGSTRÖM, *Sweden*
- FRI-286** **YI** **Cracking the notch code in alagille syndrome: single-cell receptor-ligand interactions and outcomes in vivo, and an emerging role of immune cells**
 Jan MAŠEK, *Sweden*
- FRI-287** **Top 10%** **Real-world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy**
 Jan STANGE, *United States*

- FRI-288** **Liver ultrasonic transient elastometry (fibrosan (r)) in hepatic amyloidosis: results of a multicenter cohort of 26 cases**
Jean-françois CADRANEL, *France*
- FRI-289** **Directed protein evolution as a tool to innovate gene therapy for hereditary tyrosinemia type 1**
Jessie NEUCKERMANS, *Belgium*
- FRI-290** **Hospitalization rates of Budd Chiari syndrome in the United States**
Joseph ALUKAL, *United States*
- FRI-291** **Health care burden and in-hospital mortality of BCS in the United States between 1998 and 2016**
Joseph ALUKAL, *United States*
- FRI-292** **Genome-wide protective variants in MARC1 and HSD17B13 are associated with reduced inflammation and lower fibrosis stage on biopsy in children with NAFLD**
Top 10%
Jake MANN, *United Kingdom*
- FRI-293** **Non-invasive screening for liver fibrosis by acoustic radiation force impulse in patients with ciliopathies**
YI
Johanna BRESCH, *Germany*
- FRI-294** **Cholestatic phenotype of a mouse model for organic solute transporter ? (OST?/SLC51B) deficiency suggest a role of the beta subunit beyond an OST? chaperone**
Top 10%
Stan VAN DE GRAAF, *Netherlands*
- FRI-295** **Comparative pharmacokinetic profile of two distinct trientine salt formulations used for treatment of Wilson's disease**
Karl Heinz WEISS, *Germany*
- FRI-296** **Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency**
Top 10%
Kenneth SETCHELL, *United States*
- FRI-297** **Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (Pi*MZ genotype)**
Top 10%
YI
Karim HAMESCH, *Germany*
- FRI-298** **Customized xenograft model development: liver repopulation of FRG® KO mice with primary hepatocytes from donors carrying specific genetic variants**
Lander FOQUET, *United States*
- FRI-299** **Alpha-1-antitrypsin deficiency liver disease: patients lost in the system**
YI
Maria Angeles RUIZ-RAMIREZ, *Spain*

Rare liver diseases (including pediatric and genetic) (*Cont.*)

- FRI-300** **Neurodegenerative patterns in Wilson's disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging**
YI Marlene PANZER, *Austria*
- FRI-301** **Liver transplantation for acute intermittent porphyria in Europe**
Mattias LISSING, *Sweden*
- FRI-302** **Magnetic resonance iron quantification facilitates venesection decision making in iron overload**
YI Meha BHUVA, *United Kingdom*
- FRI-303** **Major depressive disorder in patients with Wilson's disease: relationship with liver disease, neurological disease and quality of life**
YI Michelle CAMARATA, *United Kingdom*
- FRI-304** **Mortality in patients with Wilson's disease in England: a national register-based study**
YI Michelle CAMARATA, *United Kingdom*
- FRI-305** **Survival in HFE hemochromatosis: influence of polymorphisms in HSD17B13, GNPAT, and PCSK7**
Moritz TOBIASCH, *Austria*
- FRI-306** **Analysis of survival and influence of genetic modifiers in HFE- and non-HFE-associated iron overload**
Moritz TOBIASCH, *Austria*
- FRI-307** **Validation of the new proposed histological criteria for the diagnosis of porto-sinusoidal vascular disease in a single tertiary center**
YI Oana NICOARA-FARCAU, *Romania*
- FRI-308** **Non-invasive diagnostic tools in porto sinusoidal vascular liver disease. A pilot study**
YI Oana NICOARA-FARCAU, *Romania*
- FRI-309** **Simplification of Wilson's disease maintenance therapy with a single daily dose: safety and efficacy in difficult to treat patients**
Olivier GUILLAUD, *France*
- FRI-310** **A phase 1/2 open label extension study of givosiran, an investigational RNAi therapeutic, in patients with acute intermittent porphyria**
Penelope STEIN, *United Kingdom*
- FRI-311** **Good clinical outcomes after direct intrahepatic portocaval stent (DIPS) insertion for Budd-Chiari syndrome**
Rosemary FAULKES, *United Kingdom*

- FRI-312** **Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group**
 Shannon M. VANDRIEL, *Canada*
Top 10%
YI
- FRI-313** **Proteolytic immuno-srm-ms/ms analysis of ATP7b in dried blood spots: a potential application for the screening and diagnosis of Wilson's disease**
 Sihoun HAHN, *United States*
- FRI-314** **Wilson's disease: epidemiologic and therapeutic insights from German hospital and ambulatory invoicing data**
 Steffen WAHLER, *Germany*
- FRI-315** **The role of liver stiffness by ARFI elastography in the diagnosis of porto-sinusoidal vascular disease: comparison with patients with chronic portal vein thrombosis**
 Stefania GIOIA, *Italy*
YI
- FRI-316** **Elevated serum bile acid and alanine aminotransferase concentrations in intrahepatic cholestasis of pregnancy are associated with increased fetal NT-proBNP which is ameliorated by ursodeoxycholic acid treatment**
 Tharni VASAVAN, *United Kingdom*
Top 10%
YI
- FRI-317** **Penetrance, cancer incidence and survival of hemochromatosis in a long-term follow-up and epidemiological modelling study**
 Thomas KALLAB, *Austria*
Top 10%
YI
- FRI-318** **Prevalence and characteristics of cystic fibrosis associated-liver disease in a cohort of cystic fibrosis patients**
 Zaina ISSA, *Belgium*
YI
- FRI-319** **Liver cirrhosis development and value of transient elastography among a large cohort of Wilson's disease patients with a long-term follow-up in Spain**
 Zoe MARIÑO, *Spain*

Nurses and Allied Health Professionals research hepatology

- FRI-320** **Employment after liver transplantation and contributing factors**
YI Anna VAN DEN BURG, *Netherlands*
- FRI-321** **Development of a district general hospital liver nurse service for patients with acute and chronic liver conditions**
Top 10% Amy THATCHER, *United Kingdom*
YI
- FRI-322** **Managing decompensated cirrhosis – the importance of multidisciplinary engagement**
Dev KATAREY, *United Kingdom*
- FRI-323** **The first step towards comprehensive nurse-led hepatology care: evolution of the Hull specialist liver nurse service (SLNS)**
Top 10% Dianne BACKHOUSE, *United Kingdom*
YI
- FRI-324** **Prospective study of therapeutic education (TE) designed with a multidisciplinary team and participation of patients to improve the adherence to treatment of the patients and their quality of life (QOL)**
Dominique LARREY, *France*
- FRI-325** **Hepatitis B testing in Bcr-Abl tyrosine kinase inhibitor therapy**
YI Fatema JESSA, *United Kingdom*
- FRI-326** **Impact of a nurse educational program for patient empowerment during sequential systemic therapy for hepatocellular carcinoma**
YI Gemma ISERTE, *Spain*
- FRI-327** **Treatment with sorafenib on hepatocellular carcinoma -10 years' experience in a nursing-led outpatient clinic**
Gordana GRUJCIC, *Sweden*
- FRI-328** **Pilot of an advanced liver disease nurse education program and its intersection with emerging models of advanced hepatology nursing practice**
Janice PRITCHARD-JONES, *Australia*
- FRI-329** **Diet lifestyle management of non-alcoholic fatty liver disease (NAFLD): a cross-sectional survey of clinicians**
YI Laura HAIGH, *United Kingdom*
- FRI-330** **Development of clinical professional standards for liver transplant nursing**
Michelle CLAYTON, *United Kingdom*
- FRI-331** **Nurse assisted follow-up after admission with decompensation in cirrhosis: a systematic review and meta-analysis**
YI Malene BARFOD O'CONNELL, *Denmark*

FRI-332 **Prospective evaluation of a non-alcoholic fatty liver disease assessment pathway; impact of clinical nurse specialist role**

Marie MCGRATH, Ireland

FRI-333 **Illustrations supporting patient counseling before and after liver transplantation**

Patrizia KUENZLER-HEULE, *Switzerland*

Poster – FRI-001 – FRI-520

Immunology except viral hepatitis

- FRI-334 Soluble CEACAM1 induces regulatory T cells in vitro**
Andrea HORST, *Germany*
- FRI-335 Activity of pyruvate kinase M2 regulates T cell polarization**
Andrea HORST, *Germany*
- FRI-336 Innate chemokine (C-C motif) ligand 3-expressing cells control early murine cytomegalovirus infection**
Fernando MAGDALENO, *Germany*
- FRI-337 The alarmin IL-33 drives a ST2+ Treg-mediated anti-inflammatory immune response during immune-mediated hepatitis**
Top 10%
Katrin NEUMANN, *Germany*
- FRI-338 Plasmacytoid dendritic cells protect against acute liver injury via IL-35**
Yuzo KODA, *Japan*
- FRI-339 Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma**
Luigi BUONAGURO, *Italy*
- FRI-340 High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients.**
Maria TAGLIAMONTE, *Italy*
- FRI-341 Myeloid derived suppressor cells enhance regulatory T cell suppressive activity via IL-10, iNOS and PDL-2 in cirrhotic patients with sepsis**
YI
Rashi SEHGAL, *India*
- FRI-342 Neutrophils are recruited at the periportal area in alcoholic liver disease and promote ductular reaction expansion**
YI
Silvia ARIÑO MONS, *Spain*
- FRI-343 Obeticholic acid suppresses expansion of hepatic immune cell populations in a diet-induced obese and biopsy-confirmed model of non-alcoholic steatohepatitis**
Sanne VEIDAL, *Denmark*
- FRI-344 Drug screening against complement disorders using human stem cell-derived endothelium and liver organoids**
Yasunori NIO, *Japan*
- FRI-345 Polarization of tissue-resident Tph cells by exosomal IL-10 in hepatocellular carcinoma bridges naive B cell inflammation and regulatory B cell polarization**
YI
Linsen YE, *China*
- FRI-346 Immune cells restricted C/EBPbeta deficiency is associated with distorted hepatic mononuclear phagocytes composition, weight loss and spontaneous hepatitis**
Ehud ZIGMOND, *Israel*

Viral Hepatitis A, B, C, D, E: Immunology

- FRI-347**
YI **Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis**
Qirong JIANG, *China*
- FRI-348**
YI **Entecavir-induced interferon-lambda 1 suppresses innate lymphoid cells 2 in patients with hepatitis B virus-related liver cirrhosis**
Siqi WANG, *China*
- FRI-349**
Top 10% **A new therapeutic candidate vaccine can overcome hepatitis B virus-induced immune tolerance in a mouse model of chronic infection**
Babak BAYAT, *Belgium*
- FRI-350** **Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod**
Diana CHEN, *United States*
- FRI-351** **Immunogenicity and efficacy of an HBV vaccine with an intrinsic checkpoint inhibitor**
Hildegund ERTL, *United States*
- FRI-352** **Extracellular HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV pathogenesis**
Valeria FUMAGALLI, *Italy*
- FRI-353** **Analysis of regulatory T cells frequency and phenotype in chronic hepatitis C patients undergoing interferon-free therapies**
George KOUTSODAKIS, *Spain*
- FRI-354** **Characterization of the HBV-specific T cell pool reveals shared epitope usage but different phenotypes of HBV-reactive T cells across patients**
Hassen KARED, *Singapore*
- FRI-355**
YI **Hepatitis B virus kinetics after nucleos(t)ide-analogue withdrawal in chronic HBeAg(-) hepatitis correlates with HBV-specific CD8+ response and HBsAg level**
Julia PEÑA ASENSIO, *Spain*
- FRI-356**
YI **Interleukin-15 restores the reactivity of the peripheral memory-like pool in the exhausted hepatitis B virus-specific CD8+ T cell population during persistent HBeAg(-) infection**
Julia PEÑA ASENSIO, *Spain*
- FRI-357**
YI **Hepatitis B virus-specific CXCR5+ CD8+ T cells may be related to hepatitis B virus clearance in chronic hepatitis B patients treated with pegylated interferon alpha**
Li ZHANG, *China*

Viral Hepatitis A, B, C, D, E: Immunology (*Cont.*)

- FRI-358** **Hepatitis B virus-specific CXCR5+ CD8+ T cells shows stronger functional activity in a mouse model of acute hepatitis B virus infection**
YI Li ZHANG, *China*
- FRI-359** **Hepatitis D coinfection is associated with enhanced CXCR3 receptor expression of CD4 memory T cells and intrahepatic CXCR3 ligand expression compared to chronic hepatitis B patients.**
Jan-Hendrik BOCKMANN, *Germany*
- FRI-360** **Magnitude and functionality of HEV-specific CD8+ and CD4+ T cell responses in asymptomatic blood donors resemble those in acute and symptomatic patients**
YI Janine KEMMING, *Germany*
- FRI-361** **Peripheral soluble protein, transcriptomic, and methylation biomarkers associated with HBsAg loss in patients with chronic hepatitis B**
Jeffrey WALLIN, *United States*
- FRI-362** **Tox expression on HBV-specific CD8+ T cells is linked to clinical stage of chronic HBV infection**
YI Kathrin HEIM, *Germany*
- FRI-363** **Antigen modulation and re-activation of anti-viral immunity lead to control of chronic hepatitis B virus infection**
YI Katrin MANSKE, *Germany*
- FRI-364** **Distinct serum HBsAg levels show minimal effect on gene expression profiles of blood leukocyte subpopulations in non-viremic chronic HBV patients.**
YI Noé Axel MONTANARI, *Netherlands*
- FRI-365** **Hepatitis C virus chronicity is associated with a tox-1(high), Eomes(high), T-bet(dim) and PD1(high) phenotype of HCV-specific CD8+ T cells**
YI Nils WILDNER, *Germany*
- FRI-366** **Targeting dysregulated intracellular signaling pathways can restore anti-viral HBV-specific T cell responses in chronic hepatitis B**
Paola FISICARO, *Italy*
- FRI-367** **Profiles of expression of costimulatory molecules OX40 and OX40I in PBMCs and levels of soluble OX40/OX40I in plasma in chronic hepatitis B patients and health subjects**
Mengru ZHAN, *China*

- FRI-368** **Phenotypic variation among myeloid-derived suppressor cells (MDSC) in natural history phases of chronic HBV infection differentially impacts HBV-specific T cell response and homing: lack of functional normalization after anti-viral therapy**
Sourina PAL, *India*
- FRI-369** **Integrated analysis of serum immunological biomarkers in patients with chronic hepatitis C upon direct-acting antiviral treatment**
Rosângela TEIXEIRA, *Brazil*
- FRI-370** **Higher proportion of responders with hepatitis B antibody levels ≥ 100 mIU/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)**
Timo VESIKARI, *Finland*
- FRI-371** **Hepatocyte-derived l-carnitine impedes HBsAg clearance in chronic HBV infection**
Yongyin LI, *China*
- FRI-372** **Interferon alpha-induced CXCL13 and IL-6 from intrahepatic monocytes facilitate HBV antigen seroconversion in chronic HBV infection**
Yongyin LI, *China*

Viral hepatitis B/D: Clinical aspects except therapy

- FRI-373** **Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy**
Alkistis Maria PAPTAEODORIDI, *Greece*
- FRI-374** **Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response?**
Antonella OLIVERO, *Italy*
- FRI-375** **Comparison of the risk of hepatocellular carcinoma in nucleos(t)ide analogue-naïve chronic hepatitis B patients treated with entecavir versus tenofovir : a systematic review and meta-analysis**
Hyunwoo OH, *Korea, Rep. of South*
- FRI-376** **Is it possible to stop nucleos(t)ide analogue safely in patients with preemptive or preventive therapy for HBV reactivation?**
Akihiro TAMORI, *Japan*
- FRI-377** **Hepatocellular carcinoma risk steadily persists over time despite long-term antiviral therapy for hepatitis B: a multicenter study**
Beom Kyung KIM, *Korea, Rep. of South*
- FRI-378** **Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era**
David KAPLAN, *United States*
- FRI-379** **Excess body weight is associated with HBV-related HCC despite antiviral treatment**
Jian SUN, *China*
- FRI-380** **Commonly used non-invasive markers do not reliably predict liver fibrosis in those patients of chronic hepatitis B who really need it: a prospective multi-centre study**
Akash SHUKLA, *India*
- FRI-381** **Evaluation of dried plasma spot on the cobas(r) plasma separation card as a sample type for hepatitis B virus load quantification on the cobas(r) 6800 system**
Ed G. MARINS, *United States*
- FRI-382** **Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years**
Enrico GALMOZZI, *Italy*

- FRI-383** **PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy**
George PAPTAEODORIDIS, *Greece*
- FRI-384** **Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection**
Tetsuya HOSAKA, *Japan*
- FRI-385** **Plasma adipocyte fatty acid-binding protein and adiponectin levels are associated with fibrosis regression in nucleoside analogue-treated chronic hepatitis B: a prospective study with paired transient elastography**
Rex Wan-Hin HUI, *Hong Kong*
- FRI-386** **Higher pregnancy hbcrag and pg HBV RNA concentrations are observed in treated and untreated chronic hepatitis B mothers with post-partum alt flares**
Ivana CAREY, *United Kingdom*
- FRI-387** **Gender disparity in the association of interleukin-10 and interleukin-12 polymorphisms with the progression of hepatitis B virus infection in Caucasians**
Janett FISCHER, *Germany*
- FRI-388** **Association between quantitative hepatitis B virus core antibody levels and surface antigen in chronic low viraemic patients**
YI
Jing LI, *China*
- FRI-389** **Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure – results from a territory-wide Hong Kong ibd registry study**
YI
Joyce Wing Yan MAK, *Hong Kong*
- FRI-390** **Sarcopenia is associated with type 2 diabetes and sedentary lifestyle in patients with chronic hepatitis B**
Luciana DINIZ SILVA, *Brazil*
- FRI-391** **Incidence of young-onset hepatocellular carcinoma in young adults with chronic hepatitis B virus infection: potential implication for surveillance**
YI
Myung Ji GOH, *Korea, Rep. of South*
- FRI-392** **Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B**
Mamta JAIN, *United States*
- FRI-393** **Rituximab monotherapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation**
Mar RIVEIRO BARCIELA, *Spain*

Viral hepatitis B/D: Clinical aspects except therapy (Cont.)

- FRI-394** **Not uncommon: HBV genotype g co-infection in HBeAg-negative chronic HBV infected patients**
Michael BASIC, *Germany*
- FRI-395** **Poor improvement of on-treatment FIB-4 index after initiation of nucleos(t)ide analogs is associated with development of hepatocellular carcinoma in both cirrhotic and non-cirrhotic chronic hepatitis B patients**
Miyako MURAKAWA, *Japan*
- FRI-396** **The integrated use of accurate virological and serological HBV markers can help identifying HBsAg-negative/anti-HBc -positive patients at higher risk of HBV-reactivation and optimizing the duration of prophylaxis in oncohematological setting**
Mohammad ALKHATIB, *Italy*
- FRI-397** **A comparative study of risks for hepatocellular carcinoma and mortality in chronic hepatitis B patients initially treated with entecavir or tenofovir**
Eileen YOON, *Korea, Rep. of South*
- FRI-398** **Reverse transcriptase droplet digital PCR versus reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification**
Natthaya CHUAYPEN, *Thailand*
- FRI-399** **Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium**
Özgür KOC, *Belgium*
- FRI-400** **Three HBsAg kinetic profiles in HBeAg negative infection and chronic hepatitis are associated with different chances of HBsAg clearance**
Piero COLOMBATTO, *Italy*
- FRI-401** **Impact of HBV infection in HCV/HBV coinfecting patients treated with DAAs in north Italy**
Paolo FABRIS, *Italy*
- FRI-402** **Quantitative HBeAg varies in the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation**
Lorenzo PIERMATTEO, *Italy*
- FRI-403** **Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B**
Qi HUANG, *United States*
- FRI-404** **Very low rates of receiving antiviral therapy among treatment eligible chronic hepatitis B virus infected patients**
Robert WONG, *United States*

- FRI-405** **Impact of hepatitis B virus-related immune reconstitution inflammatory syndrome on HBsAg loss in patients co-infected with human immunodeficiency virus**
Sachiyo YOSHIO, *Japan*
- FRI-406** **Response to a double dose (40 mcg) and an accelerated schedule (0-1-2 months) of hepatitis B vaccine in patients with advance cirrhosis. A prospective study**
Sergio RODRÍGUEZ-TAJES, *Spain*
- FRI-407** **Presence of significant histopathology in HBeAg-positive chronic infection patients identified by four international guidelines: a Chinese multi-center study**
Yidi JIA, *China*
- FRI-408** **Detectable HBV DNA during nucleos(t)ide analogues is useful for stratification of page-b predictive hepatocellular carcinoma risk score**
Shun KANEKO, *Japan*
- FRI-409** **Liver transplantation for hepatitis delta in the United States**
Tatyana KUSHNER, *United States*
- FRI-410** **Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy – a territory-wide study of 32,150 subjects**
Terry Cheuk-Fung YIP, *Hong Kong*
- FRI-411** **Clinical effectiveness of a newly developed and fully automated high-sensitive hepatitis B core-related antigen assay for monitoring nucleos(t)ide analogues therapy in hepatitis B envelope antigen-negative patients**
Takako INOUE, *Japan*
- FRI-412** **Clinical efficacy of a newly developed high-sensitive hepatitis B core-related antigen assay for monitoring hepatitis B virus reactivation**
Takako INOUE, *Japan*
- FRI-413** **Treatment advantage in HBV/HIV coinfection compared to HBV mono-infection in a South African cohort**
Tongai Gibson MAPONGA, *South Africa*
- FRI-414** **Clonal expansion of hepatocytes and state of hepatitis B virus DNA integration in patients with nucleos(t)ide analogue therapy**
Ning CHOW, *Hong Kong*
- FRI-415** **Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B**
Maximilian WÜBBOLDING, *Germany*

Viral hepatitis B/D: Clinical aspects except therapy (*Cont.*)

- FRI-416** **Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis**
YI
Yandi XIE, *China*
- FRI-417** **Prevalence of liver fibrosis in the natural course of chronic hepatitis B virus infection: a systematic review with meta-analysis**
Yan WANG, *China*
- FRI-418** **Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States**
Zobair YOUNOSSI, *United States*

Viral hepatitis C: Post SVR and long term follow up

- FRI-419** **Exaggerated risk of vitamin B12 deficiency after HCV eradication with direct-acting antivirals**
YI Diego CASAS DEZA, *Spain*
- FRI-420** **Risk of hepatocellular carcinoma recurrence in patients treated with direct acting antiviral therapy**
 Asmaa GOMAA, *Egypt*
- FRI-421** **Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy**
 Jisoo Amy KWON, *Australia*
- FRI-422** **HIV co-infection is associated with lower risk of liver cancer after HCV-cure**
YI Anaïs CORMA-GÓMEZ, *Spain*
- FRI-423** **Statins use corrects the impact of direct acting antiviral agents on lipid profile in hepatitis C virus patients**
YI Anna MANTOVANI, *Italy*
- FRI-424** **Medium-term outcomes of hepatitis C virus-infected patients with a sustained viral response according to albumin-bilirubin grade**
 Akihiro TAMORI, *Japan*
- FRI-425** **Identification of serum miRNAs whose expression were associated with and changed after HCV eradication**
 Atsumasa KOMORI, *Japan*
- FRI-426** **Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies**
YI Bernhard SCHEINER, *Austria*
- FRI-427** **The severity of biopsy-proven fibrosis and sustained virologic response determine long-term outcomes in patients with chronic hepatitis C virus infection**
 Soon Kyu LEE, *Korea, Rep. of South*
- FRI-428** **HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaICONA and PITER cohorts.**
 Roberto ROSSOTTI, *Italy*
- FRI-429** **Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DASSs-induced viral eradication**
YI Chiara MANULI, *Italy*

Viral hepatitis C: Post SVR and long term follow up (*Cont.*)

- FRI-430** **Development of hepatocellular carcinoma by patients aged 75 years or over after HCV elimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study**
Eiichi OGAWA, *Japan*
- FRI-431** **Deteriorated lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication**
Chung-Feng HUANG, *Taiwan*
- FRI-432** **Dynamic of cytokine profiles predicts risk of HCC among HCV patients with advanced fibrosis after successful antiviral therapy**
Ming-Lung YU, *Taiwan*
- FRI-433** **Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis**
YI
Giordano SIGON, *Italy*
- FRI-434** **Direct-acting antivirals improve treatment outcomes in patients with chronic hepatitis C-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study**
YI
Hye Kyung HYUN, *Korea, Rep. of South*
- FRI-435** **Patients treated for hepatitis C: an observational study with the French administrative healthcare database (SNDS)**
Ingrid RODRIGUEZ, *France*
- FRI-436** **Role of pre- and post-treatment transient elastography measurements in predicting hepatocellular carcinoma (HCC) among hepatitis C patients treated with direct acting antivirals (DAAs)**
Jacob CHARETTE, *Canada*
- FRI-437** **Non-invasive tests predict the risk of hepatocellular carcinoma in hepatitis C patients after sustained virological response: impact on HCC surveillance**
YI
Javier AMPUERO, *Spain*
- FRI-438** **Reinfection with hepatitis C following cure: results from the TraP Hep C program in Iceland – a prospective nationwide, population-based study**
Jon M JOHANNESSON, *Iceland*
- FRI-439** **Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma**
Frank JÜHLING, *France*
- FRI-440** **Simple blood test criteria for non-cirrhosis plus age and post-treatment AFP rule-out the risk of hepatocellular carcinoma development after SVR**
Masayuki KUROSAKI, *Japan*

- FRI-441** **Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir**
Laura TELEP, *United States*
- FRI-442** **The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort**
Top 10%
Loreta KONDILI, *Italy*
- FRI-443** **Clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus**
YI
Marco DI PETRILLO, *Italy*
- FRI-444** **Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis**
Marie-laure PLISSONNIER, *France*
- FRI-445** **Impact on health perception, quality of life and labor productivity of antiviral treatment for hepatitis C in patients without significant fibrosis**
Matias ESTEVEZ, *Spain*
- FRI-446** **Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease**
YI
Mattias MANDORFER, *Austria*
- FRI-447** **The one-year outcome of hepatitis B virus in Taiwanese patients with chronic hepatitis B and C co-infection after direct-acting antivirals**
Ming-Lun YEH, *Taiwan*
- FRI-448** **Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland**
YI
Madeleine CAVEN, *United Kingdom*
- FRI-449** **Hepatitis C virus eradication with direct-acting agents elevates the serum small dense low-density lipoprotein cholesterol level**
Naoyuki HINO, *Japan*
- FRI-450** **Influence of DAA treatment in patients with HCV-cirrhosis and esophageal varices on liver transplant free survival and risk of developing hepatocellular carcinoma**
YI
Noelia RODRÍGUEZ FERREIRO, *Spain*
- FRI-451** **Dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy**
Pisit TANGKIJVANICH, *Thailand*

Viral hepatitis C: Post SVR and long term follow up (*Cont.*)

- FRI-452** **Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis**
Rajender REDDY, *United States*
- FRI-453** **Hepatocellular carcinoma following direct acting antiviral therapy does not display an aggressive pattern: a prospective study**
YI
Reham SOLIMAN, *Egypt*
- FRI-454** **Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development**
YI
Riccardo NEVOLA, *Italy*
- FRI-455** **Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk**
Ruchi SHUKLA, *United Kingdom*
- FRI-456** **Post-treatment wisteria floribunda agglutinin-positive mac-2-binding protein is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication**
Shunsuke SATO, *Japan*
- FRI-457** **Eradication of HCV with direct-acting antivirals increased small LDL particle number in SVR48**
YI
Vanesa BERNAL MONTERDE, *Spain*
- FRI-458** **Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance**
Vincenza CALVARUSO, *Italy*
- FRI-459** **Partial restoration of brain structural and connectivity changes after HCV cure with direct acting antivirals (DAA)**
Zoe MARIÑO, *Spain*

Liver tumours: Experimental and pathophysiology

- FRI-460** **Glycogen synthase 2 (GYS2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocellular carcinoma**
YI Di WU, *China*
- FRI-461** **EIF4EBP3, methylated in gastric cancer, acts as a tumor suppressor restraining tumor proliferation and liver metastasis via targeting EIF4E/B-catenin axis**
YI Zhongjie LIN, *China*
- FRI-462** **Molecular characterization of hepatocellular carcinoma in Mongolia delineates unique genomic features**
Top 10% Marc PUIGVEHÍ, *Spain*
- FRI-463** **NK-cell dysfunction in hepatocellular carcinoma: modulatory approaches for functional restoration**
YI Alessandra ZECCA, *Italy*
- FRI-464** **Global characterisation of tumour infiltrate of intrahepatic cholangiocarcinoma by single cell sequencing**
Ana LLEO, *Italy*
- FRI-465** **New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma**
YI Anne OLBRICH, *Germany*
- FRI-466** **Ganglioside patterns in the human cholangiocarcinoma stem cell subset**
YI Benedetta PIOMBANTI, *Italy*
- FRI-467** **T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma**
Bertram BENGSCHE, *Germany*
- FRI-468** **Lactate promotes invasion and metastasis of hepatocellular carcinoma via changes in mitochondrial and histone acetylation**
Jianye CAI, *China*
- FRI-469** **Dysregulation of aquaporin-1 in human CCA cells triggers epithelial-mesenchymal transition**
YI César GASPARI, *Argentina*
- FRI-470** **Diagnostic performance of PIVKA-II in patients with hepatocellular carcinoma**
Claudio GALLI, *Italy*
- FRI-471** **TGF-beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers**
Top 10% Corentin LOUIS, *France*
YI

Liver tumours: Experimental and pathophysiology (Cont.)

- FRI-472** **Tracking neutrophils within the hepatocellular carcinoma microenvironment – development of relevant orthotopic and ex-vivo 3D liver-HCC culture models**
YI Daniel GEH, *United Kingdom*
- FRI-473** **Identification of PD-L1- expressing exosome-derived microRNAs in human hepatocellular carcinoma**
Yu Rim LEE, *Korea, Rep. of South*
- FRI-474** **Long interspersed nuclear element-1 (line-1) hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma**
Yu Rim LEE, *Korea, Rep. of South*
- FRI-475** **Tristetraprolin is a key driver of hepatic inflammation, fibrosis and cancer development in vivo**
Top 10% Dobrochna DOLICKA, *Switzerland*
YI
- FRI-476** **Identification of neoantigens as potential vaccines in hepatocellular carcinoma**
YI David REPARAZ, *Spain*
- FRI-477** **SIMBA: a user-friendly high-throughput tool for spheroid invasion analysis of hepatocellular carcinoma cell lines**
YI Elias VAN DE VIJVER, *Belgium*
- FRI-478** **Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology**
YI Ewald DOORNEBAL, *United Kingdom*
- FRI-479** **Macrophage autophagy protects against hepatocellular carcinoma by modulation of the hepatic immune microenvironment**
Fatima TEIXEIRA-CLERC, *France*
- FRI-480** **Platelet activation promotes carcinogenesis and tumor growth in hepatocellular carcinoma**
Top 10% Femke HEINDRYCKX, *Sweden*
YI
- FRI-481** **Blocking IRE1a-endoribonuclease activity in hepatic stellate cells decreases tumor cell proliferation and metastasis in hepatocellular carcinoma**
YI Femke HEINDRYCKX, *Sweden*
- FRI-482** **Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection**
Fukiko KAWAI-KITAHATA, *Japan*

- FRI-484** **TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma**
Zhouhong GE, *Netherlands*
- FRI-485** **Regulation of the biology of cholangiocarcinoma (CCA) cells by the extracellular-signal regulated kinase 5 (ERK5)**
Giulia LORI, *Italy*
- FRI-486** **Fatty acids regulate the biology of cholangiocarcinoma cells**
Giulia LORI, *Italy*
- FRI-487** **Circulating exosomal microRNA-125b inhibits metastasis of hepatocellular carcinoma**
Hye Seon KIM, *Korea, Rep. of South*
- FRI-488** **Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance**
Jiaye LIU, *Netherlands*
- FRI-489** **C-Rel is a novel tumour suppressor and early prognostic indicator of hepatocellular carcinoma development**
Jack LESLIE, *United Kingdom*
- FRI-490** **ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signaling between tumor cells and cancer-associated fibroblasts**
Javier VAQUERO, *Spain*
- FRI-491** **The role and mechanisms of high fat diet on the increased risk of hepatocellular carcinoma in hepatitis B virus transgenic mice**
Jaw-Ching WU, *Taiwan*
- FRI-492** **DNA damage response protein checkpoint kinase 2 (CHK2) links chromosomal instability to cellular metabolism in hepatocellular carcinoma (HCC)**
Krista ROMBOUTS, *United Kingdom*
- FRI-493** **Interplay of PNPLA and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients**
Carla DE BENEDITTIS, *Italy*
- FRI-494** **Alisporivir, a cyclophilin inhibitor, reduces fibrosis and tumor burden derived from non-alcoholic steatohepatitis in a mouse model**
Joseph KUO, *United States*
- FRI-495** **2-deoxy-D-glucose encapsulated PLGA nanoparticles suppress hepatocellular carcinoma through cytotoxic effect and activation of antitumor immunity**
Kyo SASAKI, *Japan*

Top 10%

Liver tumours: Experimental and pathophysiology (Cont.)

- FRI-496** **SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways**
Yao LIU, *China*
- FRI-497** **Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization**
Luca URBANI, *United Kingdom*
- FRI-498** **Interplay between O-GlcNAc transferase and enhancer of zeste homolog 2 in hepatocellular carcinoma**
Margot THIRION, *France*
- FRI-499** **The metabolic plasticity of neoplastic cholangiocytes: perspective for target therapy in intrahepatic cholangiocarcinoma.**
Michela Anna POLIDORO, *Italy*
- FRI-500** **Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma**
Mirella PASTORE, *Italy*
- FRI-501** **Engineering of immunosuppressant-resistant HBV-redirected TCR T cells for post-transplant HBV-HCC immunotherapy**
Morteza HAFEZI, *Singapore*
- FRI-502** **NEDD8 specific protease 1 (NEDP1) as a tumor suppressor in hepatocellular carcinoma**
Marina SERRANO-MACIA, *Spain*
- FRI-503** **Piddosome-controlled liver ploidy is predictive for HCC outcome**
Nataliya ROHR-UDILOVA, *Austria*
- FRI-504** **TERT promoter mutations and liver carcinogenesis: identification and quantification of mutation status by digital PCR analysis on formol-fixed paraffin-embedded samples**
Paisley SARAH, *France*
- FRI-505** **The role of insulin degrading enzyme in gender disparity of hepatocellular carcinoma progression and sorafenib response**
Yu PAN, *China*
- FRI-507** **A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis.**
Philipp LUTZ, *Germany*

- FRI-508** **Deleting in vivo beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or mesenchymal hepatoblastoma similarly to APC loss-of-function**
Robin LOESCH, *France*
- FRI-509** **Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1**
Top 10% Ruth BROERING, *Germany*
- FRI-510** **Natural killer cells target XP01: a therapeutic opportunity for HCC**
Salim KHAKOO, *United Kingdom*
- FRI-511** **Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma**
Top 10% Sanne VAN CAMPENHOUT, *Belgium*
- FRI-512** **TAK1 is a novel therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance**
Top 10% Shunjie XIA, *China*
- FRI-513** **Exposing the regulation of MDM2 expression by ADAR-mediated A-to-I editing in human hepatocellular carcinoma: application of a large-scale on-step predicting platform in oncology research**
Guangqi SONG, *China*
- FRI-514** **Androgen receptor sensitized sorafenib efficacy via enriched EPCAM stemness in hepatocellular carcinoma**
Top 10% Hsueh-Chou LAI, *Taiwan*
- FRI-515** **BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features**
YI Theo HIRSCH, *France*
- FRI-516** **PPEF2 suppresses hepatocellular carcinoma by inhibiting c-Myc signal pathway**
YI Nuoqing WENG, *China*
- FRI-517** **Transforming growth factor-beta and AXL causes neutrophil infiltration and activation of matrix metalloproteinase 2/9 in hepatocellular carcinoma**
Wolfgang MIKULITS, *Austria*
- FRI-519** **Intracellular retention of HBV contributes to mitochondrial energy deprivation, lipid metabolism disorders and Warburg effect in HBV-associated HCC**
Jenny Yuh-Jin LIANG, *Taiwan*
- FRI-520** **T cell exhaustion dynamics are linked to clinical outcomes in hepatocellular carcinoma**
YI Zhen ZHANG, *Germany*

POSTERS

SAT-001 – SAT-520

Poster programme version as of 10.04.2020



NAFLD: Experimental and pathophysiology

- SAT-001**
YI **Lipoprotein lipase deletion induces a proinflammatory phenotype in liver-infiltrating monocytes during non-alcoholic steatohepatitis**
Anja KOOP, *Germany*
- SAT-002**
A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis
Anita M. VAN DEN HOEK, *Netherlands*
- SAT-003**
YI **Aberrant hepatic protein tyrosine phosphatase receptor type delta expression is a driver of metabolic liver disease**
Armando Andres ROCA SUAREZ, *France*
- SAT-004**
Top 10%
YI **LncRNA-H19 as a marker of liver progression from steatosis to hepatocellular carcinoma**
Ángela ROJAS, *Spain*
- SAT-005**
YI **The lipid composition of the liver: assessing differences in obese patients with and without non-alcoholic steatohepatitis**
Anna HERNÁNDEZ-AGUILERA, *Spain*
- SAT-006**
YI **AXL inhibition prevents NAFLD progression in mice with soluble AXL as marker of the NAFLD to NASH transition**
Anna TUTUSAUS, *Spain*
- SAT-007**
Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model
Archana VIJAYAKUMAR, *United States*
- SAT-008**
PBI-4050 restores liver and adipose tissue metabolic homeostasis, and decreases fibrosis in a high-fat-diet mouse model of non-alcoholic fatty liver disease
Brigitte GROUX, *Canada*
- SAT-009**
YI **Adipose tissue macrophages acquire a pro-inflammatory phenotype which is associated to liver fibrogenesis in an experimental model of NAFLD in mice**
Celia MARTÍNEZ SÁNCHEZ, *Spain*
- SAT-010**
Top 10%
Intermittent hypoxia featuring the obstructive sleep apnea syndrome contributes to hepatosteatosis by upregulating the intrahepatic expression of fatty acid translocase CD36 and lipogenic genes
Carmelo GARCIA-MONZON, *Spain*
- SAT-011**
The symbiotic supplementation modulate gut microbiota, regulation beta-catenin expression and prevents weight gain in ob/ob mice with non-alcoholic fatty liver disease (NAFLD)
Claudia OLIVEIRA, *Brazil*

- SAT-012** **Treatment with the endothelin receptor inhibitor bosentan alleviates the NAFLD-associated increased intrahepatic vascular resistance and reduces steatosis and liver damage in a rat model of early NAFLD**
Denise VAN DER GRAAFF, *Belgium*
- SAT-013** **Liver sinusoidal endothelial cell-specific RUNX-1 gene knockdown decreases hepatic inflammation and myeloid cells infiltration in pre-clinical animal models non-alcoholic steatohepatitis**
Dinesh Mani TRIPATHI, *India*
- SAT-014** **Identification of novel biomarkers and therapeutic targets for steatohepatitis and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD): an in silico analysis**
Douglas MAYA-MILES, *Spain*
- SAT-015** **Liver-chip: a model for understanding diet-induced liver disease and drug efficacy assessment**
Dwayne CARTER, *United States*
- SAT-017** **Propionate intervention attenuates NASH while negatively affecting cognition**
Eveline GART, *Netherlands*
- SAT-018** **A shortcut from non-alcoholic fatty liver disease to HCC: c-Myc, a promising theranostic target**
Feifei GUO, *Spain*
- SAT-019** **Sex differences of adipose tissue dynamic changes in NASH progression of morbid obese patients: a preliminary study**
Gerard BAIGES, *Spain*
- SAT-020** **Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of non-alcoholic fatty liver disease (NAFLD)**
Giovanni DI MAIRA, *Italy*
- SAT-021** **MicroRNAs involved in the progression of non-alcoholic fatty liver**
Guillermo Nahúm LÓPEZ-SÁNCHEZ, *Mexico*
- SAT-022** **Simultaneous intra-operative sampling from multiple anatomical sites reveals pro-inflammatory liver homing T cells in liver, adipose tissue and peripheral blood in patients with NASH**
James BRINDLEY, *United Kingdom*
- SAT-023** **The influence of obesity, non-alcoholic steatohepatitis and bariatric surgery on plasma lipid profile**
Helena CASTAÑÉ, *Spain*
- SAT-024** **Growth differentiation factor 11 promotes progression of non-alcoholic fatty liver disease**
Jan FRÖHLICH, *Czech Republic*

NAFLD: Experimental and pathophysiology (*Cont.*)

- SAT-025** **The influence of TRPM8 variant on brown adipose tissue activity and contribution to increased susceptibility to non-alcoholic fatty liver disease among South Asians**
Jane GROVE, *United Kingdom*
- SAT-026** **Combinatorial effect of ezetimibe and empagliflozin in non-alcoholic fatty liver disease in a mouse model and a liver organoid for disease modeling of hepatic steatosis**
YI
Dongyun KIM, *Korea, Rep. of South*
- SAT-027** **Deviations of the peripheral blood and intrahepatic immune cell landscape between NAFLD patients and healthy controls**
Top 10%
Julian SCHULZE ZUR WIESCH, *Germany*
- SAT-028** **High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity**
YI
Katherine JOHNSON, *United Kingdom*
- SAT-029** **Ageing causes lipid metabolism imbalance and exacerbates steatohepatitis in high-fat diet-fed mice**
Kazuyoshi KON, *Japan*
- SAT-030** **Assessment of the utility of soluble CD14 in discriminating non-alcoholic steatohepatitis in the early stage of fibrosis from non-alcoholic fatty liver disease**
Kenichi MORIKAWA, *Japan*
- SAT-031** **Genome-wide in vivo functional genetic screen to identify novel modulators of non-alcoholic fatty liver disease**
Top 10%
YI
Puja KHANNA, *Singapore*
- SAT-032** **Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model**
Kevin KLUCHER, *United States*
- SAT-033** **Cognitive dysfunction occurs early in experimentally induced NAFLD and is associated with systemic inflammation**
Kristoffer KJÆRGAARD, *Denmark*
- SAT-034** **Thr B-selective agonist MGL-3196 improves NAS score and plasma lipoprotein profile in the liver-humanized FRGN KO NASH model**
YI
Lander FOQUET, *United States*
- SAT-035** **TM6SF2/PNPLA3/MBOAT7 loss-of function genetic variants impact on NAFLD development and progression both in patients and in in vitro models**
Top 10%
YI
Miriam LONGO, *Italy*

- SAT-036** **Enhancing autophagy improves and slows the progression of non-alcoholic steatohepatitis disease**
YI Maria RUART, *Spain*
- SAT-037** **The PSRC1 rs599839 A>G variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients**
Top 10%
YI Marica MERONI, *Italy*
- SAT-038** **The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH**
Top 10%
 Marie O'FARRELL, *United States*
- SAT-039** **SERPINB3 inhibition as a novel target therapy for non-alcoholic steatohepatitis**
Top 10%
YI Andrea MARTINI, *Italy*
- SAT-040** **Metabolism of human liver on a genome scale in non-alcoholic fatty liver disease**
 Matej OREŠIČ, *Sweden*
- SAT-041** **Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease**
YI Marta B. AFONSO, *Portugal*
- SAT-042** **A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models**
 Mary CHAU, *United States*
- SAT-043** **Kupffer cell depletion and breakage of TLR4-mediated hepatic tolerance drive susceptibility to injury and infections in the early phases of non-alcoholic fatty liver disease**
Top 10%
 Gustavo MENEZES, *Brazil*
- SAT-044** **Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice**
YI Michihiro IWAKI, *Japan*
- SAT-045** **The role of RIPK3 in non-alcoholic fatty liver disease: a multi-omics perspective**
YI Miguel MATEUS-PINHEIRO, *Portugal*
- SAT-046** **Muscle fat is higher in NAFLD, and increases with fibrosis stage – a retrospective liver biopsy controlled magnetic resonance imaging-based body composition study**
 Mikael FORSGREN, *Sweden*

NAFLD: Experimental and pathophysiology (*Cont.*)

- SAT-047** **Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice**
YI Mikhail VAN HERCK, *Belgium*
- SAT-048** **Synergic effect of a combined treatment with atorvastatin and ambrisentan in a rat model of NASH**
Top 10% Miren BRAVO, *Spain*
YI
- SAT-049** **Obesity and non-alcoholic steatohepatitis: assessing lipid diversity in adipose tissue**
Top 10% Montserrat FIBLA SIMÓ, *Spain*
- SAT-050** **N1-methylnicotinamide ameliorates hepatic steatosis through not only sirtuin activation but also modulation of bile acid metabolism and microbiota**
 Shusuke MORIZONO, *Japan*
- SAT-051** **Blocking IL-1 signaling in hepatocytes undergoing metabolic stress protects against metabolic inflammation and attenuates pro-coagulant factors**
 Nadine GEHRKE, *Germany*
- SAT-052** **Monocyte chemoattractant protein-induced protein 1 level negatively correlates with steatosis in fatty liver patients**
YI Natalia PYDYN, *Poland*
- SAT-053** **Ultrastructural changes in perfusion-fixed human non-alcoholic fatty liver disease biopsies**
YI Pauline VERHAEGH, *Netherlands*
- SAT-054** **mIR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD**
YI Pedro Miguel RODRIGUES, *Spain*
- SAT-055** **Inhibition of autotaxin-lysophosphatidic acid signaling pathway by a novel autotaxin inhibitor FP10.47 ameliorates non-alcoholic steatohepatitis in vivo**
Top 10% Richell BOOIJINK, *Netherlands*
YI
- SAT-056** **Recombinant glutamine synthetase reduces ammonia and hepatic fibrosis in in vitro and in vivo models of non-alcoholic fatty liver disease**
YI Antria SIAKALLI, *United Kingdom*
- SAT-057** **Absence of histidine triad nucleotide binding protein-2 (HINT-2) triggers mitochondrial dysfunction and aggravates steatosis**
 Raviprasadh RAJASEKARAN, *India*
- SAT-058** **GPNMB modulates hepatic steatogenesis and liver cancer**
 Seddik HAMMAD, *Germany*

- SAT-059** **TM6SF2 E167K variant increases the severity of NAFLD in high fat diet-fed mice**
Shousheng LIU, *China*
- SAT-060** **Unrevealing the HDL lipidome in NAFLD: a possible explanation for the increased CVD risk of these patients**
Sofia KARTSOLI, *Greece*
- SAT-061** **A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis**
Stéphanie LE CORRE, *France*
- SAT-062** **Evaluation of pharmacological intervention using a deep learning approach for histopathological scoring in a diet-induced obese and biopsy-confirmed mouse model of NASH with fibrosis**
Sanne VEIDAL, *Denmark*
- SAT-063** **MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASH**
Sanne VEIDAL, *Denmark*
- SAT-064** **S1pr2 is a key mediator of endoplasmic reticulum stress in NAFLD/NASH pathogenesis**
Stefania VETRANO, *Italy*
- SAT-065** **Infiltrative monocyte derived adenosine deaminase 2 promotes liver fibrosis via signaling through extracellular inosine**
Shilpa TIWARI HECKLER, *United States*
- SAT-066** **TERN-501, a potent and selective agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent models**
Thorsten KIRSCHBERG, *United States*
- SAT-067** **Western diet induced nuclear NFATC1 activates pro-apoptotic endoplasmic reticulum (ER) stress signaling, and progresses NAFLD to NASH**
Muhammad Umair LATIF, *Germany*
- SAT-068** **Overproduction of ITIH1 after loss of G alpha 13 in liver exacerbates systemic insulin resistance**
Won KIM, *Korea, Rep. of South*
- SAT-069** **Chorionic-plate-derived mesenchymal stem cells attenuate hepatic steatosis via restoration of mitochondrial function**
Yun Bin LEE, *Korea, Rep. of South*

SAT-070 **Glucagon-like peptide 1 receptor is localized in hepatocytes with macrovesicular steatosis attached to monocyte in non-alcoholic steatohepatitis**
YI
Hiroaki YOKOMORI, *Japan*

SAT-071 **Iron loss-induced mitophagy via mitochondria ferritin suppresses NASH-related hepatocellular carcinoma**
Yuichi HARA, *Japan*

Cirrhosis and its complications: Clinical

- SAT-076** **Application of the new GLIM criteria for the diagnosis of malnutrition in patients with liver cirrhosis and usefulness of three different screening tools**
YI Diego CASAS DEZA, *Spain*
- SAT-077** **Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis – data from a real world cohort**
YI Adam HERBER, *Germany*
- SAT-078** **Covered TIPSS does not improve long term survival in refractory ascites – a single- centre experience**
YI Amritpal DHALIWAL, *United Kingdom*
- SAT-079** **Comparison of skeletal muscle index (SMI) and transversal psoas muscle thickness (TPMT) for the diagnosis of sarcopenia in cirrhosis**
YI Alessandra PIGLIACELLI, *Italy*
- SAT-080** **PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions**
 Alison BOYLE, *United Kingdom*
- SAT-081** **Building a better mousetrap: can MELD-Na be improved?**
Top 10% Allison KWONG, *United States*
YI
- SAT-082** **Systemic inflammation is associated with cardiodynamic state in acute-on-chronic liver failure**
Top 10% Sofia MONTEIRO, *Portugal*
YI
- SAT-083** **Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study**
YI Angelo BRUNI, *Italy*
- SAT-084** **Optimizing nutrition in patients with cirrhosis may reduce hospital readmissions in medium and high risk groups: a quality improvement project**
YI Angela LIAROS, *United Kingdom*
- SAT-085** **Adipopenia, among the nutritional parameters, is the rapid screening tool that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study**
 Anna LOMBARDI, *Italy*
- SAT-086** **Leptin as a key player in insulin resistance of liver cirrhosis**
 Anna MRZLJAK, *Croatia*

Cirrhosis and its complications: Clinical (Cont.)

- SAT-087** **Femur fractures are associated with high morbimortality in patients with cirrhosis**
YI
Anna BRUJATS, *Spain*
- SAT-088** **The presence of infection during hospitalization is associated with an increased risk of procedure-related bleeding in cirrhosis**
YI
Abhishek SHENOY, *United States*
- SAT-089** **Role of urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and cystatin C as markers of mild kidney function impairment in patients with liver cirrhosis**
Anna SZYMANEK-PASTERNAK, *Poland*
- SAT-090** **Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema**
Akemi TSUTSUI, *Japan*
- SAT-091** **Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding**
YI
Aurélien WALTER, *France*
- SAT-092** **Esophageal varices recurrence after eradication: are there any predictors ?**
YI
Myriam AYARI, *Tunisia*
- SAT-093** **Sarcopenia is associated with lack of therapeutic response and higher mortality in hepatocellular carcinoma patients**
Hanaa BADRAN, *Egypt*
- SAT-094** **A telephone survey to screen for frailty pre-liver transplant evaluation: validation of an easy to use survey**
Bandar ALJUDAIBI, *United States*
- SAT-095** **Risk factors associated with mortality in upper gastrointestinal bleeding in cirrhotic patients**
YI
Andra BARBULESCU, *Romania*
- SAT-096** **Epithelial cell death markers M65 and M30 are significantly up-regulated in decompensated liver cirrhosis and decreased by correction of portal hypertension**
YI
Beatrice-Victoria JAHN, *Germany*
- SAT-097** **Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis**
YI
Chiara BECCHETTI, *Switzerland*
- SAT-098** **Bacterial translocation-induced inflammation promotes liver fibrogenesis in patients with advanced chronic liver disease**
YI
Benedikt SIMBRUNNER, *Austria*

- SAT-099** **Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension**
YI Benedikt SIMBRUNNER, *Austria*
- SAT-100** **Impact of extended- spectrum- beta- lactamase faecal carrier on cirrhotic patients: a retrospective study on clinical outcomes before and after liver transplantation**
YI Bianca MAGRO, *Italy*
- SAT-101** **A randomized, double-blind study to evaluate the safety and tolerability of KB174, a novel synthetic glycan, in patients with well-compensated cirrhosis**
Robert S MITTLEMAN, *United States*
- SAT-102** **Renal clearance measured by iohexol identifies cirrhotic patients with normal creatinine at risk of serious adverse events**
YI Carlos GONZÁLEZ-ALAYÓN, *Spain*
- SAT-103** **Clinical relevance of sarcopenia in liver transplant candidates**
Top 10% Chiara MAZZARELLI, *Italy*
- SAT-104** **Impact of non-selective beta-blockers on hepatic encephalopathy in patients with liver cirrhosis**
YI Christian LABENZ, *Germany*
- SAT-105** **Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy**
Carmina MONTOLIU, *Spain*
- SAT-106** **Role and prognostic value of routine doppler sonography in patients with severe liver disease – a prospective cohort study in an intensive care unit**
YI Constantin MAIER-STOCKER, *Germany*
- SAT-107** **Lack of evidence of significant tubular injury in patients with cirrhosis and persistent hepatorenal syndrome. implications for liver transplantation**
YI Cristina SOLÉ MARTÍ, *Spain*
- SAT-108** **Hepatic and splenic elastography: are they predictors of recurrence of esophageal varices after complete eradication?**
YI Daniela REIS, *Portugal*
- SAT-109** **Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?**
YI Daniela CAMPION, *Italy*
- SAT-110** **Flash glucose monitoring system: a required tool to improve glycaemic control in patients with liver cirrhosis**
YI Dalila COSTA, *Portugal*

Cirrhosis and its complications: Clinical (*Cont.*)

- SAT-111** **Incorporation of frailty estimated by gait speed within MELD and**
YI **the predictive potential for mortality in cirrhosis**
You DENG, *China*
- SAT-112** **Serologically assessed fragments of type VI collagen are predictors of**
progression free survival and death in patients with hepatocellular carcinoma
Diana Julie LEEMING, *Denmark*
- SAT-113** **Mechanical ventilation in patients with hepatopulmonary syndrome:**
prevalence, resource utilization, and prognosis: a nationwide analysis
Ahmad KHAN, *United States*
- SAT-114** **Acute kidney injury: a predictor of worse outcomes in variceal bleeding**
Ahmad KHAN, *United States*
- SAT-115** **The prospective prognostic values of diabetic conditions based on 75g oral**
glucose tolerance test in cirrhotic patients
Moon Young KIM, *Korea, Rep. of South*
- SAT-116** **PROSPER study reveals reduction in bed days per hospitalisation and**
decreased risk of mortality for patients observed on rifaximin-alpha 550mg
compared to a cohort on standard of care
Dave WALKER, *United Kingdom*
- SAT-117** **Hemodynamic effects of direct-acting antivirals in patients with hepatitis-C**
YI **virus-associated cirrhosis and portal hypertension non responsive to**
beta-blockers
Edilmar ALVARADO, *Spain*
- SAT-118** **Improving nutritional care in patients with liver cirrhosis: a quality**
YI **improvement project**
Syazeddy SAMANI, *United Kingdom*
- SAT-119** **90-day mortality is lower after as compared to before transjugular**
YI **intrahepatic portosystemic shunt at the same model for end-stage liver**
disease score
Laurie EICHER, *Germany*
- SAT-120** **Long-term prospective study of development of hepatocellular carcinoma**
YI **in compensated cirrhosis**
Alessandra PIVETTI, *Italy*
- SAT-121** **First-line empirical antibiotics failed to control bacterial infections resistant**
YI **to multi drugs in patients hospitalized with cirrhosis**
Zhujun CAO, *China*

- SAT-122** **The SALTFOOD trial: a randomized, controlled trial of home-delivered low-sodium meals for the management of refractory ascites**
 Elliot TAPPER, *United States*
- SAT-123** **The diagnosis of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis**
 Top 10%
 Nicoletta FABRINI, *Italy*
YI
- SAT-124** **Interest of echocardiography in the management of acute kidney injury in cirrhotic patients with ascites. Results of the prospective pilot cirren study**
 YI
 Fanny LEBOSSÉ, *France*
- SAT-125** **Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients**
 Top 10%
 Muhammad Farooq HANIF, *Pakistan*
- SAT-126** **Head to head comparison of liver stiffness measurement using transient elastography, 2D-shear wave elastography and magnetic resonance elastography for non-invasive evaluation of clinical significant portal hypertension**
 YI
 Filipe ANDRADE, *Portugal*
- SAT-127** **A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis**
 Fanny TURON, *Spain*
- SAT-128** **Comparison of the diagnostic quality of aspiration and core biopsy needles for transjugular liver biopsy**
 YI
 Georg SEMMLER, *Austria*
- SAT-129** **Spleen stiffness-based models can predict presence of esophageal varices in patients with compensated liver cirrhosis stratified by liver disease etiology**
 YI
 Mauro GIUFFRÉ, *Italy*
- SAT-130** **Ammonia is an independent biomarker of poor outcomes in patients with advanced cirrhosis**
 YI
 Gonçalo ALEXANDRINO, *Portugal*
- SAT-131** **Survival outcomes of SBP, BA and CNNA in a large Scottish cohort**
 YI
 Malgorzata GRZELKA, *United Kingdom*
- SAT-132** **Risk stratification and the effects of early tips among patients with Child-Pugh B cirrhosis and acute variceal bleeding**
 Guohong HAN, *China*
- SAT-133** **Risk factors for sarcopenia and its impacts on clinical outcome in patients with liver cirrhosis**
 Tao HAN, *China*

Cirrhosis and its complications: Clinical (Cont.)

- SAT-134** **The burden of cirrhosis on the Canadian healthcare system: a comparison between alcoholic and non-alcoholic cirrhosis patients**
YI Hassan AZHARI, *Canada*
- SAT-135** **Developed and validated a prognostic nomogram incorporating body compositions for long-term mortality in cirrhosis: a sex-stratified analysis**
YI Lijun HOU, *China*
- SAT-136** **Collagen type XVIII is associated with platelet count and meld score in patients with trans-jugular intrahepatic portosystemic shunt**
YI Ida VILLESSEN, *Denmark*
- SAT-137** **Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis**
YI Ilaria GIOVO, *Italy*
- SAT-138** **Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites**
Ioannis PETRIDIS, *Italy*
- SAT-139** **Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial**
Jasmohan BAJAJ, *United States*
- SAT-140** **Salivary and stool microbiota differences are related to differences in 90-day hospitalizations in Mexican compared to American patients with cirrhosis**
Jasmohan S BAJAJ, *United States*
- SAT-141** **Validation of encephalapp stroop for minimal hepatic encephalopathy diagnosis in elderly patients with cirrhosis: a multi-center study**
Jasmohan S BAJAJ, *United States*
- SAT-142** **Lactulose withdrawal can potentiate breakthrough overt hepatic encephalopathy in patients controlled with rifaximin plus lactulose therapy: a post hoc analysis of a randomized controlled trial**
Jasmohan S BAJAJ, *United States*
- SAT-143** **Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study**
Top 10% Jasmohan S BAJAJ, *United States*

- SAT-144** **KB174 reduces relative abundance of multidrug resistance (MDR) enterobacteriaceae in fecal samples from patients with cirrhosis in an ex vivo test system**
Top 10%
 Jasmohan S BAJAJ, *United States*
- SAT-145** **Prevalence and clinical significance of portal vein thrombosis in cirrhotic patients with acute decompensation**
YI
 Yan ZHANG, *China*
- SAT-146** **Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis**
 Juan Carlos GARCIA PAGAN, *Spain*
- SAT-147** **Increased risk of perinatal complications in women with cirrhosis: a population-based matched cohort study**
 Jennifer FLEMMING, *Canada*
- SAT-148** **Does the wedge hepatic vein pressure estimates the portal pressure in patients with NASH cirrhosis?**
YI
 José FERRUSQUÍA-ACOSTA, *Spain*
- SAT-149** **Clinical outcomes of sedation during emergency endoscopic band ligation for variceal bleeding: a multicenter retrospective cohort study**
 Jang Han JUNG, *Korea, Rep. of South*
- SAT-150** **Prediction of variceal eradication in decompensated liver cirrhosis: a novel model**
 Xing WANG, *China*
- SAT-151** **A comparison of non-invasive methods for the screening of gastroesophageal varices in patients with compensated cirrhosis**
YI
 Jonathan NG, *Australia*
- SAT-152** **Pre-procedural blood product transfusion and bleeding predictors in patients with chronic liver disease undergoing elective invasive procedures at a tertiary liver unit**
YI
 Jonathan DURBIN, *United Kingdom*
- SAT-153** **Urinary liver fatty-acid binding protein (UL-FABP) predicts acute-on-chronic liver failure (ACLF) and mortality in patients with decompensated cirrhosis**
YI
 Adria JUANOLA, *Spain*
- SAT-154** **Sarcopenia and liver cirrhosis: comparison of the European working group on sarcopenia criteria 2010 and 2019**
 Julia TRAUB, *Austria*
- SAT-155** **Validation of diagnostic usefulness of the spot urine Na/K ratio for replacement of 24-hour urine NA excretion in cirrhotic patients with ascites**
 Jinwook LEE, *Korea, Rep. of South*

Cirrhosis and its complications: Clinical (Cont.)

- SAT-156** **Proton pump inhibitor use is associated with an increased risk of hepatic encephalopathy in a large cohort of patients with cirrhosis**
YI Koos DE WIT, *Netherlands*
- SAT-157** **Quality improvement campaign led to higher surveillance rate for hepatocellular carcinoma in primary care clinic**
YI Kanit BUNNAG, *Thailand*
- SAT-158** **Calf circumference as an easy surrogate marker for the screening of Japanese patients with chronic liver disease**
Kei ENDO, *Japan*
- SAT-159** **A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimally hepatic encephalopathy?**
Bugra Tolga KONDUK, *Turkey*
- SAT-160** **Real-world treatment patterns and outcomes in hepatorenal syndrome: results from a retrospective chart review study in the United Kingdom**
Katharina VERLEGER, *Germany*
- SAT-161** **Validation of HCC risk calculator in a UK centre and implications of thresholds for screening**
YI Laura ATKINS, *United Kingdom*
- SAT-162** **Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease in patients with portal hypertension**
Laure ELKRIEF, *France*
- SAT-163** **The utilisation of palliative care in patients with end-stage liver disease**
Lauren ANDERSSON, *Australia*
- SAT-164** **Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicenter study**
YI Beiling LI, *China*
- SAT-165** **Continuous infusion of terlipressin for hepatorenal syndrome therapy: evaluation of efficacy and safety in real-life setting**
Fernanda S. LINHARES, *Brazil*
- SAT-166** **Frailty assessed by the liver frailty index (LFI) predicts poor health-related quality of life (QOL) in patients hospitalised with liver cirrhosis**
Lubomir SKLADANY, *Slovakia*
- SAT-167** **A novel score to predict mortality after transjugular intrahepatic portosystemic shunt in patients with renal insufficiency**
YI Luisa FUERSCHUB, *Austria*

- SAT-168** **Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension**
YI Lukas HARTL, *Austria*
- SAT-169** **Prospective study of magnetic resonance spectroscopy identifies specific metabolic changes in covert hepatic encephalopathy**
 Mark DANTA, *Australia*
- SAT-170** **Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity**
YI Maria Corina PLAZ TORRES, *Italy*
- SAT-171** **Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment**
YI Manuel TUFONI, *Italy*
- SAT-172** **Subtle changes of serum creatinine and C-reactive protein during the index hospitalization predict early readmission in patients with decompensated cirrhosis**
YI Manuel TUFONI, *Italy*
- SAT-173** **Value of Hitachi shear wave elastography (SWE) for exclusion of esophageal varices in patients with compensated advanced liver disease**
YI Marcel RAZPOTNIK, *Austria*
- SAT-174** **Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria**
YI Marcel RAZPOTNIK, *Austria*
- SAT-175** **Prevalence of cirrhotic cardiomyopathy according to the old and new diagnostic criteria**
YI Marcel RAZPOTNIK, *Austria*
- SAT-176** **Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection**
YI Marco SENZOLO, *Italy*
- SAT-177** **Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis**
YI Marcus MÜCKE, *Germany*
- SAT-178** **Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis**
YI Mario ROMERO CRISTÓBAL, *Spain*
- SAT-179** **Zinc deficiency in cirrhosis predicts hepatic decompensation and mortality**
YI Marta HERNÁNDEZ CONDE, *Spain*

Cirrhosis and its complications: Clinical (*Cont.*)

- SAT-180** **A nomogram as an indirect method to identify sarcopenia in patients with liver cirrhosis**
YI Marta HERNÁNDEZ CONDE, *Spain*
- SAT-181** **Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response**
Top 10% Mathias JACHS, *Austria*
YI
- SAT-182** **Protective effects of statin therapy in liver cirrhosis are limited by the common SLC01B1 variant**
YI Melissa MERKEL, *Germany*
- SAT-183** **Shifting the focus of liver cirrhosis to prevention with the help of the SEAL program**
YI Nagel MICHAEL, *Germany*
- SAT-184** **Algorithm to predict development of sarcopenia after transjugular intrahepatic portosystemic shunt in decompensated cirrhosis**
YI Michael PRAKTIKNJO, *Germany*
- SAT-185** **In-hospital falls and fall-related injury in patients with liver-cirrhosis – malnutrition matters**
YI Nada ABEDIN, *Germany*
- SAT-186** **Body composition parameters predict outcomes of acute kidney injury in patients with cirrhosis**
Naomi LANGE, *Switzerland*
- SAT-187** **Usefulness of handgrip as a non-invasive tool to predict the outcome of patients with cirrhosis. A prospective study**
YI Nesrine AMARI, *Belgium*
- SAT-188** **Longitudinal assessment of progressive decrease in platelet counts as a surrogate marker of liver fibrosis and portal hypertension**
Neta GOTLIEB, *Israel*
- SAT-189** **Factor VIII/protein C and not ADAMTS13/VWF: Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score**
YI Niccolò BITTO, *Italy*
- SAT-190** **Baveno VI criteria as a prognosis index for clinical complications in patients with cirrhosis**
YI Nicolas ASESIO, *France*
- SAT-191** **Systemic and splanchnic hemodynamic features of patients with porto-sinusoidal disease as compared with cirrhosis**
YI Nicolas DRILHON, *France*

- SAT-192** **Circulating microfibrillar-associated protein 4 is an independent predictor of**
YI **transplant-free survival in compensated and decompensated cirrhosis**
Nikolaj TORP, *Denmark*
- SAT-193** **Tunneled peritoneal catheter versus large volume paracentesis for**
refractory ascites in cirrhosis: a randomized controlled trial
Nina KIMER, *Denmark*
- SAT-194** **Different prognostic role of liver stiffness according to type of liver-related**
YI **outcomes and etiology of liver disease**
Joo HYUN OH, *Korea, Rep. of South*
- SAT-195** **Prognostic value of nutritional status in patients with advanced chronic liver**
YI **disease**
Ovidiu CALAPOD, *Romania*
- SAT-196** **Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic**
YI **patients with hepatorenal syndrome – chronic kidney disease**
Paola PONZO, *Italy*
- SAT-197** **The prevalence of esophageal varices needing treatment depends on gender,**
Top 10% **etiology and BMI**
Paul CALES, *France*
- SAT-198** **Direct acting oral anticoagulant use in cirrhosis patients: real-world bleeding**
and discontinuation rates
Patrick NORTHUP, *United States*
- SAT-199** **Fluency is associated with hepatic encephalopathy using a common and**
YI **easy language task**
Patricia BLOOM, *United States*
- SAT-200** **A smartphone app is feasible for outpatient ascites management**
YI
Patricia BLOOM, *United States*
- SAT-201** **Comparative study between spontaneous fungal peritonitis and spontaneous**
bacterial peritonitis in patients with end stage liver disease
Mohamed ELNADRY, *Egypt*
- SAT-202** **Association between proton pump inhibitor use in hospitalized cirrhotics and**
YI **development of hepatic encephalopathy and spontaneous bacterial peritonitis**
Pearl TAN, *Canada*
- SAT-203** **Sarcopenia increases the risk of post transjugular intrahepatic portosystemic**
YI **shunt hepatic encephalopathy**
Puja Bhatia KAPOOR, *India*
- SAT-204** **Distinct features of the portalhypertensive syndrome in patients with**
YI **advanced chronic liver disease due to non-alcoholic steatohepatitis**
Rafael PATERNOSTRO, *Austria*

Cirrhosis and its complications: Clinical (Cont.)

- SAT-205** A novel, smartphone-based scleral image capture technique accurately determines serum bilirubin level and can be used for home-based monitoring of patients discharged from hospital, after an episode of acute decompensation
Rahul KUMAR, *Singapore*
- SAT-206** Degree of portal and systemic hemodynamic alterations predict repeated episodes of acute kidney injury and chronic kidney disease in patients with cirrhosis
Top 10% Rakhi MAIWALL, *India*
- SAT-207** Long-term 20% albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis
Raquel HORRILLO, *Spain*
- SAT-208** Aminoglycosides and metronidazole for the treatment of hepatic encephalopathy in adults with cirrhosis
Rebecca JAYARAJ, *United Kingdom*
- SAT-209** Spleen stiffness and liver stiffness for predicting high risk varices in patients with compensated liver cirrhosis
YI Renata FOFIU, *Romania*
- SAT-210** Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax
Sarah ROMERO, *Australia*
- SAT-211** Acute or recent portal vein thrombosis in cirrhosis predicts a hidden or upcoming diagnosis of hepatocellular carcinoma
Rifaat SAFADI, *Israel*
- SAT-212** The association of sarcopenia with myostatin, follistatin and irisin levels in cirrhotic patients: a multicenter cross-sectional study
Salih BOGA, *Turkey*
- SAT-213** A prospective evaluation of the Bristol prognostic score: poor sensitivity and specificity in a non-Bristol cohort
Sarah BOWERS, *United Kingdom*
- SAT-214** Blood and ascites pharmacokinetics of meropenem in patients with nosocomial spontaneous bacterial peritonitis and decompensated liver cirrhosis
YI Marie SCHULTALBERS, *Germany*
- SAT-215** Diagnostic performance of contrast-enhanced CT for the diagnosis of portosinusoidal vascular disease: a case-control study
YI Shantha VALAINATHAN, *France*

- SAT-216** **Broad defect in energy metabolism drives immune dysfunction in cirrhosis and cirrhosis associated sepsis**
Shiv Kumar SARIN, *India*
- SAT-217** **A nurse-led albumin infusion service reduces the need for therapeutic paracentesis in the outpatient day procedure setting**
Siddharth SOOD, *Australia*
- SAT-218** **Increased levels of soluble mannose receptor are associated with poor outcome in cirrhosis: results from a 2-year longitudinal study**
YI
Signe WIESE, *Denmark*
- SAT-219** **MRI-derived myocardial extracellular volume is closely associated with markers of collagen formation in cirrhosis**
YI
Signe WIESE, *Denmark*
- SAT-220** **FIB-4 and APRI-scores predict survival in patients with transjugular intrahepatic portosystemic stent shunts**
YI
Simone Anna KEIMBURG, *Germany*
- SAT-221** **Real-world effectiveness of piperacillin/tazobactam-based therapies for spontaneous bacterial peritonitis**
YI
Stefanie QUICKERT, *Germany*
- SAT-222** **Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting**
YI
Mohsan SUBHANI, *United Kingdom*
- SAT-223** **Sarcopenia is not associated with poor outcomes after transjugular intrahepatic portosystemic shunt insertion for refractory ascites**
YI
Thomas TRANAH, *United Kingdom*
- SAT-224** **Impact of acute decompensation on prognosis in patients with hepatocellular carcinoma**
Takayuki KONDO, *Japan*
- SAT-225** **Serum cholinesterase is an independent predictor of hepatic encephalopathy, acute-on-chronic liver failure and mortality after transjugular intrahepatic portosystemic shunt insertion in patients with liver cirrhosis**
YI
Lena THÖLE, *Germany*
- SAT-226** **Transjugular intrahepatic portosystemic shunt in cirrhotic elderly patients with refractory ascites – to do or not to do?**
YI
Lena THÖLE, *Germany*
- SAT-227** **Four weeks of aerobic and resistance training improves frailty in patients with liver cirrhosis-liver habilitation (Li-Hab) center outcome data**
Top 10%
YI
Varsha SHASTHRY, *India*

Cirrhosis and its complications: Clinical (*Cont.*)

- SAT-228** **Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation**
Nataliya VIRSTYUK, *Ukraine*
- SAT-229** **Between rapid diagnosis and prediction of survival in minimal hepatic encephalopathy**
YI
Vlad TARU, *Romania*
- SAT-230** **Efficacy and safety of rivaroxaban in portal vein thrombosis in patients with liver decompensated cirrhosis**
YI
Min WANG, *China*
- SAT-231** **Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomized controlled trials**
YI
Wayne BAI, *Canada*
- SAT-232** **The survival effect of sarcopenia in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt: a single-center review**
YI
Wei ZHANG, *United States*
- SAT-233** **Comparison of MELD, MELD-Na and MELD-sarcopenia in predicting mortality in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt**
Wei ZHANG, *United States*
- SAT-234** **Empirical carbapenem versus third-generation cephalosporin treatment for spontaneous bacterial peritonitis: a multicenter study**
YI
Sun Woong KIM, *Korea, Rep. of South*
- SAT-235** **Early albumin improves survival in cirrhotic patients on diuretic therapy who develop significant acute kidney injury: real-world evidence in the United States**
Top 10%
W. Ray KIM, *United States*
- SAT-236** **Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomised controlled trials**
YI
Wayne BAI, *Canada*
- SAT-237** **Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS C012 CirVir cohorts**
Isabelle OLLIVIER-HOURMAND, *France*
- SAT-238** **Development and validation of a risk scoring system for screening high-risk varices**
YI
Yuling YAN, *China*

SAT-239 **Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis**
YI *Yuly Paulin MENDOZA, Switzerland*

SAT-240 **Repeated versus single treatment of esophageal variceal ligation after esophageal variceal bleeding**
Young Youn CHO, Korea, Rep. of South

Non-invasive assessment of liver disease except NAFLD

- SAT-241** **Serum gamma-glutamyl transpeptidase as a simple and useful indicator for predicting significant fibrosis in patients with chronic hepatitis B**
YI Jian WANG, *China*
- SAT-242** **The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis**
YI Christina LEVICK, *United Kingdom*
- SAT-243** **Elast q – 2D shear wave liver elastography correlates well with vibration controlled transient elastography in patients with different etiologies of chronic liver disease**
YI David JM BAUER, *Austria*
- SAT-244** **Liver function assessment by 13C-methacetin test before and after placement of a transjugular portosystemic shunt: a prospective pilot study**
David SEMELA, *Switzerland*
- SAT-245** **A novel diagnostic model using liver stiffness measurement and platelet count that accurately predicts the presence of portal hypertensive gastropathy in patients with cirrhosis**
YI David LEE, *United States*
- SAT-246** **Endothelin-1 level at first presentation of hematemesis as indicator of recurrent bleeding within 5 days**
YI Ahmed IBRAHIM, *Egypt*
- SAT-247** **Spleen acoustic radiation force impulse (ARFI) elastography predicts decompensation in patients with liver cirrhosis**
Elba LLOP, *Spain*
- SAT-248** **Automatic high-risk fibrosis score prediction using computed tomography imaging**
Elton REXHEPAJ, *France*
- SAT-249** **The variscreen algorithm using successively platelets, liver stiffness and INR improves and secures the screening of esophageal varices needing treatment**
YI Federico RAVAIOLI, *Italy*
- SAT-250** **Breath-based monitoring of liver metabolism using exogenous volatile organic compounds – towards improved detection**
Giuseppe FERRANDINO, *United Kingdom*
- SAT-251** **Intelligent liver function testing in action: a one-year review**
Top 10% Iain MACPHERSON, *United Kingdom*
YI
- SAT-252** **ALT level in the diagnosis of chronic liver disease and advanced fibrosis**
YI Iain MACPHERSON, *United Kingdom*

- SAT-253** **Multiparametric magnetic resonance imaging of liver and spleen is a reliable non-invasive predictor of clinically relevant hepatic venous pressure gradient thresholds and predicts failure of primary prophylaxis for variceal bleeding**
Pik Eu Jason CHANG, *Singapore*
- SAT-254** **Serum keratin 19 (CYFRA 21-1) links ductal reaction with portal hypertension and outcome of advanced liver disease**
Karim HAMESCH, *Germany*
- SAT-255** **Relationship between Laennec histological subclassification of cirrhosis and clinical stage, grade of portal hypertension and liver stiffness**
Castera LAURENT, *France*
- SAT-256** **Evolving imaging in biliary disease: quantitative magnetic resonance cholangiopancreatography findings correlate with the modified Amsterdam score in patients with primary sclerosing cholangitis**
Lin CHENG, *United Kingdom*
- SAT-257** **The tissue balance of liver fibrosis: identification of fibrosis resolution biomarkers and demonstration of increased tissue formation and degradation**
Morten KARSDAL, *Denmark*
- SAT-258** **Systemic light chain AL with cardiac and liver involvement can be predicted by transient elastography**
Speranta IACOB, *Romania*
- SAT-259** **Validating the Swansea criteria in a single-centre study with cohorts of patients with acute fatty liver of pregnancy and haemolysis, elevated liver enzymes and low platelets syndrome: is it time to modify the criteria?**
Mussarat RAHIM, *United Kingdom*
- SAT-260** **Diagnostic performance of a new algorithm combining simple, non-invasive and inexpensive tests for predicting the presence of liver severe fibrosis and cirrhosis in patients with chronic hepatitis B**
Jean NANA, *France*
- SAT-261** **Heat shock protein 47 is associated with fibrogenesis in alcoholic liver disease**
Natasja GUDMANN, *Denmark*
- SAT-262** **Dysregulation of wound healing status and activity is associated with fibrosis and inflammation in early alcohol associated liver disease**
Natasja GUDMANN, *Denmark*
- SAT-263** **Liver stiffness measurement using acoustic radiation force impulse elastography is a good predictor of hepatic decompensation in pregnant cirrhotic patients**
Omar ELSHAARAWY, *Germany*

Non-invasive assessment of liver disease except NAFLD (*Cont.*)

- SAT-264** **Reliability criteria will discriminate accuracy of blood liver fibrosis tests**
Paul CALES, *France*
- SAT-265** **The usual blood liver markers provide a performant fibrosis test thanks to artificial intelligence**
Paul CALES, *France*
- SAT-266** **A gut microbiota and liver co-metabolized biomarker to monitor liver cirrhosis progression with different etiologies in humans**
Jia-bo WANG, *China*
- SAT-267** **Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma**
Rocio IR MACIAS, *Spain*
- SAT-268** **Proteomic identification of serum factors that correlate with reduction of HVPG following curative treatment for hepatitis C virus infection**
Shola RICHARDS, *Switzerland*
- SAT-269** **Genome-wide association study (GWAS) of circulating liver enzymes identifies >300 novel variants with distinct tissue expression patterns and gene set enrichment**
Vincent CHEN, *United States*
- YI**
- SAT-270** **Virtual touch quantification using acoustic radiation force impulse technology versus transient elastography for the non-invasive assessment of liver fibrosis in patients with chronic hepatitis B or C using liver biopsy as gold standard**
Victor BALDEA, *Romania*
- YI**
- SAT-271** **Quantitative magnetic resonance cholangiopancreatography imaging in patients with primary sclerosing cholangitis – feasibility and preliminary analysis for prediction of clinical outcomes**
Vijay ARE, *United States*
- SAT-272** **Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease**
Wenyi GU, *Germany*
- YI**

Public Health

- SAT-273** **Progress in hepatitis C testing as a part of the hepatitis C elimination program in Georgia**
Amiran GAMKRELIDZE, *Georgia*
- SAT-274** **Evaluation of hepatitis B virus (HBV) epidemiology, vaccine impact and treatment eligibility: a census-based community serological survey in Blantyre, Malawi**
Alexander STOCKDALE, *United Kingdom*
- SAT-275** **HCV in addiction care: different epidemiology, excellent treatment results**
Andrea AFONSO DÍAZ, *Spain*
- SAT-276** **Modelling the cost of hepatitis C virus transmission in Pakistan**
YI Aaron G. LIM, *United Kingdom*
- SAT-277** **The best strategy for retrieval of hepatitis C patients lost to follow up: randomized clinical trial**
YI Alberto HERNÁNDEZ BUSTABAD, *Spain*
- SAT-278** **Is hospital admission an ideal condition for HCV screening? A survey from the Venetian area (north-east of Italy)**
Alessandro CAROLI, *Italy*
- SAT-279** **A novel microsimulation model of chronic hepatitis B (HBV): validation of HBV viral dynamics and cumulative incidence of hepatocellular carcinoma**
YI Amir MOHAREB, *United States*
- SAT-280** **Rapid test & treat programme successfully facilitating hepatitis C micro-elimination in a women's prison**
Andrew USTIANOWSKI, *United Kingdom*
- SAT-281** **Role of immigration in chronic HBV and HCV infection in our environment. Origin and characteristics of the patients**
YI Ángela SUÁREZ-NOYA, *Spain*
- SAT-282** **From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations**
YI Adam PALAYEW, *Canada*
- SAT-283** **Insights into hepatitis B prevalence and vaccination in the Northern Territory, Australia: a longitudinal study**
YI Ashleigh QAMA, *Australia*
- SAT-284** **Treatment cascade of hepatitis C in a non-university hospital setting, that uses a hub-and-spoke model, in southern Switzerland**
Benedetta TERZIROLI, *Switzerland*

Public Health (Cont.)

- SAT-285** **A nurse led hepatitis C model of care in primary care and community services in Melbourne, Australia**
YI Brendan HARNEY, *Australia*
- SAT-286** **Barriers to hepatitis C virus elimination in Germany: why aren't diagnosed patients initiating therapy?**
 Peter BUGGISCH, *Germany*
- SAT-287** **Public health implications of stigma and discrimination towards people who inject drugs in Australia**
 Carla TRELOAR, *Australia*
- SAT-288** **Description of HBV-infected persons presenting late to specialist care in 10 Spanish centres: A retrospective registry review**
YI Camila PICCHIO, *Spain*
- SAT-289** **The prevalence of hepatitis C amongst people who use performance and image enhancing drugs – a systematic review**
YI Charlotte COOK, *United Kingdom*
- SAT-290** **Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study)**
YI Clotilde LEPEPERS, *France*
- SAT-291** **Hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington, USA**
YI Maria CORCORRAN, *United States*
- SAT-292** **Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition**
 Chikako YAMAMOTO, *Japan*
- SAT-293** **Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study**
YI Dana BUSSCHOTS, *Belgium*
- SAT-294** **Limburg is the first Belgian province on track for hepatitis C virus eradication in the most important group at risk: People who use drugs**
YI Dana BUSSCHOTS, *Belgium*
- SAT-295** **Early treatment of hepatitis C virus improves health outcomes and yields cost-savings: A modeling study in Argentina**
 Diego KANEVSKY, *Argentina*
- SAT-296** **Tailored message interventions promote the number of participants in viral hepatitis screening for Japanese workers – multicenter trial of 1,127,596 general checkup applicants**
 Masaaki KORENAGA, *Japan*

- SAT-297** **Data from a large, public sector hepatitis C program in Punjab, India**
Gagandeep Singh GROVER, *India*
- SAT-298** **Implementation of electronic monitoring and evaluation system for hepatitis C in Punjab, India**
Gagandeep Singh GROVER, *India*
- SAT-299** **Hepatitis C elimination in hemodialysis population of a county – an innovative collaborative care model in Taiwan**
Top 10% Tsung-Hui HU, *Taiwan*
- SAT-300** **Unusual occurrence of hepatitis B infection in Upper Egypt**
YI Mahmoud S. ELZALABANY, *Saudi Arabia*
- SAT-301** **A novel test and treat hepatitis C micro-elimination project among underserved communities in Islamabad, Pakistan**
Top 10% Huma QURESHI, *United States*
- SAT-302** **Classifying people living with hepatitis C virus using a population-level latent class analysis to inform optimal integration of health services**
YI Emilia CLEMENTI, *Canada*
- SAT-303** **Comparison of risk factors for cirrhosis and hepatocellular carcinoma: a large prospective study of UK women**
Emily HE, *Australia*
- SAT-304** **Hepatitis C virus testing and treatment in children: results from a global paediatric policy review**
YI Fariyah MALIK, *United Kingdom*
- SAT-305** **HCV screening strategies targeting prisoners and immigrants from endemic countries: are they cost-effective?**
Francesco MANCA, *United Kingdom*
- SAT-306** **Relationship between metabolic syndrome and ALT level with normal range in the general population**
Won SOHN, *Korea, Rep. of South*
- SAT-307** **Are UK NAFLD/NASH referral pathways ready to tackle the emerging epidemic? A rapid systematic public health evidence synthesis**
Hannah PHEASANT-OLDFIELD, *United Kingdom*
- SAT-308** **The case for testing and treating all HBV patients**
Homie RAZAVI, *United States*
- SAT-309** **Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study**
YI Heather VALERIO, *Australia*

Public Health (Cont.)

- SAT-310** **Searching for patients lost in the system with chronic hepatitis C in a tertiary hospital: a problem still to be solved**
YI
 Irene ANDALUZ, *Spain*
- SAT-311** **Economic evaluation of the hepatitis C virus screening and treatment program in Georgia**
YI
 Irina TSKHOMELIDZE, *Georgia*
- SAT-312** **Assessing the level of detection of hepatitis C virus RNA in individuals with detectable viremia following treatment with direct acting antivirals: and opportunity for new testing technologies**
Top 10%
YI
 Jake MORGAN, *United States*
- SAT-313** **A population-based intervention to improve care cascade of patients with hepatitis C infection**
 John D SCOTT, *United States*
- SAT-314** **Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission**
Top 10%
 Jeffrey LAZARUS, *Spain*
- SAT-315** **Validation of a novel rapid point-of-care ALT test in patients with viral hepatitis**
 Jessica HOWELL, *Australia*
- SAT-316** **Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic hepatitis C virus in low- and middle-income settings**
YI
 Josephine WALKER, *United Kingdom*
- SAT-317** **Cross-sectional associations between suspected non-alcoholic fatty liver disease, diabetes, and hypertension in hispanic adults living in the San Juan metropolitan area**
YI
 Josheili LLAVONA-ORTIZ, *Puerto Rico*
- SAT-318** **HCV care cascade of PWID enrolled in methadone substitution treatment program in Georgia – is this the first group of population in which hepatitis C will be eliminated in Georgia?**
 Ketevan STVILIA, *Georgia*
- SAT-319** **Screening and linkage to care of prisoners with HCV infection: the resist-HCV project**
YI
 Lorenza DI MARCO, *Italy*
- SAT-320** **Frequency of prenatal hepatitis C screening and diagnosis in British Columbia, 2008-2018**
YI
 Margo PEARCE, *Canada*

- SAT-321** **Re-capturing a lost population – the benefits of a nurse-delivered HCV community cirrhosis clinic**
Maryam NOEMAN, *United Kingdom*
- SAT-322** **Strengthening HCV elimination policies through community-based research**
Maria DONATELLI KLINGER, *France*
- SAT-323** **Preliminary results of the prevalence of non-alcoholic fatty liver disease among the greater Toronto area population**
Magdy ELKHASHAB, *Canada*
- SAT-324** **Suboptimal linkage to care after identification of serum hepatitis B surface antigen-positive individuals in territory-wide screening: a need for educational and public health policies**
KL KO, *Hong Kong*
- SAT-325** **Changes in the hepatitis C cascade of care among individuals attending primary and community health services before and after the introduction of direct-acting antiviral treatment in Australia**
Michael TRAEGER, *Australia*
- SAT-326** **Microelimination of chronic hepatitis C in Romania – another pathway to achieve national elimination goals by HepC ALERT project**
Speranta IACOB, *Romania*
- SAT-327** **What is required for achieving HCV elimination in Singapore? A modeling study**
Natasha MARTIN, *United States*
- SAT-328** **Hepatitis C virus screening of people with severe mental illness: a cost-effectiveness analysis**
Nathalie VERNAZ, *Switzerland*
- SAT-329** **Incidence of HCV infection among gbMSM in British Columbia, Canada: a population-based cohort study**
Naveed JANJUA, *Canada*
- SAT-330** **An OST (opiate substitution therapy)-based hepatology service facility (OHSF) with access to chronic hepatitis C treatment: the example of an one stop shop as a practical step towards HCV elimination in patients who use drugs (PWUD)**
Nikolaos PAPADOPOULOS, *Greece*
- SAT-331** **Recent decline in hepatocellular carcinoma rates in the United States**
Thomas OBRIEN, *United States*
- SAT-332** **HCV screening and linkage to care of homeless people in a major European city. Data from a mobile screening unit (MSU)**
Pablo RYAN, *Spain*

Top 10%

Public Health (Cont.)

- SAT-333** **Development of a supportive needs assessment tool for cirrhosis (SNAC)**
Patricia VALERY, *Australia*
- SAT-334** **Inequities in presentation and outcomes for indigenous Australians hospitalised for cirrhosis**
Patricia VALERY, *Australia*
- SAT-335** **Leveraging direct-to-patient messaging: electronic record assimilation and subsequent eradication of hepatitis C (Erase-C)**
Paul KWO, *United States*
- SAT-336** **Catalytic funding of viral hepatitis elimination program in Uzbekistan**
Top 10% Rick DUNN, *United States*
- SAT-337** **Meta-analysis: accuracy of the enhanced liver fibrosis (ELF) test in detection of advanced fibrosis or cirrhosis**
Richard PARKER, *United Kingdom*
- SAT-338** **Risk factors for liver disease cluster geographically: precision public health analysis of a UK city**
Richard PARKER, *United Kingdom*
- SAT-339** **Updated estimate for prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin**
Robert WONG, *United States*
- SAT-340** **Improving access to care for serologically positive hepatitis C blood donors in private sector**
Sabeen SHAH, *Pakistan*
- SAT-341** **Comparison of costs of different HCV screening and linkage to care interventions across Europe**
YI Sandra BIVEGETE, *United Kingdom*
- SAT-342** **High patient acceptability for a hepatitis C mobile outreach service targeting 'vulnerable' homeless communities – an important component for elimination?**
YI Sarah MONTAGUE, *United Kingdom*
- SAT-343** **Health and economic burden due to alcohol related liver diseases in New Delhi, India: a Markov probabilistic modelling approach**
Shiv Kumar SARIN, *India*
- SAT-344** **No restrictions should be placed on future treatment for patients who discontinue DAAs on their first or second attempt. A real world experience from the TraP HepC initiative in Iceland**
Top 10% Sigurdur OLAFSSON, *Iceland*

- SAT-345** **National survey among people who use drugs (PWUD) on opioid substitution treatment (OST) on their knowledge of hepatitis C virus (HCV) infection and barriers for treatment in Bulgaria**
Marieta SIMONOVA, *Bulgaria*
- SAT-346** **Demonstration of the feasibility of two innovative models of HCV testing and treatment in two unique populations in Punjab and Delhi, India-head- start project, India**
Top 10%
Sonjelle SHILTON, *Switzerland*
- SAT-347** **Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US**
Top 10%
Pimsiri SRIPONGPUN, *United States*
YI
- SAT-348** **From emergency department automated hepatitis B & C screening to care and cure in a primary care practice**
Su WANG, *United States*
- SAT-349** **Prevention of liver diseases through universal coverage with hepatitis B vaccination in India**
Umesh KAPIL, *India*
- SAT-350** **Deleterious impact of advanced non-alcoholic steatohepatitis on multiple patient-relevant outcomes: an international, cross-sectional, real-world study**
Victoria HIGGINS, *United Kingdom*
- SAT-351** **Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV)**
Vana SYPSA, *Greece*
- SAT-352** **Clinical and economic consequences of antiviral treatment for hepatitis C chronic infection in Europe: analysis of England, Italy, Romania and Spain data**
YI
Xhimi TATA, *Albania*
- SAT-353** **The head-start project: introduction of rapid diagnostic tests for hepatitis C screening in primary healthcare sites as a first step towards decentralizing hepatitis C care in Malaysia**
Xiaohui SEM, *Switzerland*
- SAT-354** **Enhancing the hepatitis B care cascade in Australia using a country-based testing program targeting new migrants: a cost-effectiveness model**
YI
Yinzong XIAO, *Australia*
- SAT-355** **Cost-effectiveness of mass screening for HCV in an Irish prison**
Zoe WARD, *United Kingdom*

Viral Hepatitis A, B, C, D, E: Virology

- SAT-356** **Hormone replacement therapy is associated with reduced liver cirrhosis risk and improved survival in treatment-naïve hepatitis B- and/or C- infected postmenopausal women: a nationwide long-term population-based cohort study**

Yuan-Tsung TSENG, *Taiwan*

- SAT-357** **Hepatitis B virus core protein variants observed in a first-in-human placebo-controlled study of a core protein inhibitor**

Amy C.H. LEE, *United States*

- SAT-358** **Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection**

Avista WAHID, *Germany*

- SAT-359** **Establishment of human induced pluripotent stem cell-derived hepatocyte-like cells permissive for serum-originated hepatitis B virus infection and allowing for covalently closed circular DNA inhibitor drug screening**

Chau-Ting YEH, *Taiwan*

- SAT-360** **Farnesoid X receptor alpha ligands inhibit hepatitis delta virus replication in vitro independently of their effect on hepatitis B virus**

Top 10%

Christophe RAMIÈRE, *France*

- SAT-361** **Analysis of hepatitis B virus quasispecies in circulating viral DNA and RNA: are genotype and complexity different?**

Cristina GODOY CRUZ, *Spain*

- SAT-362** **Mitochondrial DNA damage and mitochondrial dysfunction in patients with chronic hepatitis B**

Top 10%

Dimitri LOUREIRO, *France*

YI

- SAT-363** **Differential HBV RNA and quantitative HBsAg kinetics between HBeAg(+) and HBeAg(-) patients with chronic hepatitis B on nucleos(t)ide analogues (NA)**

Daryl LAU, *United States*

- SAT-364** **Role of hepatitis C virus core antigen in HIV-HCV co-infected and chronic kidney disease patients on hemodialysis: expanding the HCV horizon of diagnostics**

Ekta GUPTA, *India*

- SAT-365** **Characterization of acute hepatitis C virus infection and transmission clusters by next-generation sequencing among people who inject drugs in Catalonia**

Elisa MARTRÓ, *Spain*

- SAT-366** **Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice**
Harel DAHARI, *United States*
- SAT-367** **Prospective study of viral hepatitis in pregnancy and its vertical transmission in the northeast region of India**
Harpreet KAUR, *India*
- SAT-368** **Usefulness of dried plasma spots using a plasma separation card for serological diagnosis of chronic hepatitis B and C and reflex viral load testing**
Joan MARTINEZ, *Spain*
- SAT-369** **Validity of a point-of-care viral load kit for hepatitis B in a low-income setting**
Asgeir JOHANNESSEN, *Norway*
- SAT-370** **Antisense oligonucleosides with immunomodulatory SB 9000 for chronic hepatitis B therapy**
Radhakrishnan IYER, *United States*
- SAT-371** **Mechanism of action studies of inarigivir, a novel immunomodulator against chronic hepatitis B**
Top 10% Radhakrishnan IYER, *United States*
- SAT-372** **A systematic assessment of acute viral hepatitis and chronic liver diseases in northeast India with special reference to strengthening of laboratories in the region**
YI Vijaya Kumar KARRA, *India*
- SAT-373** **From in vivo to in vitro: ex vivo studies using primary human hepatocytes from chronically diseased liver-humanized FRG® KO mice**
Lander FOQUET, *United States*
- SAT-374** **The head-start project Georgia: a three-armed, cluster, non-randomised trial of the effectiveness of two novel models of HCV confirmatory testing in harm reduction sites (HRS) in Georgia**
Maia JAPARIDZE, *Georgia*
- SAT-375** **HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by selection of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication**
YI Maria PFEFFERKORN, *Germany*
- SAT-376** **Targeting hepatitis B virus with CRISPR/Cas9 approach**
YI Maria Guadalupe MARTINEZ, *France*
- SAT-377** **Evolution of full-length hepatitis B virus quasispecies in HBeAg-negative patients during spontaneous viral reactivation and remission**
Guan Huei LEE, *Singapore*

Viral Hepatitis A, B, C, D, E: Virology (Cont.)

- SAT-378** **The correlations between HBV markers and HBV cccDNA in the patients during Na treatment**
Matsui TAKESHI, *Japan*
- SAT-379** **Delineating HBV transcripts from integrated viral DNA using target enrichment and long read sequencing**
Top 10% Nicholas VAN BUUREN, *United States*
- SAT-380** **Prospective study of hepatitis B virus infection and its genotypes in the north-eastern India region**
Premashis KAR, *India*
- SAT-381** **Hepatitis D virus entry, replication and assembly in stem cell-derived hepatocytes**
YI Bingqian QU, *Germany*
- SAT-382** **Crispr/cas9-tailored hepatitis B-x protein knockdown inhibits cellular hyperplasia, invasion and tumorigenicity of HBV-infected hepatoma cells.**
YI Preety RAWAL, *India*
- SAT-383** **Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay**
YI Romina SALPINI, *Italy*
- SAT-384** **Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B**
Top 10% Sandra PHILLIPS, *United Kingdom*
- SAT-385** **Toll-like receptor 7 and 8 agonists as potent inhibitors of hepatitis delta virus infection**
Sandra WESTHAUS, *Germany*
- SAT-386** **Viral compartmentalization and carcinogenesis at single-cell level in HBV-induced hepatocellular carcinoma**
YI Antonio SAVIANO, *France*
- SAT-387** **Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C**
Steven FLAMM, *United States*
- SAT-388** **A novel intrahepatic restriction factor, HMGA1, contributes to hepatitis B virus (HBV) replication in immune tolerant phase, serving as an anti-HBV target**
YI Zhongliang SHEN, *China*

- SAT-389** **Multivariant surface quasispecies in a hepatitis B virus chronically infected individual with concomitant and continually positive surface antigen and anti-HBS biomarkers**
Suzane Kioko ONO, *Brazil*
- SAT-390** **Evaluation of the introduction of hepatitis C core antigen as a routine test to detect viraemia among patients with anti-HCV antibodies**
Stephen BARCLAY, *United Kingdom*
- SAT-391** **Virologic causes for DAA treatment failure of chronic hepatitis C**
Chun-Jen LIU, *Taiwan*
- SAT-392** **Impact of direct antiviral agents (DAAs) on the HBV virologic profile in HCV+ but HBsAg- and HBcAb+ patients**
Régine TRUCHI, *France*
- SAT-393** **Usefulness of HEV antigen determination in the diagnosis of acute hepatitis E**
YI Victor J BELTRÁN, *Spain*
- SAT-394** **Hepatitis V virus (HBV) cccDNA mini-chromosome transposase-accessible chromatin by atac-seq in infected primary human hepatocytes (PHHs)**
YI Vincenzo ALFANO, *France*
- SAT-395** **Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator R07049389 monotherapy**
Xue ZHOU, *China*
- SAT-396** **Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing**
Yang LIU, *United States*
- SAT-397** **Novel mutations within hepatitis B virus antigen promoter correlate with viral relapse through increasing covalently closed circular DNA accumulation**
Demin YU, *China*
- SAT-398** **Impact of antiviral therapy for blocking mother-to-child transmission on virus quasispecies in pregnant women with chronic HBV infection**
Zhihua LIU, *China*

Viral hepatitis A/E: Clinical aspects

- SAT-399** Significant compartment-specific impact of the RNA extraction and quantification method on the sensitivity of hepatitis E virus detection: implications for clinical care?
Patrick BEHRENDT, *Germany*
- SAT-400** Effectiveness of hepatitis A vaccination in human immunodeficiency virus-infected men who have sex with men during an outbreak of hepatitis A in Osaka, Japan
Hiroki BESSHO, *Japan*
- SAT-401** Histopathology of hepatitis E is associated with patients' immune status and preexisting liver condition
Daniela LENGGENHAGER, *Switzerland*
- SAT-402** Epidemiology of fulminant hepatitis A cases in Vienna – an informative case series
David JM BAUER, *Austria*
- SAT-403** Epidemiology of fulminant hepatitis E cases in Vienna – an informative case series
David JM BAUER, *Austria*
- SAT-404** Impact of acute kidney injury in patients with acute hepatitis A
Ahmad KHAN, *United States*
- SAT-405** Are we aligned with WHO international strategy to eliminate hepatitis C by 2030: real-world data from Khyber Pakhtunkhwa, Pakistan
Bakht BILAND, *Pakistan*
- SAT-406** Hepatitis E seroprevalence and rate of viremia in immunocompromised patients – a systematic review and meta-analysis
Gustav BUESCHER, *Germany*
- SAT-407** Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection
Midas MULDER, *Netherlands*
- SAT-408** Does glucose-6-phosphate dehydrogenase deficiency affects morbidity in acute viral hepatitis? A case control study from a tertiary care hospital in Karachi, Pakistan
Mahrukh ALI, *Pakistan*
- SAT-409** Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018
Michael PEETERS, *Belgium*

SAT-410 Hepatitis E virus infection in liver transplant recipients in Sweden

Miriam KARLSSON, *Sweden*

SAT-411 Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals

YI

Thomas HORVATITS, *Germany*

Viral hepatitis B/D: Therapy

- SAT-412** **Pradefovir in naive or experienced adult patients with chronic infection of hepatitis B virus: week24 results from 23 multicentre, double-blind, randomised, non-inferiority, phase2 trials**
Yanhang GAO, *China*
- SAT-413** **Combination of NA, PEG-IFN alpha-2b and GM-CSF enhanced hbsab production in NA experienced CHB patients (the anchor a study): an interim analysis**
Di WU, *China*
- SAT-414** **Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B**
Teresa BROQUETAS, *Spain*
- SAT-415** **Pegylated interferon beta strongly reduces all serological and intrahepatic hepatitis B virus parameters in immunodeficient humanized mice**
Andrea PIROSU, *Germany*
- SAT-416** **hzVSF, a novel HBV therapeutic candidate, shows WHsAg loss in woodchuck hepatitis model and safety in phase I clinical study**
Byoung AHN, *Korea, Rep. of South*
- SAT-417** **Safety and efficacy of up to 76 weeks 10mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis**
Alessandro LOGLIO, *Italy*
- SAT-418** **Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure**
Alessandro LOGLIO, *Italy*
- SAT-419** **The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Zanzibar, 2017-2019**
Ali SALIM, *Tanzania*
- SAT-420** **Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study**
Chien-Wei PENG, *Taiwan*
- SAT-421** **Long-term risk of primary liver cancers in tenofovir versus entecavir treatment for chronic hepatitis B**
Chao-Hung HUNG, *Taiwan*
- SAT-422** **ATI-2173, a novel phosphoramidate nucleoside prodrug for HBV cure regimens**
Douglas MAYERS, *United States*

- SAT-423** **The role of HBV genotypes in HBV relapse after cessation of entecavir or tenofovir in HBeAg-negative patients without cirrhosis**
Chien-Hung CHEN, *Taiwan*
- SAT-424** **Impact of ESC+ technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics**
Edward GANE, *New Zealand*
- SAT-425** **A once-per-week or every-two-week dosing regimen is more efficacious for the TIR7 agonist JNJ-64794964 (JNJ-4964) to induce an anti-hepatitis B virus (HBV) effect and HBV-specific immune responses in AAV-HBV mice**
Florence HERSCHKE, *Belgium*
- SAT-426** **In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus**
Florian LEMPP, *United States*
- SAT-427** **Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)**
George PAPATHEODORIDIS, *Greece*
- SAT-428** **Early PEG-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients**
YI
Hannah S.J. CHOI, *Canada*
- SAT-429** **Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study**
Harry JANSSEN, *Canada*
- SAT-430** **Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study**
Top 10%
Heiner WEDEMEYER, *Germany*
- SAT-431** **Combination drug interactions of hepatitis B virus (HBV) S-antigen transport – inhibiting oligonucleotide polymers in vitro**
Hua TAN, *United States*
- SAT-432** **Bile acid derivatives inhibit hepatitis B virus infection in vitro and in vivo**
Kiyooki ITO, *Japan*
- SAT-433** **Early on-treatment ALT normalization in patients with chronic hepatitis B is associated with lower risk of hepatocellular carcinoma development**
Jong Eun YEON, *Korea, Rep. of South*
- SAT-434** **Best in class hepatitis B virus anti-sense oligonucleotides: next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity and increasing in vivo efficacy in a mouse model**
Jin HONG, *United States*

Viral hepatitis B/D: Therapy (Cont.)

- SAT-435** Association between hepatitis B virus flare and overall survival in hepatitis B virus-related hepatocellular carcinoma in patients with undetectable serum HBV DNA levels

Jong-In CHANG, *Korea, Rep. of South*

- SAT-436** The first report of phase 1b study of a novel inhibitor of apoptosis proteins (IAPs) antagonist APG-1387 in patients with chronic hepatitis B: an interim analysis

Top 10%

Jinlin HOU, *China*

- SAT-437** The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Dar es Salaam, 2017-2019

John RWEGASHA, *Tanzania*

- SAT-438** Solving the cold chain problem – development of a heat-stable therapeutic vaccine to combat chronic hepatitis B

YI

Julia SACHERL, *Germany*

- SAT-439** Multicistronic DNA-based therapeutic vaccine as a promising candidate to treat chronic hepatitis B virus (HBV) infection

YI

Helene KERTH, *Germany*

- SAT-440** EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: preliminary results of a phase 1 study in healthy adult subjects

Kajal LARSON, *United States*

- SAT-441** Novel cell culture 3D model for HBV/HIV co-infection and antiviral evaluation

Leda BASSIT, *United States*

- SAT-442** Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study

Young-Suk LIM, *Korea, Rep. of South*

- SAT-443** Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir

Lucio BOGLIONE, *Italy*

- SAT-444** Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study)

YI

Milan SONNEVELD, *Netherlands*

- SAT-445** Silencing HBV expression using LNA gapmers: preliminary data of a new promising strategy

YI

Maria Francesca CORTESE, *Spain*

- SAT-446** **The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection**
 Maria PFEFFERKORN, *Germany*
- SAT-447** **All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naïve chronic hepatitis B patients in British Columbia, Canada**
 Mawuena BINKA, *Canada*
- SAT-448** **Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice**
 Michael CURRY, *United States*
- SAT-449** **Structural requirements for S-antigen transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion**
 Megan FITZGERALD, *United States*
- SAT-450** **Low hepatitis B surface antigen at baseline and increased ALT levels during treatment predicts significant HBsAg decline in peginterferon alfa added to long-term nucleos(t)ide analogue. Results from two randomized controlled trials in 165 patients**
 Mina FARAG, *Canada*
- SAT-451** **Efficacy and safety of switching to tenofovir alafenamide for chronic hepatitis B patients with advanced fibrosis and partial virologic response to oral nucleos(t)ide analogues (ESTAB-AFPVR) – an interim report**
 Ming-Lun YEH, *Taiwan*
- SAT-452** **Efficacy and safety of GLS4/ritonavir combined with entecavir in HBsAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study**
 Mingyuan ZHANG, *China*
- SAT-453** **Long-term efficacy of generic antiviral drugs (tenofovir and entecavir) in suppression of viral replication in chronic hepatitis B**
 Marta CASADO, *Spain*
- SAT-454** **Guideline change for antiviral therapy reduced the risk of HBV-related HCC development among cirrhotic patients in South Korea**
 David KIM, *Korea, Rep. of South*
- SAT-455** **ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B**
 Qingling ZHANG, *United States*
- SAT-456** **Longer consolidation duration is required to reduce 1-year clinical relapse rate after stopping tenofovir in HBsAg negative CHB patients**
 Rachel Wen-Juei JENG, *Taiwan*

Viral hepatitis B/D: Therapy (Cont.)

- SAT-457** **Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression**
Rajender REDDY, *United States*
- SAT-458** **Immtav, a novel immunotherapy approach to eliminate hepatitis B virus**
YI Ruth MARTINEZ HAGUE, *United Kingdom*
- SAT-459** **HBV RNA decline without concomitant HBsAg decrease is associated with**
YI **a low probability of sustained response and HBsAg loss**
Sylvia BRAKENHOFF, *Netherlands*
- SAT-460** **HBV specific ImmTAV induce a broad immune response enabling**
the elimination of HBV positive cells
Sarah LEONARD, *United Kingdom*
- SAT-461** **Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic**
hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials
Scott FUNG, *Canada*
- SAT-462** **Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV**
infection, in healthy volunteers
Sneha V. GUPTA, *United States*
- SAT-463** **Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a**
YI **therapeutic agent targeting persisting HBV infection**
Zhongliang SHEN, *China*
- SAT-464** **Optimising delivery of therapeutic hepatitis B vaccines to induce resident**
YI **memory T cells in the liver**
Tamsin CARGILL, *United Kingdom*
- SAT-465** **Entecavir versus lamivudine as antiviral prophylaxis for patients with**
hepatitis B infection undergoing anticancer cytotoxic chemotherapy:
a randomized multicenter clinical trial
Won KIM, *Korea, Rep. of South*
- SAT-466** **Functional cure based on pegylated interferon ? in long-term nucleoside**
YI **analog suppressed HBeAg negative chronic hepatitis B: a multicenter**
real-world study (Everest project in China), an interim report
Ze-Qian WU, *China*
- SAT-467** **Occurrence of hepatocellular carcinoma in chronic hepatitis B patients**
undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan
Yi-Hsiang HUANG, *Taiwan*

SAT-468 Anti-HBS induction and HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in patients with chronic HBV infection

Osamu YOSHIDA, *Japan*

SAT-469 The development and application of a prognosis prediction model for children with chronic hepatitis B

YI

Yanwei ZHONG, *China*

Poster – SAT-001 – SAT-520

Liver tumours: Therapy

- SAT-473** **Pre-operative gamma-glutamyltransferase to lymphocyte ratio predicts long-term outcomes for intrahepatic cholangiocarcinoma following hepatic resection**
YI
Jinju WANG, *China*
- SAT-474** **LXR agonism potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription**
YI
Zhongjie LIN, *China*
- SAT-475** **Ivermectin inhibits cholangiocarcinoma proliferation via induction of endoplasmic reticulum stress in vitro and vivo**
YI
Zhe WAN, *China*
- SAT-476** **Percutaneous microwave ablation versus open surgical resection for colorectal cancer liver metastasis**
Lei CHEN, *China*
- SAT-477** **5-aminolevulinic acid mediated photodynamic therapy: pathing the way towards a new therapeutic modality for hepatocellular carcinoma**
YI
Abhishek KUMAR, *France*
- SAT-479** **Transarterial radioembolization versus systemic treatment for the management of hepatocellular carcinoma with vascular invasion: analysis of the US national cancer database**
YI
Joseph AHN, *United States*
- SAT-480** **ALBI grade is a good predictive parameter for prognosis in advanced HCC patients with nivolumab therapy**
Wei TENG, *Taiwan*
- SAT-481** **Early changes in circulating FGF19 and ANG-2 levels as a possible predictive biomarker for lenvatinib therapy in hepatocellular carcinoma**
Top 10%
Makoto CHUMA, *Japan*
- SAT-482** **The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib**
YI
Claudia CAMPANI, *Italy*
- SAT-483** **Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma**
Clemens SCHOTTEN, *Germany*
- SAT-484** **HBsAg relapse after living donor liver transplantation in hepatocellular carcinoma patients with hepatitis D virus infection may result in hepatocellular carcinoma relapse**
Adil BASKIRAN, *Turkey*

- SAT-485** **13C-methacetine breath test for the prediction of liver damage caused by transarterial chemoembolization in patients with hepatocellular carcinoma**
 Florian VAN BÖMMEL, *Germany*
- SAT-486** **Influence of acute kidney injury on the prognosis of patients receiving transarterial transebolisation for hepatocellular carcinoma: based on ICA-AKI criteria**
 Won SOHN, *Korea, Rep. of South*
- SAT-487** **Radiofrequency versus microwave ablation for hepatocellular carcinoma within the Milan criteria in challenging locations: a retrospective controlled study**
 YI
 Xue HAN, *China*
- SAT-488** **Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings**
 Heechul NAM, *Korea, Rep. of South*
- SAT-489** **Intrahepatic HBV replication markers associated with tumor recurrence after surgical resection in patients with HBV-related hepatocellular carcinoma**
 I-Cheng LEE, *Taiwan*
- SAT-490** **Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma**
 YI
 Johann VON FELDEN, *Germany*
- SAT-491** **Diagnostic value of brush cytology alone and in combination with tumor marker in malignant biliary stricture**
 YI
 Jaseem ANSARI, *India*
- SAT-492** **miR-486-3p mediates sorafenib resistance through targeting FGFR4 and EGFR in hepatocellular carcinoma**
 Top 10%
 YI
 Lin Ji, *China*
- SAT-494** **Treatment strategy for single small T1/T2 hepatocellular carcinoma patients with Child-Turcotte Pugh class A; a nationwide cohort study in South Korea**
 Young-Joo JIN, *Korea, Rep. of South*
- SAT-495** **Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice**
 Katsuaki OGUSHI, *Japan*
- SAT-496** **Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies**
 Keisuke KOROKI, *Japan*

Liver tumours: Therapy (Cont.)

- SAT-497** **High rate of hepatitis B virus S-integrated human extra spindle pole bodies like 1 fusion gene is detected in hepatitis B virus-related liver cancer patients: a Chinese case-control study**
Rongming WANG, *China*
- SAT-498** **Treatment decision for hepatocellular carcinoma ?5cm: surgical resection or microwave ablation**
Ping LIANG, *China*
- SAT-499** **Chlorogenic acid decreases malignant characteristics of hepatocellular carcinoma cells by inhibiting DNMT1 expression**
Yao LIU, *China*
- SAT-500** **Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma**
Luca IELASI, *Italy*
- SAT-501** **A lncRNA-associated ceRNA regulatory network in MVI positive hepatocellular carcinoma influences their sensitivity to sorafenib**
Zhiwen LUO, *China*
- SAT-502** **In vivo performance of PEG-coated gold nanoparticles mediated ultrasound guided radiofrequency ablation: a pilot study in swine**
Tudor MOCAN, *Romania*
- SAT-503** **The «six-and-twelve» score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule**
Marco SANDUZZI ZAMPARELLI, *Spain*
- SAT-504** **Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib monotherapy in advanced hepatocellular carcinoma: a systemic review and meta-analysis**
Zhiyuan YAO, *China*
- SAT-505** **Dexamethasone prophylaxis of postembolization syndrome after transcatheter arterial chemoembolization: a randomized, double-blind, placebo-controlled study**
Panot SAINAMTHIP, *Thailand*
- SAT-506** **Relative dose intensity and response in real-world treatment with lenvatinib for advanced hepatocellular carcinoma**
Ryu SASAKI, *Japan*
- SAT-507** **Association between curative treatment after transarterial radioembolization and better survival outcomes in patients with hepatocellular carcinoma**
Yoon Ah KIM, *Korea, Rep. of South*

- SAT-509** **The real-world systemic sequential therapy of sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea**
Yoonseok LEE, *Korea, Rep. of South*
- SAT-510** **Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan**
Takuya SHO, *Japan*
- SAT-511** **Prognostic value of alpha-fetoprotein in patients achieving complete response to transarterial chemoembolisation for hepatocellular carcinoma**
Jae Seung LEE, *Korea, Rep. of South*
- Top 10%**
- SAT-512** **Quantitative high-throughput small-molecule screening identified MEK inhibitor PD198306 synergize with sorafenib in treatment for hepatocellular carcinoma (HCC) via ERK-dependent up-regulation of Bim and ERK-independent down regulation of MCL1**
Junjie HONG, *China*
- SAT-513** **Updated data from an ongoing study with ADP-A2AFP spears T-cells**
Tim MEYER, *United Kingdom*
- SAT-514** **A nationwide multicenter study of Japanese patients with unresectable hepatocellular carcinoma treated with regorafenib in real-world practice**
Kaoru TSUCHIYA, *Japan*
- SAT-515** **Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma**
Tsuguru HAYASHI, *Japan*
- SAT-516** **No risk of hepatitis B reactivation in hepatocellular carcinoma patients with HBV-DNA > 100 iu/ml undergoing immune checkpoint inhibitor immunotherapy by pre-emptive strategy**
Pei-Chang LEE, *Taiwan*
- SAT-517** **Effect of antibiotics, proton pump inhibitors and steroids on survival and response to immune-checkpoint inhibitors in patients with hepatocellular carcinoma**
Pei-Chang LEE, *Taiwan*
- SAT-518** **Nucleos(t)ide analogs reduces hepatocellular carcinoma mortality in patients with low HBV-DNA levels**
ZhiYun YANG, *China*
- SAT-519** **Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure**
Yun Bin LEE, *Korea, Rep. of South*
- SAT-520** **Zinc phthalocyanine/sorafenib-conjugated bovine serum albumin nanoparticles provide effective synergistic therapy against hepatocellular carcinoma**
Ji-Min ZHU, *China*